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ABSTRACT 
 
TING ZHOU: DESIGN, SYNTHESIS, AND STRUCTURE-ACTIVITY RELATIONSHIP 
INVESTIGATION OF 3’,4’-DISUBSTITUTED PYRANOCHROMONE DERIVATIVES 
WITH DIVERSE BIOLOGICAL ACTIVITIES  
(Under the direction of Kenan Professor Kuo-Hsiung Lee) 
 
        The overall goals of this research are to design and synthesize novel 3’,4’-
disubstituted pyranochromone derivatives, to evaluate their anti-HIV activity and 
chemosensitizing potency, to elucidate structure-activity relationships (SAR), and to 
discover novel chemical entities. 
        3’R,4’R-Di-camphanoyl-khellactone analogs (DCKs) was first identified in our 
laboratory with high anti-HIV activity against wild-type HIV strain early in 1994.  
Using SAR-directed strategy, 3’R,4’R-di-camphanoyl-pyranochromone analogs 
(DCPs) were synthesized and evaluated in a continuing study, which showed high 
potency against both wild-type and multi-RT inhibitor-resistant strains. Mechanism 
study of DCK and its derivatives suggested that the compounds target HIV-RT in a 
unique way, by inhibiting its DNA-dependent DNA polymerase activity. 
          A microwave-assisted one-pot reaction was first developed in our study and 
successfully applied in the preparation of 2’,2’-dimethyl-chromone motifs which were 
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key intermediates in DCK and DCP derivatives. The highly efficient microwave 
synthesis shrinked the reaction time over 12-fold with much higher yield than 
traditional heating system previously reported.  
         Utilizing the optimized synthesis method, novel DCP analogs were designed 
and synthesized to further explore functionality requirements on the 
pyranochromone ring and to improve water solubility. SAR studies led us identified 
5-alkyl-DCPs (98, 102) with increased efficacy against both wild-type and drug-
resistant HIV strains. Simultaneously, novel DCPs (98, 115) also presented 5- and 
10-time higher water-solubility than 2-EDCP (69). 
        Furthermore, we explored the interaction between the planar ring and the 
binding pocket by constructing a tri-aryl-conjugated system, pyranoxanthones 
(DCXs). DCX and its analogs maintained and even increased the π-π stacking 
interaction with the residues inside the binding pocket. Several DCX analogs (131, 
135, 144) increased anti-HIV potency against both virus strains and six analogs 
exhibited improved therapeutic index (TI) compared to the control 2-EDCP (69). 
        Finally, we discovered that 3’,4’-disubstituted pyranochomone (DSP) analogs 
showed strong potential to reverse multi-drug resistance (MDR) in cancer cell line. A 
SAR study were established and three DSP analogs (194, 197 and 204) fully 
resolved vincristine (VCR) resistance in KB-Vin cancer cells, which are over 2-fold 
more potent than verapamil, a prototype chemosensitizer. Preliminary mechanism 
study revealed that the chemosensitizing activity of DSP analogs results from the 
inhibition of cellular P-glycoprotein (P-gp) function. 
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CHAPTER 1 
HIV/AIDS AND TREATMENTS 
1.1 Overview of Acquired Immunodeficiency Syndrome (AIDS) 
        Acquired immunodeficiency syndrome (AIDS) is a set of symptoms and 
infections resulting from the damage to the human immune system caused by the 
human immunodeficiency virus (HIV). 1 The first case in the United States (US) was 
reported in 1981. 2 In 1987, the first antiretroviral drug zidovudine (AZT), a 
nucleoside analog, was approved by the US Food and Drug Administration (FDA) for 
the treatment of AIDS patients. Since then, enormous progress has been made in 
both basic and clinical research. However, neither a cure for this disease nor a 
vaccine to stop the spread of the pandemic is available. 
    By 2007, the Joint United Nations Program on HIV/AIDS reported that an 
estimated 33.4 million people were living with HIV worldwide, including 2.1 million 
children. 3 In the US, an estimated 1.1 million persons were living with diagnosed or 
undiagnosed HIV/AIDS at the end of 2006 and 42,655 new cases of HIV/AIDS in 
adults, adolescents and children were diagnosed in 2007 alone, based on reports by 
Centers of Disease Control and Prevention. 4 
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1.2 HIV 
        HIV is a member of the lentiviruses, a subfamily of the retroviruses. Infection 
with HIV occurs by the transfer of virus in blood, semen, vaginal fluid, pre-ejaculate, 
or breast milk. The four major routes for transmission of HIV are unsafe sex, 
contaminated needles, breast milk, and vertical transmission (transmission from an 
infected mother to her baby at birth). HIV can infect various immune cells, such as 
CD4+ T lymphocyte cells, macrophages that express the CD4 molecule on the 
surface, and dendritic cells. 
        Two types of HIV are known to exist: HIV-1 and HIV-2. HIV-1 is the virus that 
was initially discovered. HIV-1 is more virulent and infective, and it accounts for the 
vast majority of HIV infections worldwide, with HIV-2 present mainly in Western 
Africa. 5        
         The first isolation of the new human retrovirus, subsequently shown to be the 
causative agent of AIDS, was reported in 1983 by Montagnier and colleagues.6 The 
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virus was isolated from the lymph node lymphocytes of a French homosexual patient 
with generalized hyperplastic lymphadenopathy. The virus was named 
lymphadenopathy-associated virus (LAV-I). The association of LAV to AIDS 
remained obscure until Dr. Robert Gallo reported the isolation and characterization 
of a retrovirus from patients with or at risk of AIDS. This virus was named human T-
lymphotrophic virus III (HTLV-III) in 1984.7 Subsequent studies have shown LAV and 
HTLV-III to be virtually identical. In addition, similar viruses known as AIDS-related 
viruses (ARV) were isolated from homosexuals in San Francisco.8 All isolates of 
these related retroviruses are now termed human immunodeficiency virus type I 
(HIV-I).9-13 
1.2.1 Structure of HIV-1 
    The mature HIV-1 particles are 
spherical with a diameter of about 100-
120 nanometers. (Figure 1-2) HIV 
particles surround themselves with a 
coat of fatty material known as the viral 
envelope. The spikes projecting from this 
envelope are formed from the Env 
glycoprotein, a heterodimer that contains 
the surface gp120, which is non-
covalently attached to the transmembrane subunit gp41. Each spike contains three 
gp120 and three gp41 molecules, held together in a triangular symmetry.14 The 
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glycoprotein complex plays a significant role to facilitate viral entry, which enables 
the virus to attach to and fuse with target cells and initiate the infectious cycle. 15, 16,17 
Below the viral envelope is a layer called the matrix, which is composed of an 
association of the viral protein p17.18 The function of the matrix is to ensure the 
integrity of the virion particle. The viral capsid is usually bullet-shaped and is made 
from protein p24. 19 Inside the capsid are three enzymes required for HIV replication 
called reverse transcriptase (RT), integrase (IN), and protease (PR). Also held within 
the core is HIV’s genetic material, which consists of two copies of positive single-
stranded RNA. (Figure 1-3) 
 
      The RNA genome of HIV-1 encodes the major structural and non-structural 
proteins common to all replication-competent retroviruses. 20 (Figure 1-4) From its 5’ 
to 3’ –end, the genome contains gag (for group-specific antigen), pol (for 
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polymerase), and env (for envelope glycoprotein) genes, which encode 
corresponding structural proteins. The gag gene encodes a polyprotein precursor, 
Pr55Gag, which is cleaved by the viral PR to release four mature gag proteins, matrix 
(MA), capsid (CA), nucleocapsid (NC), and p6. The pol-encoded enzymes are 
initially synthesized as part of a large polyprotein precursor, Pr160Gagpol. The 
individual pol-encoded enzymes, PR, RT, and IN, are cleaved from Pr160Gagpol by 
the viral PR. The env gene encodes the envelope glycoprotein precursor gp160. The 
gp160 is processed not by PR but instead by a cellular protease in Golgi apparatus, 
which generates the surface Env glycoprotein gp120 and the transmembrane 
glycoprotein gp41. The function of each protein will be described in detail in Chapter 
1.2.2.  
        HIV-1 also encodes a number of regulatory proteins, Tat, Rev, and accessory 
proteins Vpu, Vif, Vpr, and Nef. Tat is critical for transcription from HIV-1LTR, and 
Rev plays a major role in the transport of viral RNAs from the nucleus to the 
cytoplasm.  
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1.2.2 Replication Cycle of HIV-1 
        HIV replication proceeds in a series of events that can be divided into several 
steps. Based on current understanding, molecular events in the replication cycle of 
HIV-1 include the following steps (Figure 1-5): virus entry and fusion (1), reverse 
transcription (2), integration and gene expression (3), and assembly and maturation 
(4). 
(1) Virus entry and fusion 
The entry of HIV into the host cell requires the presence of certain receptors 
(CD4 receptors) and co-receptors (e.g., CCR5 and CXCR4) on the cell surface. 20 
These cellular receptors interact with virus protein complexes composed of gp120 
and gp41 glycoproteins, which are embedded in the viral envelope. When HIV 
approaches its target cell, gp120 binds to the CD4 receptors. Binding to CD4 
triggers a conformational change in gp120 that exposes a binding site for a 
7 
 
chemokine receptor that acts as a co-receptor.17 Interaction with the co-receptor 
promotes the formation of a transient intermediate, in which gp41 spans both the 
viral and the cellular membrane and facilitates the fusion of the two membranes.21 
However, a recent study explored the fusion process by using population-
based measurements of the viral content delivered into the cytosol and time-
resolved imaging of single viruses. The study demonstrated that HIV-1 
predominantly uses existing cellular endosomes as transport carriers to gain access 
to the cytoplasm, rather than using conventional fusion upon interacting with cognate 
cellular receptors on the plasma membrane.22  
(2) Reverse transcription 
The viral nuclear capsid enters the host cell and releases two RNA strains and 
three essential replication enzymes: IN, PR and RT. RT begins the reverse 
transcription of viral RNA. It has two catalytic domains, the ribonuclease H (RNaseH) 
active site and polymerase active site. Single-stranded viral RNA is transcribed into 
a RNA-DNA double helix. RNaseH then breaks down the RNA. Finally, the 
polymerase completes the remaining DNA strand and forms a DNA double helix.  
(3) Integration and gene expression 
The viral DNA double helix is imported into the nucleus in a process regulated 
by the viral protein Vpr. Then, the viral integrase goes into action and cleaves a di-
nucleotide from each 3’ end of the DNA, creating two sticky ends. Integrase then 
transfers the DNA into the cell nucleus, where it also makes a staggered cleavage in 
the cellular target DNA and facilitates connection of virus DNA to the ends of 
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cleaved cellular DNA. The integrated DNA is called the “provirus”. 
After integration, the host cell genome contains the genetic information of HIV. 
Activation of the cell by certain cellular transcription factors, such as NF-κB, induces 
the transcription of proviral DNA into mRNAs that ultimately encode the full 
complement of structural, regulatory, and accessory proteins used to direct virus 
replication. The HIV-1 LTR, composed of three regions, U3, R and U5, serves as the 
site of transcriptional initiation and harbors cis-acting elements required for RNA 
synthesis.23 Tat transactivates LTR-driven gene expression.24 The mRNAs are then 
translated into proteins using the cell machinery. 
(4) Assembly and maturation 
        Following the synthesis of the full complement of viral proteins, the assembly 
process begins. The assembly takes place at the plasma membrane of the infected 
cell, and Gag precursor polyprotein Pr55Gag plays an important role in membrane 
binding, targeting, and encapsidation.25,26 The MA domain of Gag is largely 
responsible for targeting and binding the plasma membrane. The specific 
encapsidation of retroviral RNAs into virus particles is mediated by interaction 
between packaging signal and the NC domain of Gag protein. Thus, the NC domain 
of Gag protein promotes the encapsidation of the viral RNA genome and the 
association with viral Env glycoproteins, gp41 and gp120 and stimulates budding 
from the cell.  
        Maturation occurs during or shortly after virus release from the plasma 
membrane of the host cell. During maturation, HIV PR cleaves the polyprotein 
precursors into individual mature HIV proteins and enzymes.27 The mature virus is 
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then able to infect another cell.    
 
 
1.3 Current Anti-retroviral Drugs  
        Currently, no vaccine or cure for HIV or AIDS is publically available. However, 
the introduction of antiretroviral drugs has significantly improved the prognosis of 
infected individuals who have access to treatment. Current anti-retroviral 
drugs/agents fall into six categories based on their different mechanisms: (A) a 
fusion inhibitor (FI); (B) entry inhibitor (CCR5 co-receptor antagonist), (C) 
nucleoside/nucleotide viral RT inhibitors (NRTIs), (D) non-nucleoside RT inhibitors 
10 
 
(NNRTIs), (E) HIV integrase strand transfer inhibitors, and (F) protease inhibitors 
(PIs).  
(A) Fusion inhibitors  
Fusion inhibitors prevent HIV from entering target cells. 28 Enfuvirtide (T-20) is 
the first and only fusion inhibitor approved by FDA for use in treatment-experienced 
patients.(Figure 1-6) 29-33 Enfuvirtide is a synthetic 36-amino acid peptide that mimics 
the residues 127-162 of the extracellular portion of gp41 and prevents the 
conformational change of gp41 required for virus-cell fusion.34 Enfuvirtide is 
considered to be a drug with a low genetic barrier to resistance development.28,35 
Other limitations associated with enfuvirtide treatment include the high cost of the 
peptide manufacturing process and its mode of delivery. The drug must be 
administered by subcutaneous injection because oral administration leads to rapid 
degradation in the gastrointestinal (GI) tract.36 
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(B) CCR5 antagonist 
The CCR5 antagonists are antiretroviral agents with an extracellular, host-
targeted mechanism of action against HIV. Maraviroc was the first approved oral 
receptor-binding inhibitor. (Figure 1-7)37 The binding of the medication with CCR5 
causes a conformational change that blocks gp41 mediated fusion of viral and 
cellular membranes.38,39 However, maraviroc has no efficacy against CXCR4 tropic 
virus and minimal effect on mixed/dual-tropic virus.40 Hence, FDA approval of 
maraviroc stipulates that it is used as therapy for treatment-experienced adult 
patients in which only R5-tropic HIV-1 is detectable.37 
12 
 
 
(C) Nucleoside/nucleotide RT inhibitors (NRTIs) 
NRTIs are nucleoside/nucleotide analogs that replace natural nucleotides in 
the viral DNA nucleic acid sequence. 41,42 NRTIs were also the first drugs to be used 
clinically as antiretroviral agents and they remain in the mainstream of therapy 
against HIV infections. FDA approved NRTIs include AZT, d4T, 3TC, ddC, ddI, ABC, 
and FTC. (Figure 1-8) 43-45  All analogs mimic endogenous nucleosides and are 
metabolically activated by host cellular kinases to their corresponding triphosphate 
forms, which are then incorporated into DNA by HIV-1 RT and therefore terminate 
the DNA chain elongation. 46 Major limitations include mitochondrial toxicity,47,48 lack 
of activity in some cell types, and susceptibility to viral resistance.49  
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(D) Non-nucleoside RT inhibitors (NNRTIs) 
Compared with NRTIs, NNRTIs are small allosteric inhibitors. They non-
competitively inhibit DNA polymerization, and bind to a non-active site pocket in 
RT.50,51 NNRTIs are structurally and chemically diverse, with more than 30 
structurally different classes of compounds being identified.52 The FDA has 
approved four NNRTIs: nevirapine, delavirdine, efavirenz, and etravirine. (Figure 1-9) 
The major limitation of NNRTIs is their low genetic barrier to resistance. Single point 
mutations at the NNRTI binding site can cause high levels of resistance and cross-
resistance to other NNRTIs.53 Etravirine is a newly approved second generation 
NNRTI. Its structure flexibility allows it to bind efficiently to the binding pocket even in 
the presence of significant NNRTI resistance-associated mutations. However, 
etravirine still loses its potency when two or more mutations occur simultaneously.54  
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(E) HIV IN inhibitor  
IN is the newest target of AIDS and retroviral therapy.55 Raltegravir is the first 
and the only IN inhibitor approved by the FDA (2007) for the treatment of patients 
who are failing highly active anti-retroviral therapy (HAART). (Figure 1-10)56 The 
medication is well-tolerated and highly potent, and has a good pharmacokinetic 
profile.56-58 However, as observed for other anti-retrovirials, specific resistance 
mutations have been identified in patients failing to respond to treatment with 
raltegravir.59,60 Varying-degrees of cross-resistance to IN inhibitors have also been 
reported.61,62 
 
(F) Protease inhibitors (PIs) 
PIs are non-hydrolysable transition state peptidomimetics of HIV protease 
cleavage sites. 63 PIs selectively inhibit the cleavage of HIV gag and gag-pol 
15 
 
polyproteins, thereby preventing viral maturation.64 Among the 25 available anti-HIV 
drugs, nine of them, saquinavir, indinavir, ritonavir, nelfinavir, darunavir, lopinavir, 
fosamprenavir calcium, atazanavir, amprenavir, and tipranavir, target the HIV PR. 
Due to their peptidomimetic nature, PIs suffer from poor aqueous solubility, low 
bioavailability, and short plasma half-lives.65 Toxicities of PIs include insulin 
resistance and lipodystrophy.66 PIs are also highly susceptible to viral resistance.67,68  
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1.4 Current retroviral Therapy and Its Issues 
        In the nearly 30 years of research, 25 anti-retroviral drugs have been approved 
for the treatment of HIV infection in the US. The introduction of antiretroviral drugs 
has significantly improved the prognosis of infected individuals who have access to 
treatment. The revolutionary introduction of HAART resulted in dramatically 
decreased morbidity, improved life expectancy, and cost-effective care for HIV-1 
infected individuals. HAART is a  combination of at least three drugs, including either 
a PI or an NNRTI and two NRTIs.69 HAART slows and prevents the emergence of 
drug resistant virus. Minor variants with pre-existing drug resistance to one drug can 
be suppressed by other drugs in a combination. In addition, drug combination can be 
additive or synergistic, blocking HIV-1 replication more extensively than individual 
drugs and, thus, preventing the development of new drug resistant mutations.   
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         However, some emerging issues are having increasingly detrimental impacts 
on the treatment options and disease outcome. While HAART has been successful 
in prolonging the life-spans of HIV infected patients, it does not allow viral 
eradication. In addition, as a consequence of the long-term use of anti-retrovirals, a 
larger dose-increase is often required due to decreased susceptibility. Development 
of viral resistance is rapid, which makes use of current therapeutic approaches 
toward AIDS difficult. Furthermore, the treatment itself has serious adverse side 
effects on the liver and hematophietic organs (e.g., bone marrow suppression and 
anemia), metabolic effects resulting in increased levels of lipid and sugar in the 
blood, as well as peripheral neuropathy.70-72 Another concern is the high cost of 
lifelong treatment. The expensive cost of HAART also limits access of a broad range 
of HIV-infected patients to the medications. These limitations have stimulated an 
emergent need for new anti-HIV agents, especially those with new structures and (or) 
new action mechanisms to improve convenience, reduce toxicity, and particularly to 
provide antiretroviral activity against viral strains resistant to the currently available 
antiretroviral agents.  
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CHAPTER 2 
PLANT-DERIVED NATURAL COUMARINS AND DERIVATIVES AS POTENT 
ANTI-HIV AGENTS 
 
2.1 Introduction 
        The development of new anti-HIV agents focusing on novel structures and (or) 
new mechanisms of action is still urgently needed due to the limitations of current 
anti-HIV drugs. Natural products are typically secondary metabolites, which are 
produced by organisms in response to external stimuli such as nutritional changes, 
infection, and competition. They have been the source and inspiration for long-
established medicinal agents and the majority of current FDA-approved drugs. 
According to statistical results, one third of all new chemical entities that were 
approved by the FDA between 1981-2006 fall into the categories of natural product 
and natural product-derived small molecules.2 Undoubtedly, natural products will 
continue to provide a source and inspiration for new pharmacological entities.  
         In our laboratory, identification and development of plant-derived natural 
product lead compounds involves three steps:  (1) bioactivity-guided isolation and 
characterization of active fractions or compounds; (2) rational drug design and 
analog synthesis; and (3) mechanism of action studies.3-7 Examples of such 
compounds evaluated intensely in our laboratory are coumarins and their derivatives 
with potent in vitro anti-HIV activity.  
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2.2 Recent Advances in Coumarins as Anti-HIV Agents 
        Coumarins are an important class of oxygen heterocycles. The parent coumarin 
was isolated from Tanka beans in the 19th century. Since then, a number of naturally 
occurring coumarins have been isolated mainly from various plant sources in recent 
years. Extracts of these plants have been employed as traditional medicines in 
different areas of the world.8 Naturally occurring coumarins have exhibited multiple 
biological activities, including anti-tumor, anti-fungal, anti-bacterial,9 anti-
inflammatory,10 anti-hypertension, anti-arrhythmia, and anti-osteoporosis effects as 
well as  pain relief and prevention  of asthma and sepsis.  
        In recent years, studies have found that many naturally occurring coumarins or 
coumarin derivatives exhibit anti-HIV activity. Suksdorfin (1), a khellactone coumarin, 
was isolated from the fruit of Lomatium suksdorfii in our laboratory in 1994. It 
showed anti-HIV activity with an acceptable therapeutic index (TI) value in H9 
lymphocyte cells.11, 12 Also discovered in our laboratory in 2000, imperatorin (2), 
isolated from the root of Rerula sumbul, exhibited high anti-HIV activity against the 
H9 cell line.13 Two 4-phenyl coumarins mesuol (3) and isomesuol A (4) were isolated 
from the leaves and twigs of M. pluricostata. Both compounds suppressed HIV-1 
replication in Jurkat T cells.14, 15 In 1992, a series of tetracyclic coumarins was 
isolated from the tree of Calophyllum lanigerum. (+)-Calanolide A (5) and (-)-
calanolide B (6) exhibited inhibitory activity against HIV-1 RT.16 In 2002, a screening 
study was performed on various 4-hydroxycoumarins identify HIV-1 PIs. Both 
phenprocoumon (7) and warfarin (8) were identified as potential PIs.17 In another 
massive screening involving protein crystallography and molecular modeling, 
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PD099560 (9) was first identified as a nonpeptide competitive HIV-1 PI. 18 
Modification of 9 based on computational study led to the discovery of the more 
potent 10, which had an IC50 value of 0.52 µM in an HIV protease assay.19  
Figure 2-1. Structures of naturally-occuring coumarins with anti-HIV activity
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2.3 Modification of Suksdorfin 
        As mentioned above, suksdorfin (1) was first isolated and identified as a lead 
compound against HIV-1 in our laboratory in 1994. Suksdorin had an EC50 value of 
2.6 µM and a therapeutic index (TI) of 30.6 against the infected H9 lymphocyte cell 
line. 11 In addition, suksdorfin was also suppressive during acute HIV-1 infections of 
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peripheral blood mononuclear cells, monocyte/macrophages and the promonocytic 
cell line U937. Compound 1 represents a novel class of potent anti-HIV agents, 
which is structurally unique compared with other known anti-AIDS drugs. In order to 
obtain more effective analogs and investigate the mechanism of action, 1 has been 
chosen as a lead compound for various structural modifications.  
2.3.1 Modification of Dihydroxypyrano 3’,4’ Positions 
        Compound 1 contains two chiral centers at the 3’ and 4’ positions on the pyrano 
ring system, both with R configurations. Fourteen different dihydroseselin 
(khellactone) derivatives, including all four stereochemical isomers, were designed, 
synthesized, and evaluated for anti-HIV activity (Table 2-1).11, 12 These compounds 
included khellactone itself (12), various acetyl-khellactones (1, 11, 22, 24), and 
khellactone diesters (13–21). The ester groups introduced at the 4’ and (or) 3’ 
positions included simple and branched alkyl systems, aromatic rings and large 
bulky groups.  3’,4’-Di-(O)-(-)-camphanoyl-(+)-cis-khellactone (DCK, 18) 
demonstrated the most promising inhibitory activity against HIV replication in H9 
cells. With an EC50 value of 2.56 x 10-4 µM, DCK was 100-fold more potent than AZT 
(0.045 µM) in the same assay. The anti-HIV activity of DCK was highly sterospecific 
as the (-)-cis, (-)-trans, and (+)-trans isomers were much less active.12, 20 In addition, 
other racemic khellactone analogs with diverse ester groups at the 3’ and 4’ 
positions were inactive or 10,000 times less active. 
 
 
Tabl
 
e 2-1. Anti-HIV activity of khell
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actone derivatives in H9-lymphocytes. 
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a EC50 = concentration that inhibits viral replication by 50%.  b TI = in vitro therapeutic 
index, ratio of IC50/EC50. IC50 = inhibitory concentration for cytotoxicity (not shown).   
c NS = No suppression.  * Optically pure (+)-cis-khellactone compound; ** Optically 
pure (-)-cis-khellactone compound 
 
 
2.3.2 Modifications of Substitutions on Khellactone 
        The prior research identified (+)-cis-DCK (18) as a new lead compound for 
further development. Over 30 DCK analogs with diverse functional groups on the 
coumarin ring system have been designed, synthesized, and evaluated in initial SAR 
studies against HIV-IIIB replication in H9 cells (Table 2-2). 
         The SAR study of DCK analogs indicated that compounds with methyl or 
methyoxy groups at one or two of the 3-, 4- and 5-positions of DCK exhibited 
comparable (29–31 and 33–35) or even better (25–27) anti-HIV activity than DCK 
(18). 4-MethylDCK (4-MDCK, 26) and 5-MDCK (27) exhibited the greatest anti-HIV 
activity. However; similar modifications at the 6-position (28, 32) negatively 
influenced the anti-HIV activity. Larger groups, such as linear or branched propyl 
groups (52, 53) and phenyl (54), on the chromone ring also adversely  influenced the 
activity. These results indicated that a methyl group on the coumarin ring probably 
fits well into a hydrophobic cleft on the target’s active surface and greatly increases 
both the agent’s target affinity and the desired pharmacological response. Larger 
groups could affect the planarity of the ring system and, therefore, interfere with 
target binding. A phenyl substituent (54) may not fit into the binding site. 20, 21  
        Compounds with CH2OH and CH2OAc groups at the 3-position (37–38 and 42–
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43) maintained comparable or had better anti-HIV activity compared with DCK. (Note, 
a different assay system was being used, and the EC50 of DCK when screened in 
parallel with these compounds was 0.049 µM). On the other hand, aminomethyl-
substituted derivatives (39, 40) showed decreased activity. Most DCK derivatives 
displayed potency comparable or better than AZT against wild strain HIV-1 IIIB in H9 
or CEM-SS cell lines. 22, 23 
        However, most of the DCK analogs were active against HIV-RTMDR1 strains. 
HIV-RTMDR1 is a multi-drug resistant HIV strain that contains four RT mutations, 
(M41L, l74V, V106A, T215Y) and is resistant to most NRTIs and NNRTIs.  
Table 2-2. Anti-HIV activity of DCKs in acutely infected H9 lymphocytes  
OO O
R1
R2R3
R4
O
O O
O
O
O
O
O  
 R1 R2 R3 R4 EC50a 
(µM) 
IC50b 
(µM) 
TI c 
18  
(DCK) H H H H 2.56x10
-4 35 1.4x105 
25 CH3 H H H 5.25x10-5 >113 >2.2x106
26 H CH3 H H 1.83x10-6 >126 >6.0x107
27 H H CH3 H 2.39x10-7 >95 >4.0x108
28 H H H CH3 0.151 33 218 
29 OCH3 H H H 2.38x10-3 >153 >6.4x104
30 H OCH3 H H 2.99x10-3 >153 >1.5x104
31 H H OCH3 H 1.92x10-4 >153 >8.0x105
32 H H H OCH3 15.8 >153 >9.7 
33 CH3 CH3 H H 1.92x10-3 >154 >3.7x104
34 H CH3 CH3 H 4.19x10-3 >154 >1.7x104
35 H CH3 H CH3 4.69x10-3 3.75 1.3x103 
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36* CH2Br H H H 0.059 >11.1 >186 
37* CH2OAc H H H 0.017 11.6 676 
38* CH2OH H H H 0.029 23.0 806 
39* CH2NH2 H H H 0.667 >15.4 >23 
40* CH2NEt2 H H H 3.67 >14.1 >4 
41* CH2Br CH3 H H 1.1x10-4 >20.9 >1.9x105
42* CH2OAc CH3 H H 0.026 14.8 567 
43* CH2OH CH3 H H 0.0042 24.9 6000 
44* H CH3 H CH2Br 0.156 >13.7 >88 
45* H CH3 H CH2OAc 0.544 >14.1 >26 
46* H CH3 H CH2OH 0.111 >15.0 >102 
47* H CH3 H CH2NH2 0.148 >15.0 >102 
48 H CH3 OCH3 H 0.076 >15.0 86 
49 Cl CH3 H H 2.01x10-3 104 5.2x104 
50* Br CH3 H H 0.155 >14.0 91 
51* COOH H H H NS >15.0 NS 
52 CH2CH2C
H3 
H H H 1.75x10-2 >200 >8.6x103
53 CH2(CH3)2 H H H 3.15x10-2 >128 >4.8x103
54* C6H5 H H H 0.12 >143 >1.2x103
55* CF3 H H H 1.81 >145 >80.1 
AZT     0.045 1875.0 4.2x104 
a EC50 = concentration that inhibits viral replication by 50%.  b IC50 = inhibitory 
concentration for cytotoxicity.  C TI = in vitro therapeutic index, ratio of IC50/EC50.   
d NS = No suppression.  * The activity was tested using a diverse screening assy. 
These compounds were screened initially in MT-2 cells and then in H9 lymphocytes 
with ELISA for confirmation. Under this assay system, DCK (18) exhibited an EC50 of 
0.049 µM and TI of >328.  
 
 
2.3.3 Development of Bio-isosteres of DCK Analogs 
        Based on the concept of bio-isosterism, new analogs were designed and 
synthesized (Figure 2-2). The thio-bioisosters of DCK (56, 57) contain sulfur rather 
than oxygen in ring A, and retained anti-HIV activity in comparison to the substituted 
DCKs. In the CEM-SS cell line, 57 showed promising potency with an EC50 value of 
0.064 µM and TI over 3149. It was more active than DCK (EC50 0.14 µM and 
TI >100) in the same cell line. 24 
        DCK lactam analogs were also synthesized asymmetrically and evaluated for 
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anti-HIV activity against HIV-1 in H9 lymphocytes. Both compounds (58, 59) retained 
high anti-HIV activity. The EC50 values of 58 and 59 against HIV-IIIB in H9 cell line 
were 2.5x10-4 and 4.6x10-3 µM, respectively (EC50 of DCK was 2.56x10-4 µM).25  
        Modification on ring C was also conducted and 7-thia and 7-carbo DCK 
derivatives were designed and synthesized (60–64).26, 27 Bioassay results indicated 
that both 7-thia and 7-carbo DCKs could be potential anti-HIV agents. Compound 60 
exhibited potent inhibitory activity against HIV-1 replication with an EC50 value of 
0.14 µM and TI value of 1110,26 while compounds 62–64 were also potent with EC50 
value ranging from 0.068-0.39 µM (EC50 of DCK was 0.049 µM in the same assay 
system). 27 
 
 
2.3.4 Development of Pyranochromone Derivatives (DCPs) as Novel Anti-HIV 
Agents 
        DCP (3’,4’-di-O-(-)-camphanoyl-2’,2’-dimethyldihydropyrano[2,3-f]chromone, 65) 
was developed from DCK with the intention to further extend the SAR study.28, 29 In 
order to introduce structural variety, the 2H–pyran-2-one system in DCK was 
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replaced with a 4H-pyran-4-one in DCP. Diverse substitutions (mostly alkyl groups) 
were introduced on the pyranochromone ring skeleton. Compared with DCK analogs, 
the synthesized DCP analogs, not only showed high potency against a wild-type 
HIV-IIIB strain, but most of them also exhibited activity against a multi-drug resistant 
HIV RTMDR-1 strain. (Table 3) 
        The initial SAR study of DCPs suggested that DCP analogs are more promising 
than DCK analogs due to their potential to inhibit the replication of HIV RTMDR-1, 
which is resistant to DCKs. Methyl and ethyl groups at the 2- or 3-position (66, 68, 
69) of the DCP chromone ring system were critical for anti-HIV activity against both 
HIV strains. In fact, 2-EDCP (69) presented the best anti-HIV activity against both 
wild-type and drug-resistant HIV-1 strains. Larger substituents at the 2-, 3-, and 6-
positions of the chromone ring dramatically decreased the anti-HIV activity against 
both wild-type and drug-resistant strains.  
Table 2-3. Anti-HIV activity of DCP analogs  
OO
R3
O
O O
O
O
O
O
O
O
R1
R2
2
3
 
Compd R1 R2 R3 
HIV-IIIBa HIV-1 RTMDR1b 
EC50(µM) TI EC50(µM) TI 
65 H H H 0.0013 1.1x105 NSc NS 
66 H CH3 H 9.9x10-4 1.5x105 1.38 2.5 
67 H C6H5 H 1.54 23.3 NS NS 
68 CH3 H H 0.0031 8600 0.19 62.5 
69 CH2CH3 H H 3.2x10-4 1.2x105 0.06 718 
70 CH2CH2CH3 H H 0.02 1860 0.14 272 
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71 CH(CH3)2 H H 0.07 483 0.14 >111 
72 CH2OCH2CH3 H H 0.1 151 0.37 >34 
73 C6H5 H H 0.129 >277 0.17 71 
74 CH3 CH3 H 0.007 1500 0.31 15 
75 CH2CH3 H C(CH3)3 1.62 22 7.36 1.9 
DCK    0.049 >328 12.06 1.3 
26    0.0059 >6660 9.43 1.7 
AZT    0.044 4.3x105 0.1 >375 
a This assay was performed in H9 lymphocytes by Panacos, Inc 
b This assay was performed in the MT-4 cell line by Dr. Chin-Ho Chen, Duke 
University, NC 
c NS = no suppression at the concentration of 10 µg/mL. 
2.4 Studies on Mechanism of Action 
        Suksdorfin and DCK analogs are coumarin derivatives that exhibited potent 
anti-HIV activity. The chemical structure of DCK is unique compared with the drugs 
currently used in AIDS therapy. Although DCK is a potent inhibitor of many HIV-1 
isolates, the compound is ineffective against an HIV-1 strain resistant to both NRTIs 
and NNRTI.28 Because this resistant strain is also resistant to DCK, HIV-1 RT might 
be the target of these coumarin-derived compounds.  
2.4.1 Structure of HIV-1 RT 
HIV-RT is a main target of drugs used in the treatment of AIDS. It is part of the 
the HIV viral protein shell surrounding the nucleic acid core and is essential for the 
replication of the virus. 
 HIV-RT is a heterodimer enzyme composed of two related subunits, one with 
66kDa-p66 and another with 51kDa-p51.The latter is a proteolytic cleavage product 
of p66 polypeptide, having the same sequence but adopting a different conformation. 
The additional residues at the carboxy terminus of p66 comprise the RNaseH 
domain. As p51 is a proteolytic product of p66, any amino acid mutations in the HIV 
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genome affect both subunits.30 The p66 subunit includes four subdomains 
designated thumb, palm, finger, and connection, because of its similarity with a right 
hand.1(Figure 2-3) The p51 interacts with the p66 subunit via the connection 
domains as well as through several other parts of the peptide chain. The p66 finger 
and thumb domains are very flexible, acquiring an open structure when the DNA fits 
between the fingers and the thumb.31, 32  
                     
2.4.2 Mechanism Study of DCK and Its dDerivatives 
        Several mechanistic studies have been conducted on suksdorfin, DCK, and 
DCK derivatives. The earliest study in 1994 indicated that suksdorfin and DCK inhibit 
HIV-1 at a step after HIV-1 entry, but before integration of HIV-1 DNA in host 
chromosomes.12 The compounds were inactive in an assay that primarily detects the 
RNA-dependent DNA polymerase activity of HIV-RT. (Figure 2-4, adapted from 
Huang, et al.12) These results suggested a unique mechanism of action for this 
compound series.         
 
Figure 2-3. Model of HIV-1 RT with NNRTI, 
DNA primer/template, and incoming dNTP. 
Adapted from Pata et al. 1 
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        DCP and its analogs are DCK derivatives that were designed to improve the 
drug-resistance profile of DCK.28 Compared with DCK, the major advantage of DCP 
analogs is their potential to overcome the drug-resistance problem against HIV-
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analogs displayed better potency than DCK against a HIV-RTMDR1 strain. The 
mechanism of action studies indicated that DCK and its derivatives target HIV-1 RT  
by interacting with the DNA-dependent DNA polymerase activity of HIV-RT, while 
most available NNRTIs function by inhibiting the RDDP activity of HIV-1. Therefore, 
DCK and DCP derivatives are structurally and mechanistically unique from clinically 
used anti-HIV agents.  However, DCP derivatives show low water solubility and poor 
bioavailability, which limits their potential as drug candidates for clinical use. 
Therefore, it is necessary and urgent to discover and develop novel DCP analogs as 
drug candidates with potent anti-HIV activity and pharmaceutically desirable water 
solubility and bioavailability.  
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CHAPTER 3 
EFFICIENT MICROWAVE-ASSISTED ONE-POT PREPARATION OF ANGULAR 
2,2-DIMETHYL-2H-CHROMONE CONTAINING COMPOUNDS 
 
Copyright © 2010 Elsevier Ltd. Tetrahedron Letts. 2010, 33, 4382-4386. 
 
3.1 Introduction 
        As introduced in Chapter 2, Suksdorfin (1), isolated from Lomatium suksdorfii 
was discovered in early 1994 to exhibit anti-HIV activity.1 Continuing research led to 
the discovery of DCK and DCP analogs, some of which demonstrated much more 
significant anti-HIV activity than 1. 2-5 4-MDCK (26) and 2-EDCP (69) are potent 
representatives of these two series and were selected as lead compounds for further 
modification to investigate more potent and selective anti-HIV agents as clinical trial 
candidate. The skeletons of 1, 26 and 69 share a similar motif, 2,2-dimethyl-2H-
chromones (rings B and C shown in Figure 3-1). Since the synthesis of 2,2-dimethyl-
2H-chromone motif is the first and the key step in the synthesis of DCK and DCP 
series, the efficiency of accomplishing this reaction dramatically affects the synthesis 
of the desired final products. 
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        In our previous studies, different methods were utilized to construct C ring. In 
the investigation of DCKs, a two-step reaction was involved. a) nucleophilic 
substitution with 3-chloro-3-methyl-1-butyne, followed by b) Claisen rearrangement 
and cyclization in N,N-diethylaniline at reflux temperature over 200oC.3  This 
transformation generally needs over 48 hours and the yield averages below 40%. In 
the course of the investigation of DCP analogues, a one-pot synthesis succeeded, 
by which alkylation and cyclization were accomplished by addition of 4,4-dimethoxy-
2-methyl-2-butanol gradually into the refluxing solution of 1-(2,4-dihydroxyphenyl) 
ethanone in pyridine (at approximately 140 oC). 5 The maximum yield of the desired 
product derived from this conversion, however, still remained low (< 40%) even with 
48-hour reaction. Both conventional syntheses to make 2,2-dimethyl-2H-chromone 
were not time and yield efficient, partially attributing to the formation of a linear by-
product (b- series as 87b shown in scheme 3-1). Therefore, a more efficient 
synthetic approach is needed to shorten reaction time, increased yield of the desired 
product (a-series), and better control of the formation of the linear by-products in 
order for scaling-up synthesis, 
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        Microwave (MW) synthesis has been considered as a useful approach in this 
study.  One of benefits of MW synthesis is to manage the desired reaction under 
appropriate conditions (time, temperature, and pressure) to achieve the desired 
product in a reasonable high yield.  In this paper, we report herein our recent study 
in design and conduction of a series of MW synthesis with variations of reaction 
duration, temperature, and reagent, in order to optimize the synthesis of angular 2,2-
dimethyl-2H-chromones (a-series), a key and desired intermediate in our DCK and 
DCP analog synthesis.   
3.2 Results  
        In our previous report, 2,2-dimethyl-2H-chromones, such as 87a in Scheme 3-1, 
was  synthesized by reaction of 1-(2,4-dihydroxyphenyl) ethanone with 4,4-
dimethoxy-2-methyl-2-butanol in pyridine through alkylation and cyclization (38% of 
the best yield).  The by-product 87b was also obtained in 6.40 % (Scheme 3-1). The 
possible mechanism was proposed in scheme 3-2, which illustrated the formation of 
the desired angular product 87a and the undesired by-product 87b.   The activated 
alkylation reagent, 4,4-dimethoxy-2-methyl-2-butanol initially attacks at electron-rich 
position 3 or 5 of the ethanone and leads the lone-pair electron of ketone oxo at 4-
position to approach the electrophilic carbon, followed by the leaving of CH3OH to 
form the angular (a-series) or linear (b-series) products. Using the same reagent, a 
series of experiments were designed and conducted in our MW synthesis study to 
search a better condition to selectively make 87a than that from the conventional 
synthesis. The result was listed in Table 3-1. The reaction temperature was set up 
from 140 oC to 240 oC with 20 oC interval and the reaction duration was set up from 
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2 hours to 8 hours with two-hour interval. It was observed that the yields of 87a and 
b increased with temperature rising and time extending. The best MW condition in 
this experiment is 220 oC / 4 hours, with the yield of 87a up to 57.4%. Prolonging 
/shortening reaction time other than 4 hours or rising / lowering reaction temperature 
other than 220 oC resulted in lowered yield of 87a.  Although comparing with the 
best report reaction condition, at 140 oC for 48 hour, the yield of 87b under MW 
condition also slightly increased (6.40% vs. 7.32%), this condition is still significantly 
improved and reasonably acceptable to reach the maximal amount of 87a. 
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Table 3-1 . Yields of compounds 87a and 87b under varied microwave 
conditions  
 Yield of compound 87a (%) Yield of compound 87b (%) 
 2 h 4h 6h 8 h 2 h 4 h 6 h 8 h 
140 oC --- a 3.38 --- --- --- 0.49 --- --- 
160  oC --- 15.2 23.1 23.8 --- 1.40 2.33 2.47 
180  oC --- 35.5 41.5 41.9 --- 4.11 5.02 7.76 
200  oC --- 45.7 49.3 54.0 --- 6.06 6.27 7.14 
220  oC 52.7 57.4 54.0 --- 6.4 7.32 8.05 --- 
240  oC --- 38.0 35.8 --- --- 5.92 5.60 --- 
 a:  not available 
        To verify the application of the optimized MW reaction condition, 3-hydroxy-9H-
xanthane-9-one (82) was selected as the starting material to make the 
corresponding product (entry 7 in Table 3-3) under a series of MW conditions and 
the results were listed in Table 3-2.  The best condition to achieve 55.7% of the 
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desired product 93a was obtained at 220 oC for 4 hours as well, which is about 10 
times better than the yield obtained from the traditional method utilizing the same 
alkylation reagent (4.34%, table 3-4, entry 7), suggesting that 220oC/4h may be an 
applicable condition for different substances to make 2,2-dimethyl-2H-chromones 
related products, 8,8-dimethyl-8H-pyrano[2,3-f]chromones, 3,3-dimethyl-pyrano[2,3-
c]xanthen-7(3H)-ones or other products, such as 3,3,12-trimethyl-3H-pyrano[2,3-
c]acidin-7(12H)-one.  
        A scope of different substances which contain similar phenol moiety (B ring) 
and diverse fused A-rings were applied with the optimized MW condition. The results 
were listed in Table 3-3.   It was observed that most reactions generated two new 
products besides the starting materials recovered, the desired product (a) and the 
undesired by-product (b), except the entries 3 and 5 (Table 3-3), in which only the 
desired angular products (a) were monitored by TLC and MS.  Generally, the 
desired angular products (a) were predominant compared to the undesired linear 
products b (Table 3-3), implying that the MW reaction condition is efficient and 
applicable to synthesize diverse desired products (a).  The products, a and b were 
able to be separated over silica gel chromatograph and identified by NMR.  
        The data in table 3-3 further indicated that the reaction substances with alkyl 
groups, such as methyl and ethyl groups at 6-positoin of 1-(2,4-dihydroxyphenyl) 
ethanone (Table 3-3, entries 2-3) generated better yields of the desired products 
(66.4% for 88a and 72.6% for 89a, entries 2 and 3) than the yield of 87a (57.4%, 
entry 1) though 88b was a bit higher than 87b . Interestingly, the undesired by-
product 89b was not detected under the applied reaction condition, with 
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approximately 25% of the starting material 78 recovered, suggesting a stereo 
favorable cyclization toward at the 3-position. With propan-1-one (79) as starting 
material (Table 3-3, entry 4), the desired 90a was obtained in 63.5%, almost 6% 
higher than 87a in entry 1, in which the ethan-1-one was used as the starting 
material, while the undesired 90b was about 6% lower the undesired product 87b in 
entry 1.  Besides 3-hydroxy-9H-xanthane-9-one (82) mentioned above, a series of 
substances (80-85) with a fused A ring (Table 3-3, entries 5-10) were treated with 
4,4-dimethoxy-2-methyl-2-butanol under the MW reaction condition. Corresponding 
products and the yields were listed in Table 3-3.   Although the yields of the desired 
products were relatively low relative to the single ring reactants 76-79, they are 
generally workable with much improved yields compared with the conventional 
reaction condition utilizing the same alkylation reagent, by which the yields of the 
desired products 91a, 92a, and 93a are 13.5%, 23.9%, and 4,34%, respectively 
(Table 3-4). Unexpectedly, 91b was not detected under both conditions though the 
yield of 91a was not comparably high. The starting material 80 was mainly recovered.  
The preparation of compound 94a was reported previously by reaction of 1,3-
dihydroxy-xanthen-9-one (83) with 2-chloro-2-methylbutyne.  After a two-step 
reaction, the desired product was received in a considerable low yield of 12.5%.6  
With the MW initiation condition, the yield increased up to near 40%.  A substantial 
mass of b-type product was also obtained (94b, Table 3-3), suggesting that the 3-
hydroxyl group may play a role in assisting the formation of the liner b-type product.  
Substances with methyl substitution at 6 or 7 position (84 and 85) yielded less 
amount of b-products (95b and 96b) relative to 94b, though the yields of the desired 
49 
 
a-products (95a and 96a) gave no significant change comparing to 94a.  The 
synthesis of compound 97a was reported previously, starting with 2-methyl-3-butyn-
2-ol through two or multiple-steps reactions, to have a total yield less than 20% 
(Table 3-4).7, 8 Under the optimized MW condition, we successfully synthesized 97a 
from 1,3-dihydroxy-10-methylacridin-9(10H)-one (86) in an improved yield of 36.2%.  
Table 3-2.  Yileds of compounds 93a and 93b under varied temperature and 
reaction time. 
 Yield of compound 93a (%) Yield of compound 93b (%) 
 4 h 6 h 4 h 6 h 
180 38.4 44.8 2.94 2.14 
200 49.7 --- a 3.62 --- 
220 55.7 --- 4.08 --- 
240 52.6 --- 4.58 --- 
a:  not available 
 
Table 3-3.   Products and yields derived from diverse starting materials under 
the microwave condition (220 oC, 4 hours). 
 
Entry Starting 
Material 
Angular product 
a 
Linear product b Yield 
of a 
Yield 
of b 
1 
 76 
87a
 87b 
57.4 7.32 
2 
 77 
88a 
88b 
66.4 9.54 
3 
 78 
 89a 
 89b 
72.6 N/Aa 
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4 
79 
 90a 
 
90b 
63.5 2.65 
5 
 80 
91a
 91b 
40.3 N/A 
6 
  
81  92a 
 
92b 
31.6 5.47 
7 
 
82  
93a 
 
93b 
55.7 4.08 
8 
 
83 
94a 
 
94b 
38.9 27.2 
9 
 84  
95a 
 95b 
42.6 17.4 
10 
 85  
96a 
 96b 
38.1 7.05 
11 
 
86  97a
 
97b 
36.2 4.33 
a:  not detectable by MS and TLC 
Table 3-4.   Comparisons of  conventional and microwave syntheses. 
Entry / 
Products 
Conventional heating system 
(140 oC/48h for entries 1, 5-7) 
MW condition (220oC/4h) (%) a 
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(%) a 
 Angular 
product a 
Linear product 
b 
Angular product 
a 
Linear 
product b 
1 / 86 38 6.40 57.4 7.32 
5 / 91 13.6 N/A 40.3 N/A 
6 / 92 23.9 2.55 31.6 5.47 
7 / 93 4.34 1.2 55.7 4.08 
8 / 946, b 12.5 6.3 38.9 27.2 
14 / 97 7, c 20% --- d 36.2 4.33 
a alkylation reagent: 2,2-dimethoxy-2-methyl-2-butanol. b 2-chloro-2-methylbutyne, 
two-step reaction. c alkylation reagent: 2-methyl-3-butyn-2-ol, two-step reaction. d not 
available in the reference. 
 
3.3 Discussion and Conclusions: 
        In this research work, we were able to first and successfully utilize microwave 
initiation method to synthesize the desired angular 2,2-dimethyl-2H-chromones, the 
key intermediate of the synthesis of DCP and DCK.   Through alkylation and 
cyclyzation, with an appropriate starting substance and alkylation reagent, a series 
of desired 2,2-dimethyl-2H-chromones related products, 8,8-dimethyl-8H-pyrano[2,3-
f]chromones, 3,3-dimethyl-pyrano[2,3-c]xanthen-7(3H)-ones or other products, such 
as 3,3,12-trimethyl-3H-pyrano[2,3-c]acidin-7(12H)-one were obtained in an one pot 
reaction. Comparing to literature reported methods, the newly developed microwave 
synthesis condition dramatically shortened the reaction time from 2 days to 4 hours 
with much higher to comparable yields. Increasing reaction temperature from 140 to 
220 °C and extending reaction time favor the formation of both a- and b- products 
with a relatively less increasing rate for the undesirable b-product. Although the yield 
of the desired products are still not ideal, in comparison to literature reports with 
conventional heating conditions, the currently optimized MW condition demonstrated 
significant improvement in selectively synthesis of the desired products 2,2-dimethyl-
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2H-chromones, 8,8-dimethyl-8H-pyrano[2,3-f]chromones and other products, such 
as 3,3-dimethyl-pyrano[2,3-c]xanthen-7(3H)-ones. 
        We also analyzed the factors that might affect the yield and regioselectivity in 
this reaction. Electronic effect on B ring influenced significantly on reaction yield as 
well as regioselectivity. With electron-donating groups, such as alkyl groups at 6-
postion of 1-(2,4-dihydroxyphenyl) ethanone could increase the electron density at 
3-position, which consequently enhanced alkylation reactivity. The lone-pair group 
on hydroxyl group introduced at 1-position of xanthenone (Table 3-1, entries 8-10) 
results in higher electron density at 2-position and therefore reduces the 
regioselectivity between a- and b- products. In addition, steric effect of the 
substituents may also play a role in the alkylation and cyclization. Introducing ethyl 
group on 6-position (Compound 6, table 3, entry 3) blocked the alkylation reagent 
occurring at 5 position, which led to the desired product 89a predominately.  
        The significant advancement demonstrated in this study is that, the MW method 
with the optimized condition can be wildly utilized in diverse ring systems, including 
phenoyl, chromone, xanthenone as well as acridinone, which dramatically broadens 
the possibility of further efficiently exploring DCK and DCP analogs as novel anti-HIV 
agents. This work is currently on-going in authors’ labs and the exciting results will 
be reported shortly.   
3.4 Experimental Section 
    The proton nuclear magnetic resonance (1H NMR) spectra were measured on 
a 300 MHz Varian Gemini 2000 spectrometer using TMS as internal standard. The 
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solvent used was CDCl3 unless indicated. Microwave reactions were performed with 
a Biotage initiator EXP US. Mass spectra were measured on Shimadzu LCMS-2010 
(ESI-MS). Biotage Flash and Isco Companion systems were used as medium-
pressure column chromatography. All other chemicals were obtained from Aldrich. 
        General procedure for microwave-assisted synthesis of 2,2-dimethyl-2H-
chromone containing compounds. 
 
        Diverse ethanone,s bi or tri-cycling starting materials (76-86, 1 equiv) , 4,4-
dimethoxy-2-methyl-2-butanol (2.5 equiv) and anhydrous pyridine were added into 
microwave vial and sealed. Pre-stir for 20sec then increase the reaction temperature 
to 220oC for 4 hours under high microwave absorption condition. At completion, the 
reaction mixture was cooled to room temperature, diluted with EtOAc and washed 
with aqueous HCl (10%) and brine, separately. The organic layer was collected and 
the solvent was removed under vacuum. The residue was purified by column 
chromatography (hexane:EtOAc = 97:3) to afford corresponding products.  
        6-Acetyl-2,2-dimethyl-5-hydroxy-2H-chromone (87a). MS (ESI+) m/z (%) 
219 (M+ + 1, 100); 1NMR δ 7.52 (1H, d, J = 8.7 Hz, H-7), 6.72 (1H, d, J = 7.5 Hz, H-
4), 6.33 (1H, d, J = 8.7 Hz, H-8), 6.58 (1H, d, J = 7.5 Hz, H-3), 2.54 (3H, s, COCH3-
1), 1.45 (6H, s, CH3-2,2). 
        1(7-Hydroxy-2,2-dimethyl-2H-chromen-6-yl)ethanone (87b). MS (ESI+) m/z 
(%) 219 (M+ + 1, 100); 1NMR δ 7.31 (1H, s, H-8), 6.33 (1H, s, H-5), 6.28 (1H, d, J = 
9.6 Hz, H-4), 5.58 (1H, d, J = 9.6 Hz), 2.54 (3H, s, COCH3-6), 1.45, 1.44 (each 3H, 
CH3-2,2).  
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        6-Acetyl-2,2,7-trimethyl-5-hydroxy-2H-chromone (88a). mp 56-67 oC; MS 
(ESI+) m/z (%) 233 (M+  + 1, 100); 1NMR δ 6.69 (1H, d, J = 10.2 Hz, H-4), 6.19 (1H, 
s, H-8), 5.52 (1H, d, J = 10.2 Hz, H-3), 3.31 (3H, s, COCH3-1), 2.53 (3H, s, CH3-7), 
1.43 (6H, s, CH3-2,2). 
        1-(7-Hydroxy-2,2,5-trimethyl-2H-chromen-6-yl)ethanone (88b). MS (ESI+) 
m/z (%) 233 (M+  + 1, 100); 1NMR δ 6.54 (1H, d, J = 10.2 Hz, H-4), 6.27 (1H, s, H-8), 
5.66 (1H, d, J = 10.2 Hz, H-3), 2.60 (3H, s, COCH3-6), 2.49 (3H, s, CH3-5), 1.42, 
1.42 (each 3H, s, CH3-2,2). 
        6-Acetyl-2,2-dimethyl-5-hydroxy-7-ethyl-2H-chromone  (89a). MS (ESI+) 
m/z (%) 247 (M+ + 1, 100%); 1H NMR δ 6.70 (1H, d, J = 10.2 Hz, H-4), 6.25 (1H, s, 
H-8), 6.52 (1H, d, J = 10.2 Hz, H-3), 2.86 (2H, q, J = 7.5 Hz, CH2CH3-7), 2.64 (3H, s, 
CH3CO-6), 1.42, 1.41 (each 3H, s, CH3-2,2), 1.26 (3H, t, J = 7.5 Hz, CH2CH3-7). 
        1-(5-Hydroxy-2,2-dimethylo-2H-chromen-6-yl)propan-1-one (90a). MS 
(ESI+) m/z (%); 1H NMR δ 7.56 (1H, d, J = 9.0 Hz, H-7), 6.73 (1H, d, J = 9.6 Hz, H-
4), 6.34 (1H, d, J = 9.0 Hz, H-8), 5.59 (1H, d, J = 9.6 Hz, H-3), 2.94 (2H, q, J = 7.5 
Hz, COCH2CH3-6), 1.45, 1.44 (each 3H, s, CH3-2,2), 1.23 (3H, t, J = 7.5 Hz, 
COCH2CH3-6). 
        2',2'-Dimethyl-pyrano[2,3,f]chromone (91a). MS (ESI+) m/z (%); 1H NMR δ 
7.98 (1H, d, J = 8.7 Hz, H-5), 7.81 (1H, d, J = 6.3 Hz, H-2), 6.85 (1H, d, J = 8.7 Hz, 
H-6), 6.79 (1H, d, J = 10.2 Hz, H-4’), 6.28 (1H, d, J = 6.3 Hz, H-3), 5.72 (1H, d, J = 
10.2 Hz, H-3’), 1.49, 1.49 (each 3H, s, CH3-2’,2’).  
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        Seselin (92a). MS (ESI+) m/z (%); 1H NMR δ 7.60 (1H, d, J = 9.6 Hz, H-4), 
7.21 (1H, d, J = 8.8 Hz, H-5), 6.89 (1H, d, J = 10.0 Hz, H-10), 6.73 (1H, d, J = 8.8 Hz, 
H-6), 6.23 (1H, d, J = 9.6 Hz, H-3), 5.74 (1H, d, J = 10.0 Hz, H-9), 1.48, 1.48 (each 
3H, s, CH3-8,8). 
        8,8-Dimethylpyrano[3,2-g]chromen-2(8H)-one (92b). MS (ESI+) m/z (%); 1H 
NMR δ 7.58 (1H, d, J = 9.2 Hz, H-4), 7.05 (1H, s, H-5), 6.72 (1H, s, H-10), 6.35 (1H, 
d, J = 10.0 Hz, H-6), 6.23 (1H, d, J = 9.2 Hz, H-3), 5.70 (1H, d, J = 10.0 Hz, H-7), 
1.47, 1.47 (each 3H, s, CH3-8,8).  
        3,3-Dimethylpyrano[2,3-c]xanthen-7(3H)-one (93a). MS (ESI+) m/z (%); 1H 
NMR δ 8.34 (1H, dd, J = 8.1, 1.5 Hz, H-8), 8.15 (1H, d, J = 8.7 Hz, H-6), 7.71 (1H, t, 
J = 8.1, 8.1 Hz, H-10), 7.50 (1H, d, J = 8.1 Hz, H-11), 7.38 (1H, t, J = 8.1, 8.1 Hz, H-
9), 7.00 (1H, d, J = 9.9 Hz, H-1), 6.85 (1H, d, J = 8.7 Hz, H-5), 5.76 (1H, d, J = 9.9 
Hz, H-2). 1.53, 1.53 (each 3H, s, CH3-2,2). 
        2,2-Dimethylpyrano[3,2-b]xanthen-6(2H)-one (93b). MS (ESI+) m/z (%); 1H 
NMR δ8.31 (1H, d, J = 8.0 Hz, H-7), 7.94 (1H, s, H-5), 7.68 (1H, t, J = 8.4, 7.2 Hz, H-
9), 7.45 (1H, d, J = 8.4 Hz, H-10), 7.36 (1H, t, J = 8.0, 7.2 Hz, H-8), 6.81 (1H, s, H-
12), 6.47 (1H, d, J = 10.0 Hz, H-4), 5.73 (1H, d, J = 10.0 Hz, H-3), 1.50, 1.50 (each 
3H, s, CH3-2,2).  
        6-Hydroxy-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (94a). MS (ESI+) 
m/z (%) ; 1H NMR δ 12.97 (1H, s, OH-6), 8.26 (1H, dd, J = 8.1, 1.8 Hz, H-8), 7.72 
(1H, t, J = 8.4, 6.9 Hz, H-10), 7.46 (1H, d, J = 8.4 Hz, H-11), 7.38 (1H, t, J = 6.9, 8.1 
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Hz, H-9), 6.85 (1H, d, J = 9.9 Hz, H-1), 6.27 (1H, s, H-5), 5.63 (1H, d, J = 9.9 Hz, H-
2), 1.49, 1.49 (each 3H, s, CH3-2,2). 
        5-Hydroxy-2,2-dimethylpyrano[3,2-b]xanthen-6(2H)-one (94b). MS (ESI+) 
m/z (%) ; 1H NMR δ 13.17 (1H, s, OH-5), 8.24 (1H, dd, J = 7.8, 1.5 Hz, H-7), 7.70 
(1H, t, J = 8.4, 7.8 Hz, H-9), 7.44 (1H, d, J = 8.4 Hz, H-10), 7.37 (1H, t, J = 7.8,7.8 
Hz, H-8), 6.75 (1H, d, J = 10.2 Hz, H-4), 6.36 (1H, s, H-12), 5.62 (1H, d, J = 10.2 Hz, 
H-3), 1.49, 1.49 (each 3H, s, CH3-2,2). 
        6-Hydroxy-3,3,9-trimethylpyrano[2,3-c]xanthen-7(3H)-one (95a). MS (ESI+) 
m/z (%); 1H NMR δ 13.0 (1H, s, OH-6), 8.02 (1H, d, J = 2.7 Hz, H-8), 7.53 (1H, dd, J 
= 8.4, 2.7 Hz, H-10), 7.37 (1H, d, J = 8.4 Hz, H-11), 6.84 (1H, d, J = 9.9 Hz, H-1), 
6.26 (1H, s, H-5), 5.61 (1H, d, J = 9.9 Hz), 2.47 (3H, s, CH3-9), 1.56, 1.49 (each 3H,  
s, CH3-2,2).  
        5-Hydroxy-2,2,8-trimethylpyrano[3,2-b]xanthen-6(2H)-one (95b). MS (ESI+) 
m/z (%); 1H NMR δ 13.23 (1H, s, OH-5), 8.01 (1H, d, J = 2.4 Hz, H-7), 7.51 (1H, dd, 
J = 8.7, 2.4 Hz, H-9), 7.33 (1H, d, J = 8.7 Hz, H-10), 6.75 (1H, d, J = 9.9 Hz, H-4), 
6.34 (1H, s, H-12), 5.61 (1H, d, J = 9.9 Hz, H-3), 2.46 (3H, s, CH3-8), 1.56, 1.48 
(each 3H, s, CH3-2,2). 
        6-Hydroxy-3,3,10-trimethylpyrano[2,3-c]xanthen-7(3H)-one (96a). MS (ESI+) 
m/z (%); 1H NMR δ 13.02 (1H, s, OH-5), 8.10 (1H, d, J = 8.7 Hz, H-8), 7.24 (1H, s, 
H-11), 7.15 (1H, d, J = 8.7 Hz, H-9), 6.82 (1H, d, J = 9.9 Hz, H-1), 6.25 (1H, s, H-5), 
5.61 (1H, d, J = 9.9 Hz, H-2), 2.50 (3H, s, CH3-10), 1.49, 1.49 (each 3H, s, CH3-2,2). 
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        5-Hydroxy-2,2,9-trimethylpyrano[3,2-b]xanthen-6(2H)-one (96b). MS (ESI+) 
m/z (%); 1H NMR δ 13.23 (1H, s, OH-5), 8.10 (1H, d, J = 8.1 Hz, H-7), 7.21 (1H, s, 
H-10), 7.18 (1H, d, J = 8.1 Hz, H-8), 6.74 (1H, d, J =10.2 Hz, H-4), 6.33 (1H, s, H-12), 
5.61 (1H, d, J = 10.2 Hz, H-3), 2.49 (3H, s, CH3-9), 1.48, 1.48 (each 3H, s, CH3-2,2). 
        6-Hydroxy-3,3,12-trimethyl-3H-pyrano[2,3-c]acridin-7(12H)-one (97a). MS 
(ESI+) m/z (%);1H NMR δ 13.14 (1H, s, OH-6), 8.47 (1H, d, J = 7.8 Hz, H-8), 7.72 
(1H, t, J = 8.4, 4.2 Hz, H-10), 7.49 (1H, d, J = 8.4 Hz, H-11), 7.30 (1H, t, J = 7.8, 4.2 
Hz, H-9), 6.81 (1H, d, J = 9.9 Hz, H-1), 6.32 (1H, s, H-5), 5.60 (1H, d, J =9.9 Hz, H-
2), 3.80 (3H, s, CH3-12), 1.49, 1.49 (each 3H, s, CH3-2,2). 
        5-Hydroxy-2,2,11-trimethyl-2H-pyrano[3,2-b]acridin-6(11H)-one (97b). MS 
(ESI+) m/z (%);1H NMR δ 13.20 (1H, s, OH-5), 8.34 (1H, d, J = 8.4 Hz, H-7), 7.68 
(1H, t, J = 8.4, 4.2 Hz, H-9), 7.40 (1H, d, J = 8.4 Hz, H-10), 7.27 (1H, t, J = 8.4, 4.2 
Hz, H-8), 6.53 (1H, d, J = 9.6 Hz, H-4), 6.23 (1H, s, H-12), 5.47 (1H, d, J = 9.6 Hz, 
H-3), 3.87 (3H, s, CH3-11), 1.49, 1.49 (each 3H, s, CH3-2,2). 
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CHAPTER 4 
 DESIGN, SYNTHESIS, MOLECULAR MODELING AND STRUCTURE-ACTIVITY 
RELATIONSHIP OF NOVEL DICAMPHANOYL-2’,2’-
DIMETHYLDIHYDROPYRANOCHROMONE (DCP) ANALOGS AS POTENT ANTI-
HIV AGENTS 
 
Copyright © 2010 Elsevier Ltd. Bioorg. Med. Chem. 2010, 18, 6678-6689. 
4.1 Introduction  
        As introduced in Chapter 2, over 30 formulations have been approved by the 
US FDA to treat AIDS, however, drug resistance problems have dramatically 
reduced the efficacy of these current anti-HIV agents.1  Therefore, research to find 
new anti-HIV agents with either higher potency or novel mechanisms has attracted 
great attention to overcome this problem. 2 
        In our prior studies, DCK (18) and 4-MDCK, (26) showed high potency against 
HIV-1IIIB replication in H9 lymphocytes. The EC50 and therapeutic index (TI) values 
were reported as 0.049 µM and 328 for DCK, and, 0.0059 µM and 6660 for 4-MDCK, 
respectively (Figure 4-1).3, 4  More specifically, preliminary mechanism of action-
related studies indicated that 4-MDCK inhibited the activity of HIV-RT through 
inhibition of DNA-dependent DNA polymerase activity, in contrast to currently 
available NNRTIs that block HIV-RT by inhibiting RNA-dependent DNA 
polymerization.5 However, DCK had reduced activity against the multi-RT inhibitor 
resistant (RTMDR-1) strain. In the course of our continuing exploration of DCK 
analogs as potent anti-HIV agents, 4H-chrom-4-one derivatives (DCPs) were 
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designed and synthesized as DCK positional isomers (Figure 1).6, 7 Compared with 
DCKs, DCP analogs not only retained high activity against wild-type HIV, but also 
showed potency against HIV/RTMDR-1.7 Among the previously reported DCP 
derivatives, 2-EDCP (69) exhibited the best anti-HIV activity against both wild-type 
and drug-resistant strains with EC50 values of 0.070 and 0.11 µM and TI values of 94 
and 60, respectively. The uniqueness of DCP analogs opens a new avenue for us to 
discover a distinct class of potent, effective anti-HIV drugs for AIDS therapy.   
        The structure-activity relationship (SAR) information provided from our previous 
study on the DCP series led to the following conclusions. Steric effects of 
substitutions on position-2, -3, and -6 of the chromone system could influence the 
anti-HIV activity. Bulky substituents at position-3 or -6 dramatically reduced anti-HIV 
activity. In addition, appropriate alkyl substitution at position-2 was crucial to 
maintain high activity against both wild-type and multi-RT inhibitor-resistant strains. 
2-EDCP (69), with an ethyl group at position-2 of the chromone ring, exhibited the 
most potent activity against both virus strains.  
        However, the preliminary SAR information on DCPs was not extensive enough 
to establish a feasible pharmacological profile. Except for the steric effect, prior data 
could not illustrate how other factors such as electronic and hydrogen-bond effects 
might influence activity. In addition, all active DCP analogs synthesized had poor 
water-solubility. Therefore, additional DCP analogs with varying substituents, 
particularly different from the prior analogs, are needed in the search for an optimal 
anti-HIV-1 drug candidate from this compound class. 
 
 
61 
 
 
        In our present study, DCP analogs with different structural functionalities on the 
pyranochromone have been synthesized towards this aim. We first designed and 
synthesized several 5-alkyl-substituted DCPs to explore the steric effect at position-5, 
which was not a major focus in prior studies. Then, we introduced combinations of 
diverse functional groups at position-2, -3, -5 and -6, including halogen, cyano, and 
amino groups, to explore electronic and hydrogen-bonding effects. Furthermore, we 
introduced hydrophilic heterocyclic amine moieties at position-2 to generate 
compounds with better water solubility. All newly synthesized DCPs were evaluated 
for their activity against both wild-type and RTMDR-1 strains. Two of the active and 
more polar compounds, 98 and 115, were selected for water solubility analysis in 
comparison with the active lead compound 69. 
         A quantitative structure-activity relationship (QSAR) molecular modeling study 
was also performed in this research using Partial Least Square (PLS) method with 
QSAR-Model module of MOE 2009 to systematically study the structure-anti-HIV-
activity relationships of DCP-class compounds. With this study, we aimed not only to 
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establish a pharmacological profile of DCPs, but also to study the DCP 
pharmacophores that play an important role in anti-HIV activity. 
    In this paper, we report and discuss the chemistry and synthesis of the newly 
synthesized DCP analogs, the results of anti-HIV activity evaluation, water solubility 
analysis, QSAR-model and pharmacophore studies, as well as structure-anti-HIV 
activity relationship conclusions resulting from the studies. 
4.2 Results and Discussion 
4.2.1 Chemistry 
        Scheme 4-1 illustrates the synthesis of 6-methyl- and 6-ethyl-2,4-
dihydroxyphenyl ethanones (77-78, respectively). Compounds 122b (commercially 
available) and 122c [synthesized by reduction of 3′,5′-dihydroxyacetophenone (121)] 
were acylated through a Friedel-Crafts reaction in the presence of the Lewis acid 
ZnCl2 to afford 77 and 78, respectively (Scheme 4-1).8, 9, 10 
 
        The synthesis of 2,3,5-alkyl substituted DCP analogs is shown in Scheme 4-2. 
Commercially available 1-(2,4-dihydroxyphenyl)ethanone (76) and the synthesized 
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77, 78 were converted to 87a-89a by alkylation with 4,4-dimethoxy-2-methyl-2-
butanol in pyridine. This reaction was conducted using the modified microwave-
assisted method described in chapter 3 by reaction of ethanone and butanol in a 
microwave initiator at 220 °C for 4 h.11 Compounds 66, 68-69, 98, and 102-103 were 
synthesized following literature procedures.7 Briefly, reaction of pyrano-ring-closure 
products with diverse ethyl alkanoates in the presence of NaH followed by hydrolysis 
with Amberlyst 15 resin in isopropanol afforded the chromone ring closure products 
(125a–e). 2',2'-Dimethyl-3-methylpyaranochrmone (125f) was synthesized from 
propiophenone (123) in two steps. Commercially available 123 was treated with 
methanesulfonyl chloride in dry DMF to afford 7-hydroxy-3-methyl-chromone (124).12 
Compound 124 was converted to the corresponding pyranochromone (125f) by 
alkylation with 4,4-dimethoxy-2-methyl-2-butanol in pyridine under microwave 
conditions. The asymmetric dihydroxylation of 125a-f was accomplished using a 
catalytic Sharpless asymmetric dihydroxylation,13,14 in which K2OsO2(OH)4 served as 
catalyst and (DHQ)2PYR as chiral auxiliary.14,15 After drying in vacuo overnight, the 
diols (126a-f) were reacted with excess (S)-camphanoyl chloride in anhydrous 
dichloromethane in the presence of excess DMAP at room temperature for 2 h to 
afford the target compounds 66, 68-69, 98 and 102-103. 
        Scheme 4-3 illustrates the synthesis of novel DCP analogs with various 
functional groups at position-2. The synthesis of 104 and 105 was accomplished by 
benzylic bromination with NBS in anhydrous carbon tetrachloride in the presence of 
3-chloroperbenzoic acid (MCPBA) as a radical initiator. Dibromo-substituted DCP 
analog (106) was also obtained during the reaction as previously reported.16 
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Compound 104 was treated with KCN under mild condition in DMF to give 108.17 
Reaction of 104 with appropriate amine groups in THF at room temperature afforded 
compounds 109 and 118-120.18  
        The synthesis of novel DCP analogs 110-117 with 3-substitutions is shown in 
Scheme 4-4. Selective bromination of 68 or 69 in acetonitrile gave 110 or 111, 
respectively.19 Compound 111 was subsequently converted to 113 in the presence 
of KCN in a mixture of DMF and 95% aq EtOH.17 Reaction of 110 or 111 with 33% 
aqueous ammonium solution or methylamine at room temperature gave 114-117.18 
Compound 368 was treated with I2 in the presence of CF3CO2Ag as catalyst to 
obtain 112 in almost quantitative yield.20 
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        The synthesis of 2-cyano-3-methyl-DCP (107) is given in Scheme 4-5. Stirring 
66 with NBS in acetonitrile and heating to reflux gave 127, which was further reacted 
with NaCN to give 107, with a cyano substituent at position-2,17 rather than 
displacement of bromide to give 107a. The postulated Michael addition-elimination 
mechanism is illustrated in Scheme 4-6. Tautomerization of intermediate 128 
regains resonance stabilization and produces compound 107.   
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        The synthesis of 99-101 is shown in Scheme 4-7. Different solvents were used 
as mentioned above to selectively generate 99 and 101.16, 19 Compound 100 was 
obtained by using excess NBS.  
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4.2.2 Biological Evaluation  
        All newly synthesized DCP analogs (98 – 120) were evaluated for anti-HIV 
activity against both HIV-1/NL4-3 and HIV-1/RTMDR1 in a single cycle infection 
assay using TZM-bl cells. The data are given in Table 4-1.   
        Compounds 98-103 are novel DCP analogs with short groups at both positions-
2 and -5. Compounds 98, 102, and 103 with methyl and ethyl substituents at these 
positions exhibited promising anti-HIV activity against the non-drug-resistant strain 
HIV-1NL4-3. They also showed comparable or greater TI values compared with both 
positive DCP reference standards 69 and 68. Compound 98 (2-CH3, 5-CH3) had the 
highest potency (EC50 0.036 µM, TI 420) among these six compounds, and was two 
times and 3 times more potent than 69 and 68 (69: EC50 0.07 µM, TI 94; 68: 0.10 µM, 
TI 110). However, changing the 5-CH3 in 98 to 5-CH2Br in 101 was unfavorable to 
anti-HIV activity and also decreased the TI value (101: 0.81 µM, TI 11). Likewise, 
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adding bromine at position-3 (99) or position-3 and -6 (100) led to decreased 
potency and TI. 
        Compounds 104-109 and 118-120 are novel 2-substituted DCPs. Similarly to 
101, bromination of the alkyl group at position-2 (104-106) was unfavorable to anti-
HIV activity. The potency of 105 with bromoethyl substitution (EC50 0.46 µM, TI 7.6) 
was six times lower than that of 69; while 106 with dibromoethyl substitution, 
exhibited only mild potency (EC50 1.0 µM, TI 1.8). Compound 107 with a cyano 
group at position-2 (EC50 0.14 µM, TI 290) exhibited comparable anti-HIV activity 
and lower cytotoxicity compared with 68 and 69. However, the anti-HIV activity of 
108 with a cyanomethyl group at position 2 decreased significantly. With EC50 of 1.8 
µM, 108 was ten times less potent than 107, suggesting that a slight variation in the 
substitution at position-2 may result in a significant change in anti-HIV activity. It is 
postulated that expanding the conjugation of the chromone core structure by adding 
a cyano group at position-2 might contribute to high activity. Compound 109, with 2-
CH2NHCH3 substitution, also showed considerable anti-HIV activity (EC50 0.29 µM, 
TI >100). These results suggest that analogs with polar groups, such as cyano and 
amino, introduced appropriately at position-2, can maintain anti-HIV activity. In 
addition, these groups should increase the compounds’ polarity, which may improve 
water solubility. However, 118–120 contain large hydrophilic moieties at position-2, 
and showed either very weak (118 and 119) or no (120) activity.   
        Compounds 110-117 are novel 3-substitued DCPs. Introduction of halogens 
such as bromine (110, 111) and iodine (112) at position-3 reduced anti-HIV activity 
and TI. Compounds 110 (3-Br. EC50 0.55 µM, TI 14) and 112 (3-I. EC50 0.73 µM, TI 
 
 
71 
 
18) were five and seven times less potent, respectively, than the corresponding non-
brominated 68 (EC50 0.10 µM, TI 110). 3-Cyano-2-ethyl-DCP (113) showed 
moderate activity (EC50 0.55 µM, TI >54), and analogs with NH2 and NHCH3 
substituents at position-3 (114-117) maintained good anti-HIV activity. With a low 
EC50 value of 0.12 µM, 115 (3-NH2) was equipotent with 69 (3-H) and three times 
more potent than 117 (3-NHCH3). The 3-NH2 analogs (114, 115) showed 
comparable or greater potency and TI values than corresponding 3-NHCH3 analogs 
(116, 117).  
        In summary, the influence of position-2 and -3 substituents on anti-HIV activity 
was generally equivalent. Electronic and hydrogen-bonding effects from halogen, 
cyano, and amino groups at these positions could influence both anti-HIV activity 
and TI. Halogens were not favorable and led to decreased anti-HIV potency and 
lower TI, while amino moieties resulted in both potent anti-HIV activity and high TI 
values. Analogs with a cyano substituent, particularly at position-2, maintained good 
anti-HIV-1 activity. In addition, the extended conjugation of the chromone ring 
system might be important to the high-potency, and led to the potency difference of 
107 and 108. Anti-HIV-1 activity was quite sensitive to the substituent size at 
position-2, and large moieties were not tolerable. Functional groups at position-5 of 
the chromone ring are also important for potent anti-HIV activity. Addition of a methyl 
group at this position led to increased anti-HIV activity, as exemplified by 98 and 102. 
2,5-Dimethyl DCP (98) had the highest TI values against both wild-type and drug-
resistant HIV. 
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Table 4-1. 
Anti-HIV activity of DCP analogs 98 – 120a 
 
 R2 R3 R5 R6
IC50 
(µM
) b 
NL 4-3 HIV-1 RTMDR1 
EC5
0 
(µM)
TI EC50 (µM) TI 
98 CH3 H CH3 H 15 
0.03
6 420 0.049 310 
99 CH3 Br CH3 H >14 0.59 >24 0.91 >15 
100 CH3 Br CH3 Br >12 10 >1.2 >12 1 
101 CH3 H CH2Br H 8.9 0.81 11 1.2 7.4 
102 CH2CH3 H CH3 H 11 0.10 110 0.054 200 
103 CH2CH3 H CH2CH3 H >30 0.25 >120 0.34 >88 
104 CH2Br H H H 1.7 0.55 3.0 0.56 3.0 
105 CHBrCH3 H H H 3.5 0.46 7.6 0.24 15 
106 C(Br)2CH3 H H H 1.8 1.0 1.8 0.45 4.0 
107 CN CH3 H H 40 0.14 290 1.9 21 
108 CH2CN H H H 17 1.8 9.4 1.4 12 
109 CH2NHCH3 H H H >30 0.29 >100 0.69 >43 
110 CH3 Br H H 7.7 0.55 14 0.57 14 
111 CH2CH3 Br H H >27 1.1 >24 0.99 >28 
112 CH3 I H H 13 0.73 18 1.6 8.0 
113 CH2CH3 CN H H >30 0.55 >54 0.79 >37 
114 CH3 NH2 H H 32 0.25 130 0.47 68 
115 CH2CH3 NH2 H H 23 0.12 190 0.31 74 
116 CH3 NHCH3 H H >60 0.30 >200 0.45 
>13
0 
117 CH2CH3 NHCH3 H H 32 0.44 73 1.1 29 
118  H H H >28 2.0 >14 4.4 >6.3
119 
 
H H H 17 3.7 4.5 7.5 2.2 
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120  H H H >27 21 >1.3 21 >1.3
68  CH3 H H H 11 0.10 110 0.19 58 
69 CH2CH3 H H H 6.6 0.07 94 0.11 60 
a All data presented in this table were averaged from at least three independent 
experiments. b Cytotoxicity was determined using a Promega CytoTox-GloTM assay 
kit.     
 
        Most of the new DCP analogs were active against HIV RTMDR-1 strain, but 
were approximately two to three times less potent than against wild-type virus. 
Compounds 98 and 102 showed the most promising activity against HIV-1RTMDR-1 
with EC50 values of 0.049 and 0.054 µM and TI values of 310 and 200, respectively. 
These two compounds were approximately two-fold more potent than 69 against 
drug-resistant virus. Thus, the functional group at position-5 of the chromone ring is 
critical for potent activity against the drug-resistant strain. Halogen-substituted DCPs 
(99-101, 104-106, 110-112) showed reduced anti-HIV activity against HIV RTMDR-1 
when compared with 68 and 69. Among the halogen-substituted DCPs, 105 showed 
the best activity with EC50 of 0.24 µM. Amino-substituted DCP analogs (109, 114-
117) showed considerable activity against wild-type HIV-1Nl4-3, but reduced activity 
against the drug-resistant strain. The EC50 values of 109 and 115 against HIV-
1RTMDR-1 were 0.69 and 0.31 µM, respectively, which are approximately three times 
higher than EC50 against wild-type virus (0.29 µM and 0.12 µM). The SAR analysis 
of the synthesized DCP derivatives against the drug-resistant strain is similar to that 
for the wild-type virus. 
4.2.3 Water Solubility (WS) Analysis 
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        Because prior active DCP analogs showed poor water solubility, we were 
interested in improving this molecular parameter. We selected two active 
compounds from the preliminary SAR work for further analysis: 98, which had the 
best anti-HIV activity against both virus strains, and 115, which contains a 
hydrophilic amine group and maintains high anti-HIV activity against wild-type virus 
(Table 4-1). Both compounds showed lower predicted log P values than 2-EDCP (69) 
(Table 4-2), indicative of increased polarity that may improve the water solubility. We 
then performed a WS analysis with 98 and 115, in comparison to 69. We first 
established a standard curve of each tested compound by dissolution of the 
compound in acetonitrile at room temperature at various concentrations. The 
solubility in water could be determined by HPLC through the correlation between the 
saturated concentration of each compound in water and the correlating area 
detected by HPLC. With a solubility value less than 0.9 mg/L, 2-EDCP (69) showed 
the lowest WS among the three compounds. Compound 98 had an improved WS 
value (5.2 mg/L), and compound 115 presented the best WS value of 10.3 mg/L. 
(Table 4-2) This latter result confirmed that increasing the polarity of DCP analogs 
by introducing polar functional groups could result in improved water solubility. While 
both compounds 98 and 115 showed better WS than 2-EDCP (69), 98 also showed 
more potent anti-HIV activity than 69, and thus, could merit further development 
study as a drug candidate. 
Table 4-2. Log P values and water solubility results of 69, 98 and 115. 
Compound Predicted Log P 
value a 
Water solubility (mg/L) 
98 3.85 5.2 
115 2.88 10.3 
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69 (2-EDCP) 4.01 <0.9 
                    a calculated using ACD program 
4.2.4 Molecular Modeling 
4.2.4.1. Partial Least Square (PLS) QSAR  
        The PLS QSAR method was employed in the study using the QSAR-Model 
module of MOE 2009.21 This method is relatively less sophisticated among those 
traditional available QSAR approaches. It was explored here to test if reliable 
models could be built for underlying data sets. A set of 2,489 theoretical molecular 
descriptors used in this calculation was computed using the software Dragon v.5.5.22 
The number of components was set to no limit on the degree of the fit. The 
maximum condition number of the principal component transform of the correlation 
matrix S, the condition limit, was set to be a very large number of 1.0*106. 
    We used the structures of the 25 DCP analogs listed in Table 4-1 and their anti-
HIV activities (EC50 in µM) against both NL4-3 and RTMDR1 HIV strains to establish 
PLS models in the present study. The activity of each compound was transformed to 
the commonly used logarithm format and the log(1/EC50) ranged from -1.31 to 1.44 
for the activity against NL4-3 HIV and from -1.31 to 1.31 for the activity against 
RTMDR1 HIV. The leave-one-out cross validation scheme was used to test the 
reliability and robustness of the resulting models. One of the 25 compounds was 
excluded, and a PLS model was developed for the remaining 24 compounds. Then 
the model was used to predict the anti-HIV activity of the excluded compound. This 
procedure was repeated 25 times for each type of activity until each compound was 
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used as the external test compound. From the leave-one-out cross validation 
procedure for the PLS model, the correlation coefficients (R2) / mean absolute errors 
(MAE) for the wild type and drug resistant HIV strains were 0.67 / 0.30 (Figure 4-2a) 
and 0.60 / 0.35, respectively (Figure 4-2b). Compounds 118, 119, and 120 had 
relatively larger MAE than the remaining compounds, and compound 119 was a 
common outlier in both models. A probable reason is that these compounds have 
dissimilar R2 substituents compared with the rest of the dataset. The R2 and MAE 
values obtained from both models indicated that the newly established models can 
reliably be used to screen external chemical libraries in future studies.  
   
4.2.4.2. Pharmacophore Analysis 
    To explore DCP pharmacophores, the chemical structures of the three most 
potent compounds (69, 98, and 102) and the three weakest compounds (100, 119 
and 120) were energy minimized and superimposed using the Flexible Alignment of 
MOE 2009. Then the pharmacophore analysis was performed using the 
     (a)                                                             (b) 
         
Figure 4-2. The correlation between experimental and predicted EC50 values 
obtained from leave one out cross validation for (a) NL4-3 HIV strain and (b) 
RTMDR1 HIV strain. 
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Pharmacophore Query. The results are shown in Figures 4-3. The yellow balls 
shown in Figure 4-3 represent the identified pharmacophore. In both sets of 
compounds, the planar chromone ring, carbonyl group at position-4, and the oxygen 
at position-1′ were identified as part of the corresponding pharmacophore. However, 
in the most potent compounds (Figure 3a), the carbonyl group of the 4’-camphanoyl 
ester, which represents a hydrogen bond acceptor, was identified as a unique 
pharmacophore. In the three weakest compounds (Figure 3b), the orientation of both 
camphanoyl groups varied dramatically due to the introduction of bulky substitutions 
at position-2, which suggested that the orientations of the 3′- and 4′-camphanoyl 
groups might be critical for maintaining high anti-HIV activity. 
 
4.3 Conclusions 
(a)                                                                (b) 
 
Figure 4-3. The pharamacophore analysis of the 3 most active compounds (a) and 
3 most inactive compounds (b) using MOE 2009. The default setting was used 
except the tolerance (neighbor distance) and consensus score threshold 
(percentage of the compounds containing the pharmacophore) were changed to 0.5 
and 100% respectively. Atom coloring: gray, carbon; blue, nitrogen; red, oxygen. 
Pharmacophore schemes: purple, hydrogen bond donor; light blue, hydrogen bond 
acceptor; yellow, aromatic center.  
 
 
78 
 
    Our study identified a series of new DCP analogs with high anti-HIV potency 
against both wild-type and drug-resistant HIV-1 strains. The following SAR 
conclusions were drawn from these results.  
(1)  Position-5 of the DCP chromone ring system is critical for anti-HIV activity 
against both wild-type and drug-resistant HIV-1 strains, and appropriate alkyl 
groups on this position can improve anti-HIV activity against both virus strains.  
(2)  Electronic and hydrogen-bonding effects at position-2 and -3 can influence the 
anti-HIV activity as well as therapeutic index.  
(3) The orientations of the 3′- and 4′-camphanoyl groups are critical to maintain 
high anti-HIV activity against both virus strain, and the carbonyl group in the 4′ 
position camphanoyl ester was identified as a potential hydrogen-bond 
acceptor by pharmacophore analysis.  
        We also analyzed the water solubility of selected newly synthesized DCP 
analogs and confirmed that increasing polarity can dramatically improve the water-
solubility of DCP analogs.  
        In addition, we successfully established reliable PLS QSAR models. These 
models should help to predict the EC50 values of newly designed DCP analogs, 
which may be a useful tool for design of future new DCP analogs.  
4.4 Experimental section 
4. 4.1. Chemistry 
            Melting points were measured with a Fisher Johns melting apparatus without 
correction. The proton nuclear magnetic resonance (1H NMR) spectra were 
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measured on a 300MHz Varian Gemini 2000 spectrometer using TMS as internal 
standard. The solvent used was CDCl3 unless indicated. Microwave reactions were 
performed with a Biotage initiator EXP US. Mass spectra were measured on 
Shimadzu LCMS-2010 (ESI-MS). Optical rotation was measured with a Jasco Dip-
2000 digital polarimeter at 20oC at the sodium D line. Thin-layer chromatography 
(TLC) was performed on PLC silica gel 60 F254 plates (0.5mm, Merck). Biotage Flash 
and Isco Companion systems were used as medium-pressure column 
chromatography. Shimadzu LC-20AT prominence liquid chromatography was used 
as HPLC system. Alltima 2.1mm x 100 mm C18 3u was used as HPLC column. 
Silica gel (200-400 mesh) from Aldrich, Inc. was used for column chromatography. 
All other chemicals were obtained from Aldrich, Inc. All final compounds are >95% 
pure on the basis of the two HPLC conditions. 
        5-ethylbenzene-1,3-diol (122c). A reaction mixture of 2 g (13.1 mmol) of 3′,5′-
dihydroxyacetophenone (121), 1 g of Pd/C (10%) and 150 mL aqueous HCl (4%) 
was hydrogenated overnight (900 mL of H2). The mixture was filtered and extracted 
with three portions of Et2O. The dried solution was evaporated at reduced pressure. 
The residue was purified by column chromatography with hexanes:EtOAc = 10:1 to 
afford 122c as a white solid. 80% yield; MS (ESI+) m/z (%) 137 (M+ + 1, 100); 1H 
NMR δ 6.26 (2H, s, H-4, 6), 6.18 (1H, s, H-2), 4.90 (2H, br, OH-1, 3), 2.53(2H, q, J = 
7.5 Hz, CH2CH3-5), 1.20 (3H. t, J = 7.5 Hz, CH2CH3-5). 
        1-(2,4-dihydroxy-6-methylphenyl)ethanone (77). MeCN (0.7 mL, 20 mmol) 
and dry ZnCl2 (1.36 g, 10 mmol) were added to a solution of 3,5-dihydroxytoluene 
122b (1.24 g, 10 mmol) in Et2O (5 mL). Hydrogen chloride gas was then bubbled 
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through the mixture, and the resulting precipitate was filtered off and dissolved in 
water. This solution was neutralized by adding aqueous ammonia solution (33%) 
and was subsequently stirred for 30 min at 100 oC. The crude product was purified 
by column chromatography with hexanes:EtOAc = 7:3 to afford 77 (680 mg). 41% 
yield; MS (ESI-) m/z (%) 165 (M- - 1, 100); 1NMR δ 6.24 (1H, s, H-5), 6.23 (1H, s, H-
3), 5.44 (2H, br, OH-2, 4), 2.62 (3H, s, COCH3-1), 2.55 (3H, s, CH3-6). 
        1-(2,4-dihydroxy-6-ethylphenyl)ethanone (78). The procedure was identical 
to that used for the preparation of 77. 40% yield (starting with 2.36 g of 122c); MS 
(ESI+) m/z (%) 181 (M+ + 1, 100); 1NMR δ 6.28 (1H, s, H-5), 6.19 (1H, s, H-3), 4.85 
(2H, br, OH-2, 4), 2.91 (2H, q, J = 7.2 Hz, CH2CH3-6), 2.67 (1H, s, COCH3-1), 1.30 
(3H, t, J = 7.2 Hz, CH2CH3-6).  
        General procedure for the preparation of 87a-89a and 125f. A mixture of 
starting compound 76, 77or 78 (1 equiv) or 124, 4,4-dimethoxy-2-methyl-2-butanol 
(1.5-2 equiv) and pyridine (2-3 mL) was heated at 220 °C for 4 h under high 
absorption microwave conditions. The reaction mixture was cooled to rt, diluted with 
EtOAc and washed with aqueous HCl (10%) and brine. The organic layer was 
separated, and solvent was removed in vacuo. The residue was purified by column 
chromatography with hexanes:EtOAc = 97:3 to afford 87a-89a and 125f. 
        6-Acetyl-2,2-dimethyl-5-hydroxy-2H-chromone (87a). 57.3 % yield (starting 
with 1 g of 76); MS (ESI+) m/z (%) 219 (M+ + 1, 100); 1NMR δ 7.52 (1H, d, J = 8.7 Hz, 
H-7), 6.72 (1H, d, J = 7.5 Hz, H-4), 6.33 (1H, d, J = 8.7 Hz, H-8), 6.58 (1H, d, J = 7.5 
Hz, H-3), 2.54 (3H, s, COCH3-1), 1.45 (6H, s, CH3-2,2). 
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        6-Acetyl-2,2,7-trimethyl-5-hydroxy-2H-chromone (88a). 66.4% yield (starting 
with 77.2 mg of 77); mp 56-67 oC; MS (ESI+) m/z (%) 233 (M+  + 1, 100); 1NMR δ 
6.69 (1H, d, J = 10.2 Hz, H-4), 6.19 (1H, s, H-8), 5.52 (1H, d, J = 10.2 Hz, H-3), 3.31 
(3H, s, COCH3-1), 2.53 (3H, s, CH3-7), 1.43 (6H, s, CH3-2,2). 
        6-Acetyl-2,2-dimethyl-5-hydroxy-7-ethyl-2H-chromone  (89a). 72.4% yield 
(starting with 500 mg of 78); MS (ESI+) m/z (%) 247 (M+ + 1, 100%); 1H NMR δ 6.70 
(1H, d, J = 10.2 Hz, H-4), 6.25 (1H, s, H-8), 6.52 (1H, d, J = 10.2 Hz, H-3), 2.86 (2H, 
q, J = 7.5 Hz, CH2CH3-7), 2.64 (3H, s, CH3CO-6), 1.42, 1.41 (each 3H, s, CH3-2,2), 
1.26 (3H, t, J = 7.5 Hz, CH2CH3-7). 
        2',2',3-Trimethyl-pyrano[2,3,f]-chromone (125f). 60% yield (starting with 120 
mg of 124); mp 66-67 oC; MS (ESI+) m/z (%) 243 (M+ + 1, 100); 1H NMR δ 7.98 (1H, 
d, J = 8.7 Hz, H-5), 7.73 (1H, s, H-2), 6.81 (1H, d, J = 8.7 Hz, H-6), 6.76 (1H, d, J = 
9.9 Hz, H-4’), 5.67 (1H, d, J = 9.9 Hz, H-3’), 2.00 (3H, s, CH3-3),  1.48 (6H, s, CH3-
2’,2’). 
        General procedure for the preparation of 125a-e. A mixture of 87a, 88a or 
89a and ethyl alkanoate in absolute THF was added slowly to a sodium hydride/THF 
suspension under nitrogen. The mixture was warmed to reflux temperature for 2-6 h 
monitored by TLC, followed by neutralization with 10% aqueous HCl, and extraction 
three times with CH2Cl2. The organic layer was collected and the solvent evaporated 
under reduced pressure. The residue and Amberlyst 15 resin were stirred in 
isopropanol at reflux temperature to give 2-substituted dimethylpranochromone 
125a-e.  
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        2,2',2'-Trimethyl-pyrano[2,3,f]-chromone (125a). 56 % yield (starting with 
558.2 mg of 87a); mp 123-125 oC; MS (ESI+) m/z (%) 243 (M+ + 1, 100); 1H NMR δ 
7.92 (1H, d, J = 8.7 Hz, H-5), 6.80 (1H, d, J = 8.7 Hz, H-6), 6.78 (1H, d, J = 9.9 Hz, 
H-4’), 6.09 (1H, s, H-3), 5.68 (1H, d, J = 9.9 Hz, H-3’), 2.36 (3H, s, CH3-2),  1.48 (6H, 
s, CH3-2’,2’).  
        2,2',2'-Trimethyl-5-methylpyrano[2,3,f]-chromone (125b). 38 % yield 
(starting with 770 mg of 88a); mp 128 130 oC; MS (ESI+) m/z (%) 257 (M+ + 1, 100); 
1H NMR δ 6.74 (1H, d, J = 9.9 Hz, H-4’), 6.56 (1H, s, H-6), 6.00 (1H, s H-3), 5.64 
(1H, d, J = 9.9 Hz, H-3’), 2.76 (3H, s, CH3-5), 2.31 (3H, s, CH3-2), 1.46 (6H, s, CH3-
2’,2’). 
        2',2'-Dimethyl-2-ethylpyrano[2,3,f]-chromone (125c). 66% yield (starting with 
1.1 g of 87a); mp 97-98oC;  MS (ESI+) m/z (%) 279 (M+ + Na, 100); 1H NMR δ 7.92 
(1H, d, J = 8.7 Hz, H-5), 6.80 (1H, d, J = 8.7 Hz, H-6), 6.77 (1H, d, J = 10.2 Hz, H-4’), 
6.10 (1H, s, H-3), 5.69 (1H, d, J = 10.2 Hz, H-3’), 2.65 (2H, q, J = 7.5 Hz, CH2CH3-2), 
1.44, 1.48 (each 3H, s, CH3-2’,2’), 1.30 (3H, t, J = 7.5 Hz, CH2CH3-2). 
        2',2'-Dimethyl-2-ethyl-5-methylpyrano[2,3-f]-chromone (125d). 45% yield 
(starting with 64.8 mg of 88a); mp 123-124 oC; MS (ESI+) m/z (%) 271 (M+ + 1, 100); 
1H NMR δ 7.75 (1H, d, J = 10.5 Hz, H-4’), 6.57 (1H, s, H-6), 6.01 (1H, s, H-3), 5.64 
(1H, d, J = 10.5 Hz, H-3’), 2.77 (3H, s, CH3-5), 2.60 (2H, q, J = 7.5 Hz, CH2CH3-2), 
1.59, 1.47 (each 3H, s, CH3-2’,2’), 1.29 (3H, t, J = 7.5 Hz, CH2CH3-2). 
        2',2'-Dimethyl-2,5-diethylpyrano[2,3,f]chromone (125e). 36% yield (starting 
with 120 mg of 89a); MS (ESI+) m/z (%) 285 (M+ + 1, 100); 1H NMR δ 6.76 (1H, d, J 
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= 10.2 Hz, H-4’), 6.61 (1H, s, H-6), 6.01 (1H, s H-3), 5.64 (1H, d, J = 10.2 Hz, H-3’), 
3.24 (2H, q, J = 7.5 Hz, CH2CH3-5), 2.58 (2H, q, J = 7.5 Hz, CH2CH3-2), 1.48 (6H, s,  
CH3-2’,2’), 1.29 (3H, t, J = 7.5 Hz, CH2CH3-5), 1.22 (3H, t, J = 7.5 Hz, CH2CH3-2). 
        Preparation of 7-hydroxy-3-methylchromone (124). The commercially 
available phenol 123 (400 mg, 2.41 mmol) in dry DMF (6 mL) was heated to 50 oC, 
and a solution of methanesulfonyl chloride (0.5 mL) in dry DMF (1mL) was added 
slowly. The mixture was then reacted at 60 oC for 6 h. After cooling, the reaction 
mixture was poured into a large volume of ice-cold aqueous sodium acetate (12 
g/100 mL). The crude product was filtered off and purified by column 
chromatography with hexanes:EtOAc = 7:3 to afford 124 (120 mg). 28% yield; mp 
155-157 oC; MS (ESI+) m/z (%) 199 (M+ + Na, 100); 1H NMR δ 10.72 (1H, s, OH-7), 
8.11 (1H, s, H-2), 7.88 (1H, d, J = 9.0 Hz, H-5), 6.89 (1H, dd, J = 9.0, 2.4 Hz, H-6), 
6.80 (1H, d, J = 2.4 Hz, H-8), 1.87 (3H, s, CH3-3). 
        General procedure for the preparation of 126a-d and 126f. A mixture of 
K3Fe(CN)6 (3 equiv), K2CO3 (3 equiv), (DHQ)2-PYR (2% equiv), and K2OsO2(OH)4 (2% 
equiv) was dissolved in t-BuOH/H2O (v/v, 1:1) at rt. The solution was cooled to 0 oC 
and methanesulfonamide (1 equiv) was added with stirring. After 20 min, substituted 
pyranochromone (125a-d and 125f) was added. The mixture was stirred at 0 oC for 
1-2 days, monitored by TLC. At completion, Na2S2O5 (excess), water and CH2Cl2 
were added, and stirring was continued for 1 h at rt. The mixture was extracted with 
CH2Cl2 three times, and the combined organic layer was dried over MgSO4. The 
solvent was removed under reduced pressure, and the residue was purified by 
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column chromatography with hexanes:EtOAc = 3:7 to afford the pure substituted (+)-
cis-3',4'-dihydroxypyranochromones (126a-d and 126f).  
        3'R,4'R-Dihydroxy-2,2',2'-trimethylpyrano[2,3-f]chromone (126a). 66% yield 
(starting with 1.1 g of 125a); mp 176-178 oC; MS (ESI+) m/z (%) 276 (M+ + 1, 100); 
1H NMR (DMSO) δ 7.95 (1H, d, J = 9.0 Hz, H-5), 6.84 (1H, d, J = 9.0 Hz, H-6), 6.10 
(1H, s, H-3), 5.20 (1H, t, J = 4.2, 4.2 Hz, H-4'), 3.87 (1H, t, J = 7.2, 4.2 Hz, H-3'), 
3.44 (1H, d, J = 4.2 Hz, OH-4'), 3.18 (1H, d, J = 7.2 Hz, OH-3'), 2.40 (3H, s, CH3-2), 
1.50, 1.44 (each 3H, s, CH3-2’,2’). 
        3'R,4'R-Dihydroxy-2, 5, 2',2'-tetramethylpyrano[2,3-f]chromone (126b). 35% 
yield (starting with 325 mg of 125b); mp 114-116 oC; MS (ESI+) m/z (%) 291 (M + + 
1, 100) ; 1H NMR δ 6.61 (1H, s, H-6), 6.04 (1H, s, H-3), 5.15 (1H, t, J = 3.9, 4.5 Hz, 
H-4'), 3.85 (1H, dd, J = 4.5, 6.6 Hz, H-3'), 3.08 (1H, d, J = 3.9 Hz, OH-4'), 3.05 (1H, d, 
J = 6.6 Hz, OH-3'), 2.74 (3H, s, CH3-5), 2.35 (3H, s, CH3-2), 1.46, 1.43 (each 3H, s, 
CH3-2’,2’). 
        3'R,4'R-Dihydroxy-2',2'-dimethyl-2-ethylpyrano[2,3-f]chromone (126c). 28% 
yield (starting with 120 mg of 125c); mp 153-155 oC; MS (ESI+) m/z (%) 291 (M+ + 1, 
100); 1H NMR (DMSO) δ 7.80 (1H, d, J = 9.0 Hz, H-5), 6.83 (1H, d, J = 9.0 Hz, H-6), 
6.13 (1H, s, H-3), 4.97 (1H, t, J = 4.8, 4.2 Hz, H-4'), 3.64 (1H, t, J = 6.6, 4.8 Hz, H-3'), 
3.08 (1H, d, J = 4.2 Hz, OH-4'), 2.99 (1H, d, J = 6.6 Hz, OH-3'), 2.58 (2H, q, J = 7.5 
Hz, CH2CH3-2), 1.38, 1.37 (each 3H, s, CH3-2’,2’), 1.26 (3H, t, J = 7.5 Hz, CH2CH3-
2). 
 
 
85 
 
        3'R, 4'R-Dihydroxy-5,2',2'-trimethyl-2-ethylpyrano[2,3-f]chromone (126d). 
40% yield (starting with 272 mg of 125d); mp 114-116 oC; MS (ESI+) m/z (%) 305 
(M+ + 1, 100); 1H NMR δ 6.62 (1H, s, H-6), 6.06 (1H, s, H-3), 5.15 (1H, dd, J = 3.6, 
5.1 Hz, H-4'), 3.86 (1H, dd, J = 5.1, 6.9 Hz, H-3'), 3.01 (1H, d, J = 6.9 Hz, OH-3'), 
2.98 (1H, d, J = 3.9 Hz, OH-4'), 2.76 (3H, s, CH3-5), 2.64 (2H, q, J = 7.5 Hz, 
CH2CH3-2), 1.46, 1.42 (each 3H, s, CH3-2’,2’), 1.31 (3H, t, J = 7.5 Hz, CH2CH3-2). 
        3'R,4'R-Dihydroxy-3,2',2'-trimethylpyrano[2,3-f]chromone (126f). 55% yield 
(starting with 1.3 g of 125f); mp 180-182 oC; MS (ESI+) m/z (%) 277 (M+ + 1, 100); 
1H NMR δ 7.98 (1H, d, J = 8.7 Hz, H-5), 7.74 (1H, d, J = 1.0 Hz, H-2), 6.82 (1H, d, J 
= 8.7 Hz, H-6), 6.15 (1H, dd, J = 5.4, 3.6 Hz, H-4'), 3.85 (1H, dd, J = 5.7, 5.4 Hz, H-
3'), 3.43 (1H, d, J = 3.6 Hz, OH-4'), 3.19 (1H, d, J = 5.7 Hz, OH-3'), 1.99 (3H, d, J = 
1.0 Hz, CH3-3), 1.41, 1.42 (each 3H, s, CH3-2’,2’).  
        3'R,4'R-Di-O-(-)-camphanoyl-2',2'-dimethyl-3-bromomethyl-dihydropyrano 
[2,3-f]chromone (127). The mixture of 66 (40 mg, 0.06 mmol), NBS (18 mg, 0.1 
mmol), and MeCN (2ml) was heated to reflux for 4 h, monitored by TLC. At 
completion, the mixture was concentrated and purified by PTLC with an eluent of 
hexanes:EtOAc = 5:4 to afford pure 127 (30 mg): 70% yield; MS-ESI+ (m/z, %) 715 
(M+ + 1, 100); 1H NMR δ 8.21 (1H, d, J = 9.0 Hz, H-5), 7.96 (1H, s, H-2), 6.98 (1H, d, 
J = 9.0 Hz, H-6), 6.72 (1H, d, J = 4.8 Hz, H-4'), 5.38 (1H, d, J = 4.8 Hz, H-3’), 4.35 
(2H, s, CH2Br-3), 2.43, 2.20, 1.93, 1.85 (each 2H, m, camphanoyl CH2), 1.53, 1.49 
(each 3H, s, CH3-2',2’), 1.13, 1.10, 1.09, 1.02, 0.98, 0.91 (each 3H, s, camphanoyl 
CH3).  
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        General procedure for the preparation of 66, 68-69, 98, 102. The substituted 
3'R,4'R-dihydroxypyranochromones (126a-d and 126f), (S)-(-)-camphanic chloride 
(3 equiv), and DMAP (4 equiv) were stirred in CH2Cl2 for 1-2 h at rt, monitored by 
TLC. At completion, the mixture was diluted with CH2Cl2 and washed by water and 
brine. The solvent was then removed under reduced pressure and the residue was 
purified by PTLC with hexanes:EtOAc = 3:2 to afford the appropriately alkyl-
substituted 3'R,4'R-di-O-(-)-camphanoyl-2',2'-dimethyldihydroprano[2,3-f]chromones 
(66, 68-69, 98, 102). 
        3'R,4'R-Di-O-(-)-camphanoyl-2,2',2'-trimethyldihydropyrano[2,3-f]chromone 
(68). 70% yield (starting from 100 mg of 126a);  mp 146-148 °C; MS-ESI+ (m/z, %) 
659 (M+ + Na, 100); 1H NMR δ 8.11 (1H, d, J = 8.8 Hz, H-5), 6.90 (1H, d, J = 8.8 Hz, 
H-6), 6.75 (1H, d, J = 4.6 Hz, H-4'), 6.12 (1H, s, H-3), 5.37 (1H, d, J = 4.6 Hz, H-3'), 
2.46, 2.12, 1.92, 1.70 (each 2H, m, camphanoyl CH2), 2.27 (3H, s, CH3-2), 1.53, 
1.46 (each 3H, s, CH3-2’), 1.11, 1.10, 1.07, 1.00, 0.97, 0.94 (each 3H, s, 
camphanoyl CH3); 60% de. [R]D -69.6° (c ) 0.25, CHCl3).  
        3'R,4'R-Di-O-(-)-camphanoyl-3,2',2'-trimethyldihydropyrano[2,3-f]chromone 
(66). 75% yield (starting from 200 mg of 126f); mp 146-148 °C; MS-ESI+ (m/z, %) 
659 (M+ + Na, 100); 1H NMR δ 8.16 (1H, d, J = 9.0 Hz, H-5), 7.61 (1H, s, H-2), 6.91 
(1H, d, J = 9.0 Hz, H-6), 6.70 (1H, d, J = 4.8 Hz, H-4'), 5.36 (1H, d, J = 4.8 Hz, H-3'), 
2.56, 2.32, 2.24, 1.85 (each 2H, m, camphanoyl CH2), 2.12 (3H, s, CH3-3), 1.64, 
1.59 (each 3H, s, CH3-2’), 1.32, 1.24, 1.22, 1.12, 1.10, 1.00 (each 3H, s, 
camphanoyl CH3); 90% de. [α]D -36.2° (c ) 0.23, CHCl3). 
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        3'R,4'R-Di-O-(-)-camphanoyl-2',2'-dimethyl-2-ethyldihydropyrano[2,3-
f]chromone (69). 71% yield (starting with 146 mg of 126c); mp 90-92 °C; MS-ESI+ 
(m/z, %) 645 (M+ + Na, 100); 1H NMR δ 8.15 (1H, d, J = 9.0 Hz, H-5), 7.69 (1H, d, J 
= 6.3 Hz, H-2), 6.94 (1H, d, J = 9.0 Hz, H-6), 6.72 (1H, d, J = 4.8 Hz, H-4'), 6.32 (1H, 
d, J = 6.3 Hz, H-3), 5.37 (1H, d, J  = 4.8 Hz, H-3'), 2.46, 2.20, 1.90, 1.74 (each 2H, m, 
camphanoyl CH2), 1.52, 1.47 (each 3H, s, CH3-2’), 1.11, 1.10, 1.08, 1.02, 0.99, 0.89 
(each 3H, s, camphanoyl CH3); [α]D -95.3° (c  = 0.17, CHCl3). 
        3'R,4'R-Di-O-(-)-camphanoyl-2,5,2',2'-tetramethyldihydropyrano[2,3-
f]chromone (98). 54% yield (starting with 290 mg of 126b); mp 144-145 oC; MS-
ESI+ (m/z, %) 645 (M+ + 1, 100); 1H NMR δ 6.74 (1H, d, J = 4.8 Hz, H-4'), 6.67 (1H, 
s, H-6), 6.05 (1H, s, H-3), 5.37 (1H, d, J = 4.8 Hz, H-3'), 2.81 (3H, s, CH3-5), 2.50, 
2.20, 1.95, 1.85 (each 2H, m, camphanoyl CH2), 2.24 (3H, s, CH3-2), 1.54, 1.47 
(each 3H, s, CH3-2’,2’), 1.14, 1.13, 1.10, 1.01, 1.00, 0.96 (each 3H, s, camphanoyl 
CH3); [α]D -71.2° (c  = 0.002, CH2Cl2). 
        3'R,4'R-Di-O-(-)-camphanoyl-2',2'-dimethyl-2-ethyl-5-methyldihydropyrano 
[2,3-f]chromone (102). 60% yield (starting with 100 mg of 126d); mp 133-134 oC; 
MS-ESI+ (m/z, %) 665 (M+ + 1, 100); 1H NMR δ 6.70 (1H, d, J = 4.5 Hz, H-4'), 6.64 
(1H, s, H-6), 6.04 (1H, s H-3), 5.36 (1H, d, J = 4.5 Hz, H-3'), 2.78 (3H, s, CH3-5), 
2.50 (2H, q, J = 7.5 Hz, CH2CH3-2), 2.50, 2.14, 1.91, 1.71 (each 2H, m, camphanoyl 
CH2), 1.52, 1.44 (each 3H, s, CH3-2’,2’), 1.21 (3H, t, J = 7.5 Hz, CH2CH3-2), 1.11, 
1.10, 1.07, 0.99, 0.97, 0.95, (each 3H, s, camphanoyl CH3); [α]D -55.0° (c  = 0.003, 
CH2Cl2). 
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        3'R,4'R-di-O-(-)-camphanoyl-2,5,2',2'-tetramethyl-3-bromodihydropyrano 
[2,3-f]chromone (99). A mixture of 98 (80 mg, 0.12 mmol), NBS (32.0 mg, 0.18 
mmol) and MeCN (2 mL) was heated to 110 oC for 3 h under high-absorption 
microwave conditions. At completion, the mixture was concentrated and purified by 
PTLC with an eluent of hexanes:EtOAc = 1:1 to afford pure 99 (28 mg). 32% yield; 
mp 146-147 oC; MS-ESI+ (m/z, %) 729 (M+ , 100); 1H NMR δ 6.72 (1H, d, J = 4.8 Hz, 
H-4'), 6.71 (1H, s, H-6), 5.36 (1H, d, J = 4.8 Hz, H-3'), 2.81 (3H, s, CH3-5), 2.49 (3H, 
s, CH3-2), 2.50, 2.15, 1.95, 1.72 (each 2H, m, camphanoyl CH2), 1.53, 1.47 (each 
3H, s, CH3-2’,2’), 1.13, 1.11, 1.09, 1.00, 0.98, 0.95 (each 3H, s, camphanoyl CH3); 
[α]D -65.8° (c  = 0.018, CH3Cl). 
        3'R,4'R-Di-O-(-)-camphanoyl-2,5,2',2'-tetramethyl-3,6-dibromodihydro 
pyrano[2,3-f]chromone (100). The procedure was identical to that used for the 
preparation of 99. 10% yield (starting with 80 mg of 98); mp 148-150 oC; MS-ESI+ 
(m/z, %) 809 (M+ , 100); 1H NMR δ 6.74 (1H, d, J = 4.5 Hz, H-4'), 5.39 (1H, d, J = 4.5 
Hz, H-3'), 3.05 (3H, s, CH3-5), 2.49 (3H, s, CH3-2), 2.50, 2.16, 1.92, 1.73 (each 2H, 
m, camphanoyl CH2), 1.56 (6H, s, CH3-2’,2’), 1.13, 1.12, 1.09, 1.00, 0.99, 0.96 (each 
3H, s, camphanoyl CH3); [α]D -67.2° (c  = 0.018, CH3Cl). 
        3'R,4'R-di-O-(-)-camphanoyl-2,2',2'-trimethyl-5-bromomethyldihydro-
pyrano[2,3-f]chromone (101). A mixture of 98 (100 mg, 0.15 mmol), NBS (29.4 mg, 
0.17 mmol), and 3-chloroperbenzoic acid (2.6 mg, 0.015 mmol), dissolved in 2 mL of 
anhydrous CCl4 was heated to 100 oC for 5 h under high-absorption microwave 
conditions. At completion, the mixture was concentrated and the residue was 
purified by PTLC with an eluent of hexanes:EtOAc = 1:1 to afford pure 101 (38mg). 
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35% yield; mp 128-130 oC; MS-ESI+ (m/z, %) 729 (M+, 100); 1H NMR δ 6.97 (1H, s, 
H-6), 6.72 (1H, d, J = 4.5 Hz, H-4'), 6.15 (1H, s, H-3), 5.39 (1H, d, J = 4.5 Hz, H-3'), 
5.29 (1H, d, J = 61.2 Hz, CH2Br-5), 5.12 (1H, d, J = 61.2 Hz, CH2Br-5), 2.50, 2.18, 
1.94, 1.71 (each 2H, m, camphanoyl CH2), 2.26 (3H, s, CH3-2), 1.54, 1.48 (each 3H, 
s, CH3-2’,2’), 1.13, 1.11, 1.09, 1.02, 0.99, 0.97 (each 3H, s, camphanoyl CH3); [α]D -
66.9° (c  = 0.018, CH3Cl). 
         3'R,4'R-di-O-(-)-camphanoyl-2',2'-dimethyl-2,5-diethyldihydropyrano[2,3-
f]chromone (103). Compound 125e (50 mg) was dihydroxylated using the identical 
procedure described above for 2 days. At completion, the mixture was extracted with 
CH2Cl2, and the combined organic layer was concentrated under reduced pressure 
to give crude 3'R,4'R-dihydroxyl-DCP. Without purification, the crude product was 
stirred with camphanic chloride (3 equiv) and DMAP (4 equiv) at rt for 2 h to give 30 
mg of 103. 30% yield; mp 108-110 oC; MS-ESI+ (m/z, %) 665 (M+ + 1, 100); 1H NMR 
δ 6.70 (1H, d, J = 4.5 Hz, H-4'), 6.69 (1H, s, H-6), 6.04 (1H, s H-3), 5.37 (1H, d, J = 
4.5 Hz, H-3'), 3.25 (2H, q, J = 7.5 Hz, CH2CH3-5), 2.50, (2H, q, J = 7.5 Hz, CH2CH3-
2), 2.50, 2.15, 1.92, 1.70 (each 2H, m, camphanoyl CH2), 1.53, 1.45 (each 3H, s, 
CH3-2’,2’), 1.24 (3H, t, J = 7.5 Hz, CH2CH3-5), 1.21 (3H, t, J = 7.5 Hz, CH2CH3-2), 
1.12, 1.11, 1.07, 1.01, 0.98, 0.96, (each 3H, s, camphanoyl CH3); [α]D -6.5° (c  = 
0.003, CH2Cl2). 
        3'R,4'R-di-O-(-)-camphanoyl-2',2'-dimethyl-2-bromomethyldihydropyrano 
[2,3-f]chromone (104). A mixture of 68 (200 mg, 0.31 mmol), NBS (60.6 mg, 0.34 
mmol), and 3-chloroperbenzoic acid (5.4 mg, 0.031 mmol), dissolved in 2mL of 
anhydrous CCl4 was heated to 100 oC for 5 h under high-absorption microwave 
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conditions. At completion, the mixture was concentrated and the residue was 
purified by PTLC with an eluent of hexanes:EtOAc = 1:1 to afford pure 104 (50 mg).  
23% yield; mp 180-182 oC; MS-ESI+ (m/z, %) 717 (M+ + 1, 100); 1H NMR δ 8.13 (1H, 
d, J = 9.0 Hz, H-5), 6.93 (1H, d, J = 9.0 Hz, H-5), 6.74 (1H, d, J = 4.5 Hz, H-4'), 6.40 
(1H, s, H-3), 5.42 (1H, d, J = 4.5 Hz, H-3'), 4.12 (2H, s, CH2Br-2), 2.50, 2.17, 1.90, 
1.74 (each 2H, m, camphanoyl CH2), 1.56, 1.47 (each 3H, s, CH3-2',2’), 1.13, 1.11, 
1.09, 1.07, 1.02, 0.98, (each 3H, s, camphanoyl CH3); [α]D -13.9° (c  = 0.01, CH2Cl2). 
        3'R,4'R-di-O-(-)-camphanoyl-2',2'-dimethyl-2-(1-bromoethyl)dihydropyrano 
[2,3-f]chromone (105). The procedure was identical to that used for the preparation 
of 104: 25% yield (starting with 50 mg of 69); mp 158-159 oC; MS-ESI+ (m/z, %) 731 
(M+ + 1, 100); 1H NMR δ 8.12 (1H, d, J = 9.0 Hz, H-5), 6.92 (1H, d, J = 9.0Hz, H-5), 
6.74 (1H, d, J = 4.5 Hz, H-4'), 6.34 (1H, s, H-3), 5.42 (1H, d, J = 4.5 Hz, H-3'), 4.76 
(1H, t, J = 7.2, CHBrCH3-2), 2.50, 2.19, 1.90, 1.74 (each 2H, m, camphanoyl CH2), 
1.57, 1.47 (each 3H, s, CH3-2',2’), 1.27 (3H, d, J = 7.2, CHBrCH3-2), 1.12, 1.11, 1.08, 
1.05, 1.03, 0.98, (each 3H, s, camphanoyl CH3); [α]D -31.9° (c  = 0.005, CH2Cl2). 
        3'R,4'R-di-O-(-)-camphanoyl-2',2'-dimethyl-2-(1-dibromoethyl)dihydro-
pyrano [2,3-f]chromone (106). A mixture of 69 (50 mg, 0.08 mmol), NBS (28.5 mg, 
0.16 mmol), and 3-chloroperbenzoic acid (2 mg, 0.01 mmol), dissolved in 1 mL of 
anhydrous CCl4 was heated to 100 oC for 5 h under high-absorption microwave 
conditions. At completion, the mixture was concentrated and the residue was 
purified by PTLC with an eluent of hexanes:EtOAc = 1:1 to afford pure 13 (8mg).  12% 
yield; mp 166-168 oC; MS-ESI+ (m/z, %) 809 (M+ + 1, 100); 1H NMR δ 8.13 (1H, d, J 
= 9.0 Hz, H-5), 6.94 (1H, d, J = 9.0Hz, H-5), 6.80 (1H, d, J = 4.2 Hz, H-4'), 6.67 (1H, 
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s, H-3), 5.42 (1H, d, J = 4.2 Hz, H-3'), 2.81 (3H, s, C(Br)2CH3-2), 2.50, 2.20, 1.90, 
1.70 (each 2H, m, camphanoyl CH2), 1.57, 1.47 (each 3H, s, CH3-2',2’), 1.12, 1.11, 
1.08, 1.05, 1.03, 0.98, (each 3H, s, camphanoyl CH3); [α]D -48.1° (c  = 0.004, 
CH2Cl2). 
        3'R,4'R-di-O-(-)-camphanoyl-3,2',2'-trimethyl-2-cyanodihydropyrano[2,3-
f]chromone (107). A solution of sodium cyanide in 95% EtOH (aqueous) was 
cooled in an ice-bath. Compound 127 (50 mg, 0.07 mmol) in 0.5 mL DMF was 
added slowly to the above solution over a 15 to 20 min period. The mixture was 
stirred at rt and monitored by TLC. At completion, the mixture was poured into ice-
water and extracted with EtOAc three times. The combined organic layer was 
washed with brine and dried over MgSO4. The solvent was evaporated in vacuo and 
the residue purified by PTLC to afford pure 107 (10 mg). 22% yield; mp 196-198 oC; 
MS-ESI+ (m/z, %) 684 (M+ + Na, 100); 1H NMR δ 8.13 (1H, d, J = 9.0 Hz, H-5), 6.99 
(1H, d, J = 9.0 Hz, H-6), 6.61 (1H, d, J = 4.5 Hz, H-4'), 5.41 (1H, d, J = 4.5 Hz, H-3'), 
2.55, 2.20, 1.96, 1.85 (each 2H, m, camphanoyl CH2), 2.28 (3H, s, CH3-3), 1.52, 
1.48 (each 3H, s, CH3-2',2’), 1.13, 1.11, 1.10, 1.09, 1.05, 0.98 (each 3H, s, 
camphanoyl CH3); [α]D -39.0° (c  = 0.002, CH2Cl2). 
        3'R,4'R-di-O-(-)-camphanoyl-2',2'-dimethyl-2-methylcyanodihydropyrano 
[2,3-f]chromone (108). The procedure was identical to that used for the preparation 
of 107: 27% yield (starting with 20 mg of 104); mp 102-104 oC; MS-ESI+ (m/z, %) 
684 (M+ + Na, 100); 1H NMR δ 8.14 (1H, d, J = 9.0 Hz, H-5), 6.97 (1H, d, J = 9.0Hz, 
H-6), 6.72 (1H, d, J = 4.2 Hz, H-4'), 6.49 (1H, s, H-3), 5.40 (1H, d, J = 4.2 Hz, H-3'), 
3.63 (2H, t, J = 25.5 Hz, CH2CN-2), 2.50, 2.10, 1.95, 1.70 (each 2H, m, camphanoyl 
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CH2), 1.56, 1.49 (each 3H, s, CH3-2’,2’), 1.13, 1.11, 1.09, 1.03, 1.00, 0.98, (each 3H, 
s, camphanoyl CH3); [α]D -27.9° (c  = 0.002, CH2Cl2). 
        3'R,4'R-di-O-(-)-camphanoyl-2,2',2'-trimethyl-3-bromodihydropyrano[2,3-
f]chromone (110). The procedure was identical to that used for the preparation of 
99. 52% yield (starting from 21 mg of 68); mp 160-161 oC; MS-ESI- (m/z, %) 713 (M- 
- 1, 100); 1H NMR δ  8.16 (1H, d, J = 9.0 Hz, H-5), 6.95 (1H, d, J = 9.0 Hz, H-6), 6.75 
(1H, d, J = 4.5 Hz, H-4'), 5.38 (1H, d, J = 4.5 Hz, H-3'), 2.53 (3H, s, CH3-2), 2.46, 
2.16, 1.92, 1.73 (each 2H, m, camphanoyl CH2), 1.54, 1.48 (each 3H, s, CH3-2',2’), 
1.13, 1.12, 1.09, 1.01, 0.98, 0.96, (each 3H, s, camphanoyl CH3); [α]D -47.7° (c  = 
0.003, CH2Cl2). 
        3'R,4'R-di-O-(-)-camphanoyl-2',2'-dimethyl-2-ethyl-3-bromodihydropyrano 
[2,3-f]chromone (111). The procedure was identical to that used for the preparation 
of 99. 60% yield (starting from 20 mg of 68); mp 166-168 oC; MS-ESI+ (m/z, %) 730 
(M+  + 1, 100); 1H NMR δ  8.18 (1H, d, J = 9.0 Hz, H-5), 6.95 (1H, d, J = 9.0 Hz, H-6), 
6.74 (1H, d, J = 4.8 Hz, H-4'), 5.41 (1H, d, J = 4.8 Hz, H-3'), 3.02, 2.85 (each 1H, m, 
CH2CH3-2), 2.45, 2.10, 1.95, 1.85 (each 2H, m, camphanoyl CH2), 1.55, 1.47 (each 
3H, s, CH3-2',2’), 1.24 (3H, t, J = 7.5 Hz, CH2CH3-2), 1.13, 1.11, 1.081.03, 0.98, 0.98 
(each 3H, s, camphanoyl CH3); [α]D -34.1° (c  = 0.006, CH2Cl2). 
        3'R,4'R-di-O-(-)-camphanoyl-2,2',2'-trimethyl-3-iododihydropyrano[2,3-
f]chromone (112). An anhydrous CH2Cl2 solution of 68 (40 mg, 0.06 mmol) and 
CF3CO2Ag (13.g mg, 0.06 mmol) was cooled to 0 oC in an ice-bath. I2 (17.6 mg, 0.07 
mmol) was added slowly under N2 protection. The reaction mixture was stirred at 0 
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oC for 2 h, monitored by TLC. At completion, the mixture was concentrated and 
purified by PTLC to give pure 112 (43 mg): 90% yield;  mp 179-180 oC; MS-ESI+ 
(m/z, %) 785 (M+ + Na, 100); 1H NMR δ  8.17 (1H, d, J = 9.0 Hz, H-5), 6.95 (1H, d, J 
= 9.0 Hz, H-6), 6.76 (1H, d, J = 4.5 Hz, H-4'), 5.39 (1H, d, J = 4.5 Hz, H-3'), 2.65 (3H, 
s, CH3-2), 2.50. 2.15, 1.96, 1,85 (each 2H, m, camphanoyl CH2), 1.55, 1.49 (each 
3H, s, CH3-2',2’), 1.13, 1.11, 1.09, 1.02, 0.99, 0.96 (each 2H, s, camphanoyl CH3); 
[α]D -37.5° (c  = 0.002, CH2Cl2). 
        3'R,4'R-di-O-(-)-camphanoyl-2',2'-dimethyl-2-ethyl-3-cyanodihydropyrano 
[2,3-f]chromone (113). The procedure was identical to that used for the preparation 
of 107: 25% yield (starting with 50 mg of 111); mp 193-194 oC; MS-ESI- (m/z, %) 
674 (M- - 1, 100); 1H NMR δ  7.75 (1H, d, J = 9.0 Hz, H-5), 6.78 (1H, d, J = 9.0 Hz, 
H-6), 6.65 (1H, d, J = 4.5 Hz, H-4'), 5.38 (1H, d, J = 4.5 Hz, H-3'), 2.51 (2H, q, J = 
7.5 Hz, CH2CH3-2), 2.40, 2.16, 1.92, 1.74 (each 2H, m, camphanoyl CH2), 1.55, 1.49 
(each 3H, s, CH3-2',2’), 1.24 (3H, t, J = 7.5 Hz, CH2CH3-2), 1.21, 1.10, 1.07, 0.99, 
0.98, 0.96, (each 3H, s, camphanoyl CH3); [α]D -31.5° (c  = 0.002, CH2Cl2). 
        General procedure for the preparation of amino-substituted DCP 
derivatives (109, 114-120). A THF solution of bromo-substituted DCP analogs (104, 
110 or 111) (1 equiv), various amines or aqueous amine solution (2.5 equiv) was 
stirred at rt for 3.5 h. The mixture was poured into water (excess) and extracted with 
EtOAc. After the usual workup, the crude product was purified by PTLC with an 
eluent of hexanes:EtOAc = 7:1 to afford corresponding amino-substituted DCP 
analogs (109, 114-120). 
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        3'R,4'R-Di-O-(-)-camphanoyl-2',2'-dimethyl-2-(methylamino)methyldihydro-
pyrano[2,3-f]chromone (109). 80% yield (starting from 50 mg of 104); mp 137-138 
oC; MS-ESI+ (m/z, %) 666 (M+ + 1, 100); 1H NMR δ 8.14 (1H, d, J = 9.0 Hz, H-5), 
6.92 (1H, d, J = 9.0 Hz, H-6), 6.75 (1H, d, J = 4.5 Hz, H-4'), 6.34 (1H, s, H-3), 5.40 
(1H, d, J = 4.5 Hz, H-3'), 3.60, 3.55 (each 1H, d, J = 8.7 Hz, CH2NHCH3-2), 2.85 (1H, 
s, CH2NHCH3-2), 2.45, 2.14, 1.95, 1.71 (each 2H, m, camphanoyl CH2), 2.45 (3H, s, 
CH2NHCH3-2), 1.55, 1.48 (each 3H, s, CH3-2',2’), 1.13, 1.11, 1.08, 1.02, 0.99, 0.97, 
(each 3H, s, camphanoyl CH3); [α]D -35.8° (c  = 0.003, CH2Cl2). 
        3'R,4'R-Di-O-(-)-camphanoyl-2,2',2'-trimethyl-3-aminodihydropyrano[2,3-
f]chromone (114). 50% yield (starting from 18 mg of 110); mp 137-138 oC; MS-ESI+ 
(m/z, %) 652 (M+ + 1, 100); 1H NMR δ 7.73 (1H, d, J = 8.7 Hz, H-5), 6.75 (1H, d, J = 
4.8 Hz, H-4'), 6.70 (1H, d, J = 8.7 Hz, H-6), 5.39 (1H, d, J = 4.8 Hz, H-3'), 2.46 (2H, s, 
NH2-3), 2.45, 2.20, 1.95, 1.85 (each 2H, m, camphanoyl CH2), 2.17 (3H, s, CH3-2), 
1.48, 1.47 (each 3H, s, CH3-2',2’), 1.24, 1.10, 1.07, 0.99, 0.97, 0.86 (each 3H, s, 
camphanoyl CH3; [α]D -8.0° (c  = 0.004, CH2Cl2). 
        3'R,4'R-Di-O-(-)-camphanoyl-2',2'-dimethyl-2-ethyl-3-aminodihydropyrano 
[2,3-f]chromone (115). 40% yield (starting from 100 mg of 111); mp 145-146 oC; 
MS-ESI+ (m/z, %) 652 (M+ + 1, 100); 1H NMR δ  7.70 (1H, d, J = 8.7 Hz, H-5), 6.73 
(1H, d, J = 4.5 Hz, H-4'), 6.68 (1H, d, J = 8.7 Hz, H-6), 5.38 (1H, d, J = 4.5 Hz, H-3'), 
5.0 (2H, br, NH2-3), 2.50 (2H, q, J = 7.5 Hz, CH2CH3-2), 2.40, 2.20, 1.91, 1.60 (each 
2H, m, camphanoyl CH2), 1.52, 1.46 (each 3H, s, CH3-2',2’), 1.21 (3H, t, J = 7.5 Hz, 
CH2CH3-2), 1.11, 1.10, 1.07, 0.99, 0.97, 0.85, (each 3H, s, camphanoyl CH3); [α]D -
10.0° (c  = 0.003, CH2Cl2). 
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        3'R,4'R-Di-O-(-)-camphanoyl-3,2',2'-trimethyl-3-methylaminodihydropyrano 
[2,3-f]chromone (116). 80% yield (starting from 22.2 mg of 110); mp 122-124 oC; 
MS-ESI+ (m/z, %) 666 (M+ + 1, 100); 1H NMR δ 7.73 (1H, d, J = 8.4 Hz, H-5), 6.76 
(1H, d, J = 4.8 Hz, H-4'), 6.70 (1H, d, J = 8.4 Hz, H-6), 5.40 (1H, d, J = 4.8 Hz, H-3'), 
3.06 (3H, s, NHCH3-3), 2.54 (1H, s, NHCH3-3), 2.40, 2.20, 1.90, 1.70 (each 2H, m, 
camphanoyl CH2), 2.20 (3H, s, CH3-2), 1.52, 1.47 (each 3H, s, CH3-2',2’), 1.12, 1.10, 
1.06, 0.98, 0.95,0.83 (each 3H, s, camphanoyl CH3); [α]D -21.4° (c  = 0.003, CH2Cl2). 
         3'R,4'R-Di-O-(-)-camphanoyl-2',2'-dimethyl-2-ethyl-3-methylaminodihydro-
pyrano[2,3-f]chromone (117). 75% yield (starting from 100 mg of 111); mp 163-164 
oC; MS-ESI+ (m/z, %) 680 (M+ + 1, 100); 1H NMR δ 7.73 (1H, d, J = 8.4 Hz, H-5), 
6.76 (1H, d, J = 4.5 Hz, H-4'), 6.69 (1H, d, J = 8.4 Hz, H-6), 5.39 (1H, d, J = 4.5 Hz, 
H-3'), 3.08 (3H, s, NHCH3-3), 2.63 (2H, q, J = 7.5 Hz, CH2CH3-2), 2.48, 2.20, 1.94, 
1.77 (each 2H, m, camphanoyl CH2), 1.55, 1.48 (each 3H, s, CH3-2',2’),1.13, 1.11, 
1.07, 0.99, 0.96 ,0.87 (each 3H, s, camphanoyl CH3), 1.08 (1H, br, NHCH3-3); [α]D -
24.6° (c  = 0.013, CH2Cl2). 
        3'R,4'R-Di-O-(-)-camphanoyl-2',2'-dimethyl-2-morpholinomethyldihydro-
pyrano[2,3-f]chromone (118). 30% yield (starting from 30 mg of 104); mp 140-142 
oC; MS-ESI+ (m/z, %) 722 (M+ + 1, 100); 1H NMR δ  8.13 (1H, d, J = 9.0 Hz, H-5), 
6.92 (1H, d, J = 9.0 Hz, H-6), 6.74 (1H, d, J = 4.5 Hz, H-4'), 6.48 (1H, s, H-3), 5.38 
(1H, d, J = 4.5 Hz, H-3'), 3.72 (4H, t, J = 4.5 Hz, 4.8 Hz, morpholine CH2), 3.26, 3.42 
(each 1H, d, J = 16.5 Hz, CH2), 2.54 (4H, t, J = 4.5 Hz, 4.8 Hz, morpholine CH2), 
2.50, 2.15, 1.95, 1.70 (each 2H, m, camphanoyl CH2), 1.54, 1.48 (each 3H, s, CH3-
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2',2’), 1.13, 1.11, 1.08, 1.00, 0.98, 0.95, (each 3H, s, camphanoyl CH3); [α]D -28.5° (c  
= 0.011, CH2Cl2). 
        3'R,4'R-Di-O-(-)-camphanoyl-2',2'-dimethyl-2-(dimethylaminopropyl-
piperazin1ylmethyl)–dihydropyrano[2,3-f]chromone (119). 15% yield (starting 
from 30 mg of 104); mp 132-133 oC; MS-ESI+ (m/z, %) 806 (M+, 100); 1H NMR δ  
8.13 (1H, d, J = 8.7 Hz, H-5), 6.92 (1H, d, J = 8.7 Hz, H-6), 6.73 (1H, d, J = 4.5 Hz, 
H-4'), 6.47 (1H, s, H-3), 5.38 (1H, d, J = 4.5 Hz, H-3'), 3.30, 3.44 (each 1H, d, J = 
15.0 Hz, CH2-2), 2.50 (8H, m, piperazine CH2), 2.50, 2.15, 1.95, 1.70 (each 2H, m, 
camphanoyl CH2), 2.41 (4H, m, amino-propylpiperazine CH2), 2.28 (6H, s, 
dimethylamino-propylpiperazine CH3), 1.70 (2H, m, amino-propylpiperazine CH2 ), 
1.54, 1.48 (each 3H, s, CH3-2',2’), 1.13, 1.11, 1.08, 1.01, 0.98, 0.95, (each 3H, s, 
camphanoyl CH3); [α]D -20.3° (c  = 0.003, CH2Cl2). 
        3'R,4'R-Di-O-(-)-camphanoyl-2',2'-dimethyl-2-(pyridin-4-ylmethylamino)-
methyldihydropyrano[2,3-f]chromone (120). 25% yield (starting from 30 mg of 
104); mp 116-118 oC; MS-ESI+ (m/z, %) 806 (M+ + 1, 100); 1H NMR δ 8.55 (2H, d, J 
= 6.0 Hz, pyridine CH), 8.13 (1H, d, J = 9.0 Hz, H-5), 7.29 (2H, d, J = 6.0 Hz, 
pyridine CH), 6.92 (1H, d, J = 9.0 Hz, H-6), 6.74 (1H, d, J = 4.5 Hz, H-4'), 6.36 (1H, s, 
H-3), 5.39 (1H, d, J = 4.5 Hz, H-3'), 3.85 (1H, s, CH2NH-2), 3.59, 3.68 (each 1H, d, J 
= 15.9 Hz, CH2-2), 2.50, 2.15, 1.95, 1.70 (each 2H, m, camphanoyl CH2), 1.55, 1.48 
(each 3H, s, CH3-2'), 1.13, 1.11, 1.07, 0.99, 0.96, 0.94, (each 3H, s, camphanoyl 
CH3); [α]D -16.9° (c  = 0.003, CH2Cl2). 
4.4.2 HIV-1 Infectivity Assay 
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         Anti-HIV-1 activity was measured as reductions in Luc reporter gene 
expression after a single round of virus infection of TZM-bl cells. HIV-1 at 200 
TCID50 and various dilutions of test samples (eight dilutions, 4-fold stepwise) were 
mixed in a total volume of 100 μL growth medium in 96-well black solid plates 
(Corning-Costar). After 48-h incubation, culture medium was removed from each 
well and 100 μL of Bright Glo luciferase reagent was added to each culture well. The 
luciferase activity in the assay wells was measured using a Victor 2 luminometer. 
The 50% inhibitory dose (IC50) was defined as the sample concentration that caused 
a 50% reduction in Relative Luminescence Units (RLU) compared to virus control 
wells after subtraction of background RLU.  
4.4.3 Cytotoxicity Assay 
        The general procedure was performed according to CytoTox-GloTM cytotoxicity 
assay instructions for using product G9290, G9291 and G9292. (Promega) 
4.4.4 Water Solubility Assay 
         Each tested compound was added in excess to 1.5 mL Eppendorf tubes 
containing 1 mL of HPLC grade water. The tubes were placed into Branson 5510 
ultrasonic tank at room temperature for 1 h. The excess solid was separated from 
the solution through a PTFE syringe filter (0.2 µM diameter). The supernatant was 
dispensed into glass HPLC vials. The concentration of the samples was determined 
with HPLC, on an Alltima C18 3u column (2.1 mm × 100 mm) and a flow rate of 200 
µL/min. The samples (5 µL) were injected and run with a solution of 35% water and 
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65% MeCN. For each compound, a standard curve consisting of five concentrations 
(5-fold stepwise) in MeCN was established initially. 
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CHAPTER 5 
DESIGN, SYNTHESIS AND EVALUATION OF 1R,2R-3,3-
DIMETHYLDIHYDROPYRANO- [2,3-c]XANTHEN-7(1H)-ONE (DCX) 
DERIVATIVES AS NOVEL ANTI-HIV AGENTS  
 
5.1 Introduction 
        As introduced in Chapter 2, compounds (67, 73) with a benzyl ring substituted 
at 2 or 3 position of DCP have been synthesized and evaluated. (Figure 5-1)1 
However, compounds with an additional aromatic ring fused to the chromone ring 
system have never been studied.  
        Previous SAR study suggested that the planar chromone ring system in DCPs 
is critical to maintain anti-HIV potential against both wide type and multi-drug 
resistant HIV strains. Pharmacophore analysis described in chapter 4 also identified 
the planar ring system as a potential pharmacophore.2 We speculated that an 
extend planar system by constructing a fused aromatic ring to chromone ring can 
help keeping a more rigid planer system and the extended conjugation ring may 
sustain or even increase the π-π stacking interaction between the ligand and the 
target protein.  
        Therefore, in order to better understand the interaction between the planar ring 
system of drug molecules and binding pocket, we designed a series of tri-aryl 
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conjugated compounds, with a xanthen-9-one moiety replacing the chromone ring in 
DCK and DCP series.(Figure 5-2) We hope this modification could enhance the 
interaction between the drug molecules and the target proteins, and therefore, 
improve the anti-HIV activity profile.  
 
5.2 Design 
        Inspired from previous study, introducing appropriate alkyl or O-alkyl groups on 
the planar ring system dramatically improved the anti-HIV activity. 4-MDCK (26) and 
2-EDCP (69) exhibited 5- and 4-time better anti-HIV activity than the parent DCK (18) 
and DCP (65), respectively (Chapter 2); 5-methyl substituted DCP (compounds 98 
and 102) presented the best potency against both wild-type and drug-resistant HIV 
strains among the tested compounds. In our current study, we first designed 1R,2R-
3,3-dimethyldihydropyranoxanthone (DCX) analogs with a series of small alkyl and 
O-alkyl groups substituted on the C ring (R1 – R4 ) and A ring (R5) to evaluate the 
effects of alky substitutions (Figure 5-2, compounds 130-131, 133-140 and 148) We 
then introduced a group of other functional moieties such as halogen, cyano groups 
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with different physicochemical properties to explore how these functionalities affect 
the anti-HIV activity. The cyano group might also expand the conjugation of 
xanthenone ring besides its electron withdrawing effect, and results in the potent 
anti-HIV activity, as speculated in chapter 4. (Figure 5-2, compounds 142-147, 149-
150 and 152) 
    To increase compounds’ polarity and solve the water-solubility problem, we 
proposed to build some small polar functional groups, such as hydroxyl, amine into 
the ring system. (Figure 5-2, compounds 132, 141 and 151) Both hydroxy and amine 
moieties not only can manipulate the polarity of the drug molecule but also are able 
to be derivatized to make water soluble salt.  
  
5.3 Chemistry 
        The general synthetic route to obtain pyrano-xanthones is shown in scheme 5-1.  
Hydroxylated xanthones (169b-I, k-q) were synthesized through the cyclization 
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reaction between phloroglucinol (153) and appropriate substituted salicylic acids 
(154-168), in the presence of Eaton’s reagent (phosphorus pentoxide solution in 
methanesulfonic acid) as a catalytic condensation agent. 3 A slight excess amount of 
phloroglucinol was used to complete the desired reaction and avoid the formation of 
side products, hydroxychromeno[3,2-b]xanthenesdiones. The desired products 
(169b-I, k-q) as brownish solids were obtained after precipitation in ice-water and 
collected by filtration, which were carried to the next step reaction without further 
purification. 6-Hydroxy-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-ones (94-96a, 170-
181) were synthesized by alkylation and cyclization from xanthones (169b-I, k-q)  by 
the microwave-assisted method, described in chapter 3.4  
       Methylation of the resulting compounds, 6-hydorxy-3,3-dimethylpyrano[2,3-
c]xanthen-7(3H)-ones (94a-96a, 170-181) with MeI and K2CO3 yielded  6-methoxy-
3,3-dimethylpyranoxanthones (182b-q).5 (DCX)  analogs, 130-131, 133-146 and 148 
were synthesized by following the literature procedures1 through Sharpless 
asymmetric dihydroxylations 6, 7 and esterification7, 8 with excess (S)-camphanoyl 
chloride. 
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        Demethylation of 6-methoxy DCX (131) with 48% hydrogen bromide  acid 
solution yielded 6-hydroxy DCX (132) in 63% yield.5 (Scheme 5-3)  
 
Compounds 147, 149 and 150 were synthesized by bromination of of 131 and 135 
with NBS under appropriate conditions. Bromination at 5-position was accomplished 
in dichloromethane under microwave condition 9 to generate compounds 147 and 
149; While benzylic bromination of 135 with NBS in anhydrous carbon tetrachloride 
in the presence of MCPBA as a radical initiator2 led to compound 150. Reaction of 
145 with excess NH3 aqueous solution afforded compound 151.10 (Scheme 5-4) 
    Scheme 5-5 illustrates the synthetic pathway of 6-methoxy-10-cyano DCX (152). 
Compound 182o was treated with zinc cyanide in the presence of 
tetrakis(triphenylphosphine)palladium(0) [Pd(PPh3)4]  as a catalyst to afford 
compound 184.11 After dihydroxylation and esterification by following the existing 
procedures discussed before 6.7.8 to yield the compound 152. 
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5.4 Results and Discussion 
    All synthesized DCX analogs were screened against wild type NL4-3 HIV strain 
in a single cycle infection assay using TZM-bl cells and the result is shown in Table 
5-1. 
The structures of 130-132 are little different from each other with substitutions at 
6-position. This slight structural differentiation resulted in significant activities 
deviation. Compound 131 with a methoxy group at 6-position showed 5-fold more 
potent anti-HIV activity than 130 with EC50 value as low as 0.063 µM and 1.5-fold 
more active than 2-EDCP (69, EC50 at 0.089 µM), a positive comparison. 131 also 
presented a two-fold better TI value than 2-EDCP, suggesting a better selectivity of 
HIV-infected cells over normal cells. In contrast, compound 132, a 6-hydroxyl DCX 
analogue failed to present notable selectivity ( an average TI value less than 4 was 
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observed)  perhaps due to the intramolecular HB between C6-OH and C7 carbonyl 
oxo, which might in turn affect the H-bonding interaction between C7 carbonyl oxo 
and the target protein. These findings suggested that introducing a hydrophobic 
substituent at C6 position, is a good strategy to maintain or enhance anti-HIV activity. 
Unlike 132, compound 141, with an OH group at C8 position (R4), still remained 
certain levels of anti-HIV activity and sensitivity, suggesting an unequal HB effect 
resulted from two similar adjacent OHs and the carbonyl oxo, probably due to 
unequal molecular substitution surroundings and/or points by points interactions of 
the substituents on the drug molecule and the target protein, which may, in turn, 
weaken the intramolecular interaction of C8-OH. 
    With a bromide at 5-position (R6), both compounds 147 and 149 showed 
significantly reduced anti-HIV activity and TI values (TI below 4), in comparison to 
their parent compounds 131 and 135. 
    The size of substitution at C11 (R1) of DCX series also impacts anti-HIV activity . 
Larger substitutions at C11 seemed to adversely influence the activity in our 
preliminary study. Compound 131, with only C11-H, exhibited higher potency than 
142, a 11-fluorine DCX , which is more potent than 11-methyl-DCX (133) (EC50 of 
131, 142 and 133 are 0.063, 0.23 and 1.52 µM, respectively). 11-Methoxy-DCX (137) 
showed no detectable anti-HIV activity and selectivity against wild type HIVNL4-3 
strain.  It may be due to the fact that the substitution R1 at C11 influences the 
orientation of 1-camphanoyl group, as observed in the DCP series.2   
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    As mentioned in chapter 3, the 2 and 3-positions of chromone system  in DCP 
analogs, displayed equivalent characteristics when substituted with the same 
functionalities.2 In this study, introducing substitutions at 9 (R3) or 10 (R2) position 
showed different anti-HIV activity profile. 9-methylated (135) and 9-methoxylated 
(139) DCXs exhibited better anti-HIV activity than their analogs 10-methylated (134) 
and 10-methoxylated (138) DCXs. The EC50 of 135 and 134 are 0.065 vs 0.095 µM 
and the EC50 of 139 and 138 are 0.12 vs 0.362 µM, respectively. The anti-HIV effect 
of C9 or C10 methylated DCXs is comparable to 131, and better than 2-EDCP. 
However, methoxy group at 9- or 10-position decreased the activity compared to 131.  
    The effect of the substitution at 8-position (R4) on anti-HIV activity was studied 
and ranked as 8-F > 8-CH3 > 8-OH > 8-OCH3.  8-Fluoro-substituted DCX 144 
presented the best anti-HIV activity and selectivity of the four compounds (136, 140, 
141 and 2-EDCP), with EC50 value of 0.062 µM and TI value greater than 224, which 
is , and comparable active to 131. The finding indicated that there is non-substitution 
with size larger than proton H required at C8 position to maintain or enhance anti-
HIV activity. F atom with the similar size to H exhibits the similar activity. 
        Introducing N-containing groups at position 10 (R2) resulted in compounds 151 
and 152. 151, with a primary amine group, appeared an inactive compound, while 
152 with a C10-cyano moiety, well sustained considerable anti-HIV activity, with 
EC50 ~ 0.20 µM. 
Table 5-1. Anti-HIV activity of DCX analogs (130-152) against NL4-3 HIV strain.a 
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 R1 R2 R3 R4 R5 R6 CC50b 
µM 
EC50c 
µM 
TId 
130 H H H H H H >29.8 0.308 >96.8 
131 H H H H OCH3 H >14.3 0.063 >227.0
132 H H H H OH H N/A N/A --- e 
133 CH3 H H H OCH3 H 4.32 1.52 2.84 
134 H CH3 H H OCH3 H >14.0 0.095 >147.4
135 H H CH3 H OCH3 H 11.4 0.065 175.4 
136 H H H CH3 OCH3 H 11.6 0.15 77.3 
137 OCH3 H H H OCH3 H N/A N/A --- 
138 H OCH3 H H OCH3 H >13.7 0.362 >37.8 
139 H H OCH3 H OCH3 H 10.8 0.12 88.8 
140 H H H OCH3 OCH3 H 11.6 1.70 6.83 
141 H H H OH OCH3 H 8.1 0.33 24.5 
142 F H H H OCH3 H 7.8 0.23 33.9 
143 H H F H OCH3 H 26.0 0.10 260 
144 H H H F OCH3 H >13.9 0.062 >224.2
145 H Br H H OCH3 H N/A N/A --- 
146 H H Br H OCH3 H 9.23 1.47 6.83 
147 H H H H OCH3 Br N/A N/A --- 
148 H OCH3 H CH3 OCH3 H >26.8 0.14 >191.5
149 H H CH3 H OCH3 Br N/A N/A --- 
150 H H CH2Br H OCH3 H >25.2 4.53 >5.55 
151 H NH2 H H OCH3 H N/A  N/A --- 
152 H CN H H OCH3 H 9.08 0.20 45.4 
69 
2EDCP 
      12.1 0.089 136.0 
a All data presented in this table were averaged from at least three independent  
experiments.  
b Cytotoxicity was determined using a Promega CytoTox-GloTM assay kit.     
c This assay was performed in TZM-bl cell infected with NL4-3 HIV strain. 
d Therapeutic index = CC50 / EC50. 
e
  No selective anti-HIV activity (CC50 / EC50 < 4) 
f No suppression at 10 µg/mL 
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        New DCX analogs which showed considerable anti-HIV activity against wild-
type HIV strain were selected and screened the effectiveness against drug-resistant 
HIV RTMDR1 strain. The data are listed in Table 5-2. Interestingly, all selected DCX 
analogs (130-131, 134-136, 139 and 143-144) that are active against wild type 
HIVNL4-3 strain also showed activity against drug-resistant strain. Both EC50 and TI 
values supported that the compound 144 is most active compound followed by 
131>135>143. The activity profile recorded from anti-drug-resistant HIV strain is 
consistent to that derived from drug sensitive wild-type HIV strain.   
        In conclusion, the bioassay data generated from this study clearly 
demonstrated that the new class of DCX analogs is a series of potent and promising 
anti-HIV agents compared with DCP and DCK series. The SARs derived from this 
study are summarized as follows:  
1. The planar ring extension from a two-conjunct ring system (pyranochromone 
in DCP) to a three-conjunct ring system (pyrano-xanthone in DCX) well 
remains or even increases the anti-HIV activity against both wild-type and 
drug-resistant strains, suggesting that a conjugated planar ring system  may 
be essential to interact with the target protein through a ring stacking 
interaction and a larger DCX enables to occupy more space in binding 
pocket , and as a result interacting more efficiently  with amino acids residues 
inside the binding pocket.  
2. Substitutions at the different positions of the molecule dramatically affect the 
anti-HIV activity against both viral strains. A methyl group at the C11 (R1) 
position generated an almost inactive compound (133), while at C9 (R3) or 
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C10 (R2) achieved two potent anti-HIV agents 134 and 135. For the methoxy 
substitution, besides necessity at C6 (R5), C9-OMe substituted compound 
139 exhibited better activity than the C10-OMe and C8-OMe substituted 
compounds 138 and 140. Although with a hydroxyl group at C6, compound 
132 showed no anti-HIV activity and sensitivity, compound 141, with a C8-OH, 
appeared relatively active with EC50 value of 0.3 µM. 
3. The properties of the substitutions at the positions also play an important role.  
A free OH group at C6 resulted in an inactive compound 132.  Masked with a 
C6-methoxyl, compound 131 ranked up to the one of the most active 
compounds. Generally, methyl substituted compounds showed more potent 
anti-HIV activity than the compounds with a methoxyl substitution, except 
compound 149, which bears an additional C5 (R6) bromide. Introducing polar 
groups, such as amine or cyano influenced the anti-HIV profile variably. A 
cyano group at the C10 well maintained the activity, while an amino group 
ruined the activity completely.  
Table 5-2. Anti-HIV activity of DCX analogs against drug-resistant RTMDR1 HIV 
strain. 
 CC50  (µM) EC50a (µM) TIb 
130 >29.8 0.546 >54.6 
131 >14.3 0.074 >193.2 
134 >14.0 0.363 >38.6 
135 11.4 0.081 140.7 
136 11.6 0.37 31.4 
139 10.8 0.42 25.7 
143 26.0 0.16 162.5 
144 >13.9 0.065 >213.8 
69 12.1 0.11 110 
a This assay was performed in TZM-bl cell infected with HIV RTMDR1 strain. 
115 
 
b Therapeutic index = CC50 / EC50. 
 
5.5 Conclusion 
         Our study indentified a new entity, DCX, and a series of DCX analogs, as 
potent anti-HIV agents. Most of DCX analogs are active against both wild-type and 
drug-resistant HIV strains. Compared to the control 2-EDCP (69), three compounds 
(131, 135 and 144) showed better activity in both HIV strains, and four other 
compounds (134, 139, 143 and 148) exhibited comparable anti-HIV potency. The 
compounds that presented high anti-HIV potency also presented high therapeutic 
index. Six analogs (131, 134-135, 143-144 and 148) showed enhanced TI values in 
comparison to the control. We also established SAR study based on anti-HIV on 
both wild-type and drug-resistant HIV strains. Further modification is currently under-
going to further improve anti-HIV activity and pharmacological profile for this type of 
compounds. 
5.6 Experimental Section  
5.6.1 Chemistry 
    1H NMR spectra were measured on a 300 MHz Varian Gemini 2000 
spectrometer using TMS as internal standard. The solvent used was CDCl3 unless 
indicated. Microwave reactions were performed with a Biotage initiator EXP US. 
Mass spectra were measured on Shimadzu LCMS-2010 (ESI-MS). Biotage Flash 
and Isco Companion systems were used as medium-pressure column 
chromatography. All other chemicals were obtained from Aldrich. 
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    Synthesis of substituted 1,3-dihydroxy-9H-xanthen-9-one (169). To a 
mixture of commercially available phlorolgucinol (1.2 equiv), and appropriate 
substituted salicylic acid (1 equiv) was added slowly 20 mL of Eaton’s reagent 
(P2O5-CH3SO3H). The mixture was stirred for 3 hours at 80 oC, cooled to r.t., and 
poured onto ice. After vigorous stirring at r.t. for 2 h, brownish solid precipitated. The 
solid was collected by filtration, washed with water (pH ~ 6), and dried at 60oC to 
give 1,3-dihydorxy-9H-xanthen-9-ones as a brownish solid. In most condition, the 
brownish solid was used without further purification.     
    1,3-Dihydroxy-9H-xanthen-9-one (169b). 1NMR δ 8.15 (1H, d, J = 8.1 Hz, H-
8), 7.85 (1H, t, J = 8.1, 6.9 Hz, H-6), 7.61 (1H, d, J = 8.1 Hz, H-5), 7.49 (1H, t, J = 
8.1, 6.9 Hz, H-7), 6.41 (1H, s, H-4), 6.23 (1H, s, H-2). 
    1,3-Dihydroxy-7-methyl-9H-xanthen-9-one (169e). 1NMR δ 12.88 (1H, s, OH-
1), 11.03 (1H, s, OH-3), 7.92 (1H, s, H-8), 7.68 (1H, d, J = 8.4 Hz, H-5), 7.52 (1H, d, 
J = 8.4 Hz, H-6), 6.41 (1H, s, H-4), 6.22 (1H, s, H-2), 2.44 (3H, s, CH3-7).  
    1,3,8-Trihydroxy-9H-xanthen-9-one (169k). 1NMR δ 11.86 (1H, s, OH-1), 
11.80 (1H, s, OH-8), 7.68 (1H, t, J = 8.4, 8.4 Hz, H-6), 7.01 (1H, d, J = 8.4 Hz, H-5), 
6.80 (1H, d, J = 8.4 Hz, H-7), 6.39 (1H, d, J = 2.1 Hz, H-4), 6.23 (1H, d, J = 2.1 Hz, 
H-2). 
    Synthesis of 6-hydroxy-3,3-dimethylpyrano[2,3-c]-7(3H)-ones(170-181). A 
mixture of starting compounds 169c-i, 169k-q (1equiv), 4,4-dimethoxy-2-methyl-2-
butanol (1.5-2 equiv) and anhydrous pyridine (2-3 mL) was heated at 220 oC for 4 h 
under high-absorption microwave condition. The reaction mixture was cooled to r.t., 
117 
 
diluted with EtOAc and washed with aqueous HCl (10%), and brine. The organic 
layer was separated, and solvent was removed in vacuo. The residue was purified 
by column chromatography with Hexane:EtOAc = 97:3 to afford 170-181.   
    6-Hydroxy-3,3,11-trimethylpyrano[2,3-c]xanthen-7(3H)-one (170). 43.6% 
yield (starting from 1.0 g crude 169c); 1NMR δ 13.22 (1H, s, OH-6), 8.09 (1H, d, J = 
7.6 Hz, H-8), 7.54 (1H, d, J = 7.2 Hz, H-10), 7.25 (1H, t, J = 7.6, 7.2 Hz, H-9), 6.83 
(1H, d, J = 9.6 Hz, H-1), 6.27 (1H, s, H-5), 5.63 (1H, d, J = 9.6 Hz, H-2), 2.58 (3H, s, 
CH3-11), 1.49, 1.49 (each 3H, s, CH3-3,3). 
    6-Hydroxy-3,3,8-trimethylpyrano[2,3-c]xanthen-7(3H)-one (171). 30.0% 
yield (starting from 1.0 g crude 169f); 1NMR δ 13.32 (1H, s, OH-6), 7.53 (1H, t, J = 
8.0, 8.0 Hz, H-10), 7.30 (1H, d, J = 8.0 Hz, H-9), 7.11 (1H, d, J = 8.0 Hz, H-11), 6.82 
(1H, d, J = 9.6 Hz, H-1), 6.24 (1H, s, H-5), 5.50 (1H, d, J = 9.6 Hz, H-2), 2.90 (3H, s, 
CH3-8), 1.48, 1.48 (each 3H, s, CH3-3,3). 
    6-Hydroxy-3,3-dimethyl-11-methoxy-pyrano[2,3-c]xanthen-7(3H)-one (172). 
28.0% yield (starting from 1.5 g crude 169g); 1NMR δ 12.93 (1H, s, OH-6), 7.81 (1H, 
d, J = 8.4 Hz, H-8), 7.29 (1H, d, J = 8.0 Hz, H-10), 7.24 (1H, t, J = 8.4, 8.0 Hz, H-9), 
6.92 (1H, d, J = 10.0 Hz, H-1), 6.28 (1H, s, H-5), 5.62 (1H, d, J = 10.0 Hz, H-2), 4.02 
(3H, s, OCH3-11), 1.48, 1.48 (each 3H, s, CH3-3,3). 
    6-Hydroxy-3,3-dimethyl-10-methoxy-pyrano[2,3-c]xanthen-7(3H)-one (173). 
12.8% yield (starting from 1.0 g crude 169h); 1NMR δ 13.07 (1H, s, OH-6), 8.11 (1H, 
d, J = 9.3 Hz, H-8), 6.92 (1H, d, J = 9.3 Hz, H-9), 6.82 (1H, s, H-11), 6.81 (1H, d, J = 
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9.9 Hz, H-1), 6.24 (1H, s, H-5), 5.61 (1H, d, J = 9.9 Hz, H-2), 3.93 (3H, s, OCH3-10), 
1.48, 1.48 (each 3H, s, CH3-3,3). 
    6-Hydroxy-3,3-dimethyl-9-methoxy-pyrano[2,3-c]xanthen-7(3H)-one (174). 
42.0% yield (starting from 2.0 g crude 169i); 1NMR δ 12.98 (1H, s, OH-6), 7.61 (1H, 
d, J = 3.0 Hz, H-8), 7.41 (1H, d, J = 9.3 Hz, H-11), 7.32 (1H, dd, J = 9.3, 3.0 Hz, H-
10), 6.84 (1H, d, J = 9.9 Hz, H-1), 6.27 (1H, s, H-5), 5.61 (1H, d, J = 9.9 Hz, H-2), 
3.91 (3H, s, OCH3-9), 1.49, 1.49 (each 3H, s, CH3-3,3). 
    6,8-Dihydroxy-3,3 –dimethylpyrano[2,3-c]xanthen-7(3H)-one (175). 28.0% 
yield (starting from 1.0 g crude 169k); 1NMR δ 12.07, 11.95 (each 1H, s, OH-6,8), 
7.56 (1H, t, J = 8.1, 8.7 Hz, H-10), 6.90 (1H, d, J = 8.1 Hz, H-9), 6.81 (1H, d, J = 10.2 
Hz, H-1), 6.79 (1H, d, J = 8.7 Hz, H-11), 6.26 (1H, s, H-5), 5.63 (1H, d, J = 10.2 Hz, 
H-2), 1.49, 1.49 (each 3H, s, CH3-3,3). 
    6 -Hydroxy-11-fluoro-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (176). 
30.0% yield (starting from 1.0 g crude 169l); 1NMR δ 12.77 (1H, s, OH-6), 8.01 (1H, 
d, J = 8.4 Hz, H-8), 7.51 (1H, t, J = 8.4, 9.6 Hz, H-9), 7.29 (1H, d, J = 9.6 Hz, H-10), 
6.86 (1H, d, J = 10.4 Hz, H-1), 6.30 (1H, s, H-5), 5.63 (1H, d, J = 10.4 Hz, H-2), 1.50, 
1.50 (each 3H, s, CH3-3,3). 
    6 -Hydroxy-9-fluoro-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (177). 
20.0% yield (starting from 1.0 g crude 169m); 1NMR δ 12.77 (1H, s, OH-6), 7.90 (1H, 
dd, J = 8.0, 2.8 Hz, H-10), 7.43-7.46 (2H, m, H-8,11), 6.83 (1H, d, J = 10.0 Hz, H-1), 
6.29 (1H, s, H-5), 5.63 (1H, d, J = 10.0 Hz, H-2), 1.49, 1.49 (each 3H, s, CH3-3,3). 
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    6-Hydroxy-8-fluoro-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (178). 46.0% 
yield (starting from 1.0 g crude 169n); 1NMR δ 12.94 (1H, s, OH-6), 7.64 (1H, t, J = 
8.1, 8.4 Hz, H-10), 7.24 (1H, d, J = 8.4 Hz, H-11), 7.04 (1H, d, J = 8.1 Hz, H-9), 6.78 
(1H, d, J = 10.2 Hz, H-1), 6.25 (1H, s, H-5), 5.63 (1H, d, J = 10.2 Hz, H-2), 1.49, 1.49 
(each 3H, s, CH3-3,3). 
    6-Hydroxy-10-bromo-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (179). 
50.0% yield (starting from 1.8 g crude 169o); 1NMR δ 12.79 (1H, s, OH-6), 8.10 (1H, 
d, J = 8.4 Hz, H-8), 7.67 (1H, s, H-11), 7.50 (1H, d, J = 8.4 Hz, H-9), 6.79 (1H, d, J = 
10.0 Hz, H-1), 6.28 (1H, s, H-5), 5.64 (1H, d, J = 10.0 Hz, H-2), 1.49, 1.49 (each 3H, 
s, CH3-3,3). 
    6-Hydroxy-9-bromo-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (180). 
20.0% yield (starting from 1.0 g crude 169p); 1NMR δ 12.72 (1H, s, OH-6),  8.24 (1H, 
d, J = 2.4 Hz, H-8), 7.78 (1H, dd, J = 8.8, 2.4 Hz, H-10), 7.35 (1H, d, J = 8.8 Hz, H-
11), 6.80 (1H, d, J = 6.4 Hz, H-1), 6.27 (1H, s, H-5), 5.63 (1H, d, J = 6.4 Hz, H-2), 
1.49, 1.49 (each 3H, s, CH3-3,3).  
    6-Hydroxy-10-methoxy-3,3,8-trimethylpyrano[2,3-c]xanthen-7(3H)-one 
(181). 30.0% yield (starting from 1.0 g crude 169q); 1NMR δ 13.44 (1H, s, OH-6), 
6.76 (1H, d, J = 10.0 Hz, H-1), 6.67 (1H, s, H-9), 6.62 (1H, s, H-11), 6.18 (1H, s, H-5), 
5.56 (1H, d, J = 10.0 Hz, H-2), 3.87 (3H, s, OCH3-10), 2.81 (3H, s, CH3-8), 1.45,1.45 
(each 3H, s, CH3-3,3).  
    Synthesis of 6-methoxy-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-ones 
(182b-q). A mixture of compounds (94-96a, 170-181) (1 equiv), K2CO3 (3 equiv) in 
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anhydrous acetone (20 mL) was heated to reflux temperate for 3 hours, then allowed 
to cool to r,t. MeI (2-3 equiv) was added at r.t and the reaction was kept stirring 
overnight, monitored by TLC. At completion, the reaction mixture was filtered, and 
the filtrate was evaporated to dryness. The crude products 182j and 182n 
weredirectly carried to the dihydroxylation reaction without purification. The 
remaining crude product was purified by column chromatography using EtOAc and 
Hexane to give compounds 182b-I, k-m and o-q. 
    6-Methoxy-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (182b). 95% yield 
(starting from 150 mg of 94a); ESI+ (m/z, %), 309 (M+, 100);1NMR δ 8.29 (1H, d, J = 
8.1 Hz, H-8), 7.62 (1H, t, J = 7.2, 7.8 Hz, H-10), 7.39 (1H, d, J = 7.8 Hz, H-11), 7.32 
(1H, t, J = 7.2, 8.1 Hz, H-9), 6.89 (1H, d, J = 9.9 Hz, H-1), 6.31 (1H, s, H-5), 5.62 (1H, 
d, J = 9.9 Hz, H-2), 3.98 (3H, s, OCH3-6),  1.50, 1.50 (each 3H, s, CH3-3,3). 
    6-Methoxy-3,3,11-trimethylpyrano[2,3-c]xanthen-7(3H)-one (182c). 78% 
yield (starting from 300 mg of 170); ESI+ (m/z, %), 323 (M++1, 100);1NMR δ 8.14 
(1H, d, J = 7.6 Hz, H-8), 7.48 (1H, d, J = 7.6 Hz, H-10), 7.22 (1H, t, J = 7.6, 7.6 Hz, 
H-9), 6.88 (1H, d, J = 9.6 Hz, H-1), 6.31 (1H, s, H-5), 5.62 (1H, d, J = 9.6 Hz, H-2), 
3.98 (3H, s, OCH3-6), 2.54 (3H, s, CH3-11), 1.51, 1.51 (each 3H, s, CH3-3,3). 
    6-Methoxy-3,3,10-trimethylpyrano[2,3-c]xanthen-7(3H)-one (182d). 100% 
yield (starting from 200 mg of 96a); ESI+ (m/z, %), 323 (M++1, 100);1NMR δ 8.17 
(1H, d, J = 8.1 Hz, H-8), 7.20 (1H, s, H-11), 7.14 (1H, d, J = 8.1 Hz, H-9), 6.89 (1H, d, 
J = 9.9 Hz, H-1), 6.30 (1H, s, H-5), 5.62 (1H, d, J = 9.9 Hz, H-2), 3.97 (3H, s, OCH3-
6), 2.48 (3H, s, CH3-10), 1.50, 1.50 (each 3H, s, CH3-3,3). 
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    6-Methoxy-3,3,9-trimethylpyrano[2,3-c]xanthen-7(3H)-one (182e). 86% yield 
(starting from 399 mg of 95a); ESI+ (m/z, %), 323 (M++1, 100);1NMR δ 8.06 (1H, s, 
H-8), 7.45 (1H, d, J = 8.4 Hz, H-11), 7.31 (1H, d, J = 8.4 Hz, H-10), 6.90 (1H, d, J = 
9.9 Hz, H-1), 6.30 (1H, s, H-5), 5.62 (1H, d, J = 9.9 Hz, H-2), 3.98 (3H, s, OCH3-6), 
2.45 (3H, s, CH3-9), 1.50, 1.50 (each 3H, s, CH3-3,3). 
    6-Methoxy-3,3,8-trimethylpyrano[2,3-c]xanthen-7(3H)-one (182f). 84% yield 
(starting from 700 mg of 171); 1NMR δ 7.45 (1H, t, J = 8.0, 7.6 Hz, H-10), 7.24 (1H, d, 
J = 8.0 Hz, H-9), 7.06 (1H, d, J = 7.6 Hz, H-11), 6.87 (1H, d, J = 10.0 Hz, H-1), 6.28 
(1H, s, H-5), 5.60 (1H, d, J = 10.0 Hz, H-2), 3.98 (3H, s, OCH3-6), 2.90 (3H, s, CH3-
8), 1.50, 1.50 (each 3H, s, CH3-3,3). 
    6,11-Dimethoxy-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (182g). 40% 
yield (starting from 110 mg of 172); ESI+ (m/z, %), 339 (M++1, 100);1NMR δ 7.87 
(1H, d, J = 8.0 Hz, H-8), 7.24 (1H, t, J = 8.0, 8.0 Hz, H-9), 7,15 (1H, d, J = 8.0 Hz, H-
10), 6.97 (1H, d, J = 10.0 Hz, H-1), 6.32 (1H, s, H-5), 5.63 (1H, d, J = 10.0 Hz, H-2), 
4.01, 3.98 (each 3H, s, OCH3-6,11), 1.51, 1.51 (each 3H, s, CH3-3,3). 
    6,10-Dimethoxy-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (182h). 95% 
yield (starting from 110 mg of 173); 1NMR δ 8.17 (1H, d, J = 8.1 Hz, H-8), 7.20 (1H, 
s, H-11), 7.15 (1H, d, J = 8.1 Hz, H-9), 6.89 (1H, d, J = 9.9 Hz, H-1), 6.30 (1H, s, H-
5), 5.62 (1H, d, J = 9.9 Hz, H-2), 3.97 (3H, s, OCH3-6), 2.48 (3H, s, OCH3-10), 1.50. 
1.50 (each 3H, s, CH3-3,3). 
    6,9-Dimethoxy-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (182i). 72% 
yield (starting from 400 mg of 174); ESI+ (m/z, %), 377 (M++K, 100); 1NMR δ 7.66 
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(1H, d, J = 3.0 Hz, H-8), 7.32 (1H, d, J = 9.0 Hz, H-11), 7.20 (1H, dd, J = 9.0, 3.0 Hz, 
H-10), 6.86 (1H, d, J = 9.9 Hz, H-1), 6.27 (1H, s, H-5), 5.59 (1H, d, J = 9.9 Hz, H-2), 
3.95 (3H, s, OCH3-6), 3.87 (3H, s, OCH3-9), 1.47, 1.47 (each 3H, s, CH3-3,3). 
    6-Methoxy-3,3-dimethyl-8-hydroxy-pyrano[2,3-c]xanthen-7(3H)-one (182k). 
95% yield (starting from 100 mg of 175); 1NMR δ 13.21 (1H, s, OH-8), 7.49 (1H, t, J 
= 8.4, 8.0 Hz, H-10), 6.85 (1H, d, J = 9.6 Hz, H-1), 6.83 (1H, d, J = 8.4 Hz, H-9), 6.74 
(1H, d, J = 8.0 Hz, H-11), 6.31 (1H, s, H-5), 5.63 (1H, d, J = 9.6 Hz, H-2), 4.03 (3H, s, 
OCH3-6), 1.51, 1.51 (each 3H, s, CH3-3,3). 
    6-Methoxy-3,3-dimethyl-11-fluoro-pyrano[2,3-c]xanthen-7(3H)-one (182l). 
40% yield (starting from 303 mg of 176); 1NMR δ 8.04 (1H, d, J = 8.4 Hz, H-8), 7.41 
(1H, t, J = 8.4, 9.6 Hz, H-9), 7.24 (1H, d, J = 9.6 Hz, H-10), 6.93 (1H, d, J = 10.0 Hz, 
H-1), 6.33 (1H, s, H-5), 5.64 (1H, d, J = 10.0 Hz, H-2), 3.98 (3H, s, OCH3-6), 1.51, 
1.51 (each 3H, s, CH3-3,3).  
    6-Methoxy-3,3-dimethyl-9-fluoro-pyrano[2,3-c]xanthen-7(3H)-one (182m). 
61% yield (starting from 188 mg of 177); 1NMR δ 7.92 (1H, d, J = 8.4 Hz, H-10), 
7.27-7.41 (2H, m, H-8,11), 6.87 (1H, d, J = 10.4 Hz, H-1), 6.31 (1H, s, H-5), 5.62 (1H, 
d, J = 10.4 Hz, H-2), 3.98 (3H, s, OCH3-6), 1.51, 1.51 (each 3H, s, CH3-3,3).  
    6-Methoxy-10-bromo-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (182o). 
95% yield (starting from 295 mg of 179); 1NMR δ 8.13 (1H, d, J = 8.4 Hz, H-8), 7.60 
(1H, s, H-11), 7.44 (1H, d, J = 8.4 Hz, H-9), 6.83 (1H, d, J = 10.0 Hz, H-1), 6.31 (1H, 
s, H-5), 5.63 (1H, d, J = 10.0 Hz, H-2), 3.97 (3H, s, OCH3-6), 1.50, 1.50(each 3H, s, 
CH3-3,3).  
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    6-Methoxy-9-bromo-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (182p). 72% 
yield (starting from 70 mg of 180); ESI+ (m/z, %), 387 (M+, 100);1NMR δ 8.36 (1H, d, 
J = 2.4 Hz, H-8), 7.69 (1H, dd, J = 8.8, 2.4 Hz, H-10), 7.28 (1H, d, J = 8.8 Hz, H-11), 
6.84 (1H, d, J = 10.0 Hz, H-1), 6.30 (1H, s, H-5), 5.61 (1H, d, J = 10.0 Hz, H-2), 3.96 
(3H, s, OCH3-6), 1.48, 1.48 (each 3H, s, CH3-3,3). 
    6,10-Dimethoxy-3,3,8-trimethylpyrano[2,3-c]xanthen-7(3H)-one (182q). 54% 
yield (starting from 295 mg of 181); 1NMR δ 6.85 (1H, d, J = 10.0 Hz, H-1), 6.67 (1H, 
s, H-9), 6.63 (1H, s, H-11), 6.28 (1H, s, H-5), 5.59 (1H, d, J = 10.0 Hz, H-2), 3.96 (3H, 
s, OCH3-6), 3.88 (3H, s, OCH3-10), 2.86 (3H, s, CH3-8), 1.49, 1.49 (each 3H, s, CH3-
3,3). 
        General procedure for the preparation of 183a-q. A mixture of K3Fe(CN)6 (3 
equiv), K2CO3 (3 equiv), (DHQ)2-PYR (2% equiv), and K2OsO2(OH)4 (2% equiv) was 
dissolved in t-BuOH/H2O (v/v, 1:1) at rt. The solution was cooled to 0 oC and 
methanesulfonamide (1 equiv) was added with stirring. After 20 min, substituted 
pyranochromone (93a and 182b-q) was added. The mixture was stirred at 0 oC for 
1-2 days, monitored by TLC. At completion, Na2S2O5 (excess), water and CH2Cl2 
were added, and stirring was continued for 1 h at rt. The mixture was extracted with 
CH2Cl2 three times, and the combined organic layer was dried over MgSO4. The 
solvent was removed under reduced pressure, and the residue was purified by 
column chromatography with hexanes:EtOAc = 3:7 to afford the pure substituted (+)-
cis-3',4'-dihydroxypyranochromones (183a-b, d-n, p-q). The crude products of 183c 
and 183o were carried to the next step without purification. 
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    (1R,2R)-1,2-dihydroxy-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (183a). 
22% yield (starting from 70 mg of 93a); ESI+ (m/z, %), 313 (M++1, 100);1NMR δ 8.35 
(1H, d, J = 7.8 Hz, H-8), 8.20 (1H, d, J = 9.3 Hz, H-6), 7.71 (1H, t, J = 8.1, 8.1 Hz, H-
10), 7.49 (1H, d, J = 8.1 Hz, H-11), 7.41 (1H, t, J = 8.1, 7.8 Hz, H-9), 6.89 (1H, d, J = 
9.3 Hz, H-5), 5.35 (1H, d, J = 5.4 Hz, H-1), 3.93 (1H, br, H-2), 3.34, 3.10 (each 1H, 
br, OH-1,2), 1.52, 1.46 (each 3H, s, CH3-3,3). 
    (1R,2R)-1,2-dihydroxy-6-methoxy-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-
one (183b). 75% yield (starting from 188mg of 182b); ESI+ (m/z, %), 343 (M+, 100); 
1NMR δ 8.30 (1H, d, J = 7.8 Hz, H-8), 7.63 (1H, t, J = 6.9, 8.1 Hz, H-10), 7.38 (1H, d, 
J = 8.1 Hz, H-11), 7.36 (1H, t, J = 7.8, 6.9 Hz, H-9), 6.30 (1H, s, H-5), 5.25 (1H, br, 
H-1), 3.95 (3H, s, OCH3-6), 3.89 (1H, br, H-2), 3.37, 3.24 (each 1H, br, OH-1,2), 1.52, 
1.48 (each 3H, s, CH3-3,3). 
    (1R,2R)-1,2-dihydroxy-6-methoxy-3,3,10-trimethylpyrano[2,3-c]xanthen-
7(3H)-one (183d). 45% yield (starting from 200 mg of 182d); 1NMR δ 8.15 (1H, d, J 
= 8.4 Hz, H-8), 7.14-7.16 (2H, br, H-9,11), 6.27 (1H, s, H-5), 5.23 (1H, br, H-1), 3.94 
(3H, s, OCH3-6), 3.88 (1H, s, H-2), 3.55 (H, d, J = 3.6 Hz, OH-1), 3.30 (1H, d, J = 6.9 
Hz, OH-2), 2.46 (3H, s, CH3-10), 1.55, 1.49 (each 3H, s, CH3-3,3). 
    (1R,2R)-1,2-dihydroxy-6-methoxy-3,3,9-trimethylpyrano[2,3-c]xanthen-
7(3H)-one (183e). 59% yield (starting from 250 mg of 182e); 1NMR δ 7.97 (1H, s, H-
8), 7.34 (1H, d, J = 8.4 Hz, H-10), 7.19 (1H, d, J = 8.4 Hz, H-11), 6.20 (1H, s, H-5), 
5.20 (1H, t, J = 4.5, 4.5 Hz, H-1), 3.90 (3H, s, OCH3-6), 3.87 (1H, t, J = 4.5, 4.5 Hz, 
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H-2), 3.84 (1H, d, J = 4.5 Hz, OH-1), 3.47 (1H, d, J = 4.5 Hz, OH-2), 2.42 (3H, s, 
CH3-9), 1.55, 1.48 (each 3H, s, CH3-3,3),  
    (1R,2R)-1,2-dihydroxy-6-methoxy-3,3,8-trimethylpyrano[2,3-c]xanthen-
7(3H)-one (183f). 40% yield (starting from 180 mg of 182f); ESI+ (m/z, %), 357 
(M++1, 100); 1NMR δ 7.42 (1H, t, J = 8.4, 7.6 Hz, H-10), 7.20 (1H, d, J = 8.4 Hz, H-9), 
7.07 (1H, d, J = 7.6 Hz, H-11), 6.26 (1H, s, H-5), 5.22 (1H, d, J = 4.8 Hz, H-1), 3.95 
(3H, s, OCH3-6), 3.87 (1H, d, J = 4.8 Hz, H-2), 3.32, 3.22 (each 1H, s, OH-1,2), 2.05 
(3H, s, CH3-8), 1.50, 1.46 (each 3H, s, CH3-3,3). 
183g 60% yield (starting from 35mg mg crude 182g); ESI+ (m/z, %), 339 (M++1, 
100); ESI+ (m/z, %), 373 (M++1, 100); 
    (1R,2R)-6,10-Methoxy-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (183h). 
30% yield (starting from 110 mg of 182h); ESI+ (m/z, %), 373 (M++1, 100);1NMR δ 
8.18 (1H, d, J = 8.7 Hz, H-8), 6.90 (1H, d, J = 8.7 Hz, H-9), 6.71 (1H, s, H-11), 6.26 
(1H, s, H-5), 5.20 (1H, br, H-1), 3.92 (3H, s, OCH3-6), 3.90 (3H, s, OCH3-10), 3.50 
(1H, br, H-2), 3.30 (2H, br, OH-1,2), 1.55, 1.48 (each 3H, s, CH3-3,3),  
    (1R,2R)-1,2-dihydroxy-6,9-dimethoxy-3,3-dimethylpyrano[2,3-c]xanthen-
7(3H)-one (183i). 40% yield (starting from 200 mg of 182i); ESI+ (m/z, %), 373 
(M++1, 100); 1NMR δ 7.65 (1H, s, H-8), 7.31 (1H, d, J = 9.0 Hz, H-11), 7.22 (1H, d, J 
= 9.0 Hz, H-10), 6.27 (1H, s, H-5), 5.23 (1H, br, H-1), 3.94 (3H, s, OCH3-6), 3.90 (3H, 
s, OCH3-9), 3.35 (1H, br, H-2), 3.23, 3,23 (each 1H, s, OH-1,2), 1.51, 1.46 (each 3H, 
s, CH3-3,3). 
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    (1R,2R)-1,2-dihydroxy-6,8-dimethoxy-3,3-dimethylpyrano[2,3-c]xanthen-
7(3H)-one (183j). 50% yield (starting from 60 mg of 182j); ESI+ (m/z, %), 373 (M++1, 
100); 1NMR δ 7.51 (1H, t, J = 8.7, 8.4 Hz, H-10), 6.96 (1H, d, J = 8.7 Hz, H-11), 6.79 
(1H, d, J = 8.4 Hz, H-9), 6.26 (1H, s, H-5), 5.22 (1H, br, H-1), 3.97, 3.91 (each 3H, s, 
OCH3-6,8), 3.19 (1H, br, H-2), 1.49, 1.45 (each 3H, s, CH3-3,3). 
    (1R,2R)-1,2-dihydroxy-6-methoxy-8-hydroxy-3,3-dimethylpyrano[2,3-
c]xanthen-7(3H)-one (183k). 45% yield (starting from 50 mg of 182k); ESI+ 
(m/z, %), 357 (M++1, 100);1NMR δ 13.14 (1H, s, OH-8), 7.52 (1H, t, J = 8.4, 8.4 Hz, 
H-10), 6.96 (1H, d, J = 8.4 Hz, H-9), 6.79 (1H, d, J = 8.4 Hz, H-11), 6.32 (1H, s, H-5), 
5.23 (1H, d, J = 4.8 Hz, H-1), 3.99 (3H, s, OCH3-6), 3.89 (1H, d, J = 4.8 Hz, H-2), 
3.11, 3.10 (each 1H, s, OH-1,2), 1.50, 1.47 (each 3H, s, CH3-3,3). 
    (1R,2R)-1,2-dihydroxy-6-methoxy-11-fluoro-3,3-dimethylpyrano[2,3-
c]xanthen-7(3H)-one (183l). 50% yield (starting from 107 mg of 182l); ESI+ 
(m/z, %), 361 (M++1, 100);1NMR δ 8.06 (1H, d, J = 8.0 Hz, H-8), 7.44 (1H, t, J = 8.0, 
9.6 Hz, H-9), 7.30 (1H, d, J = 9.6 Hz, H-10), 6.34 (1H, s, H-5), 5.29 (1H, d, J = 4.4 
Hz, H-1), 3.98 (3H, s, OCH3-6), 3.91 (1H, s, OH-1), 3.39 (1H, d, J = 4.4Hz, H-2), 
3.21 (1H, s, OH-2), 1.51, 1.46 (each 3H, s, CH3-3,3).  
    (1R,2R)-1,2-dihydroxy-6-methoxy-9-fluoro-3,3-dimethylpyrano[2,3-
c]xanthen-7(3H)-one (183m). 50% yield (starting from 110 mg of 182m); ESI+ 
(m/z, %), 361 (M++1, 100); 1NMR δ 7.92 (1H, d, J = 8.4 Hz, H-10), 7.56 (1H, m, H-8), 
7.39 (1H, m, H-11), 6.34 (1H, d, J = 4.0 Hz, H-1), 6.33 (1H, s, H-5), 5.24 (1H, d, J = 
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4.0 Hz, H-2), 3.97 (2H, s, OCH3-6), 3.60, 3.40 (each 1H, s, OH-1,2), 1.49, 1.47 (each 
3H, s, CH3-3,3).  
    (1R,2R)-1,2-dihydroxy-6-methoxy-8-fluoro-3,3-dimethylpyrano[2,3-
c]xanthen-7(3H)-one (183n). 60% yield (starting from 50 mg of 182n); ESI+ 
(m/z, %), 361 (M++1, 100); 1NMR δ 7.56 (1H, d, J = 9.0 Hz, H-11), 7.21 (1H, d, J = 
9.0 Hz, H-9), 6.98 (1H, t, J = 9.0, 9.0 Hz, H-10), 6.28 (1H, s, H-5), 5.2 (1H, br, H-1), 
3.93 (3H, s, OCH3-6), 3.90 (1H, br, H-2), 3.12, 3.11 (each 1H, s, OH-1,2), 1.50, 1.57 
(each 3H, s, CH3-3,3). 
    (1R,2R)-1,2-dihydroxy-6-methoxy-9-bromo-3,3-dimethylpyrano[2,3-
c]xanthen-7(3H)-one (183p). 45% yield (starting from 50 mg 182p); ESI+ (m/z, %), 
421 (M+, 100); 1NMR δ 8.34 (1H, d, J = 1.6 Hz, H-8), 7.69 (1H, dd, J = 8.8, 1.6 Hz, 
H-10), 7.25 (1H, d, J = 8.8 Hz, H-11), 6.27 (1H, s, H-5), 5.20 (1H, d, J = 4.4 Hz, H-1), 
3.92 (3H, s, OCH3-6), 3.86 (1H, d, J = 4.4 Hz, H-2), 3.20, 3.12 (each 1H, s, OH-1,2), 
1.49, 1.45 (each 3H, s, CH3-3,3).  
     (1R,2R)-1,2-dihydroxy-6,10-dimethoxy-3,3,8-trimethylpyrano[2,3-
c]xanthen-7(3H)-one (183q). 50% yield (starting from 50 mg 182q); 1NMR δ 6.67 
(1H, s, H-9), 6.67 (1H, s, H-11), 6.28 (1H, s, H-5), 5.23 (1H, d, J = 4.4 Hz, H-1), 4.10 
(1H, d, J = 4.4 Hz, H-2), 3.93 (3H, s, OCH3-6), 3.89 (3H, s, OCH3-10), 3.13, 3.11 
(each 1H, s, OH-1,2), 2.87 (3H, s, CH3-8), 1.49, 1.46 (each 3H, s, CH3-3,3). 
    6-Methoxy-10-cyano-3,3-dimethylpyrano[2,3-c]xanthen-7(3H)-one (184). A 
mixture of 182o (10 mg, 0.025 mmoL), zinc cyanide (3.5 mg, 0.03mmoL) and 
Pd(PPh3)4 (12 mg, 0.011mmoL) was dissolved into anhydrous DMF (0.5 mL) and 
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heated to 130oC for 16 hours, monitored by TLC. At completion, the reaction mixture 
was filtered over celite and the crude product was purified by PTLC with EtOAc : 
Hexane = 1:3 to afford pure 184 as yellow solid. 90% Yield; MS-ESI+ (m/z, %) 334 
(M+ + 1, 100); 1NMR δ 8.35 (1H, d, J = 8.0 Hz, H-8), 7.72 (1H, s, H-11), 7.55 (1H, d, 
J = 8.0 Hz, H-9), 6.82 (1H, d, J = 10.0 Hz, H-1), 6.32 (1H, s, H-5), 5.64 (1H, d, J = 
10.0 Hz, H-2), 3.96 (3H, s, OCH3-6), 1.57, 1.49 (each 3H, s, CH3-2,2). 
        General procedure for the preparation of 130-131, 133-146, 148 and 152. 
The substituted 1R,2R-dihydroxypyranoxanthones (183a-r) (1 equiv), (S)-(-)-
camphanic chloride (3 equiv), and DMAP (4 equiv) were stirred in CH2Cl2 for 1-2 h at 
rt, monitored by TLC. At completion, the mixture was diluted with CH2Cl2 and 
washed by water and brine, seperately. The solvent was then removed under 
reduced pressure and the residue was purified by PTLC with hexanes:EtOAc = 3:2 
to afford the appropriately substituted 1R,2R-di-O-(-)-camphanoyl-3,3-
dimethyldihydroprano [2,3-c]xanthones (130-131, 133-146, 148 and 152). 
    1R,2R-(-)-dicamphanoyl-3,3-dimethyl-1,2-dihydropyrano[2,3-c]xanthen-
7(1H)-one  (130). 85% yield (starting from 15 mg of 183a); white solid; mp = 146-148 
oC; ESI+ (m/z, %), 695 (M++Na, 100); 1NMR δ 8.33 (1H, d, J = 7.8 Hz, H-8), 8.31 
(1H, d, J = 9.0 Hz, H-6), 7.67 (1H, t, J = 7.2, 8.4 Hz, H-10), 7.39 (1H, t, J = 7.2, 7.8 
Hz, H-9), 7.35 (1H, d, J = 8.4 Hz, H-11), 6.94 (1H, d, J = 9.0 Hz, H-5), 6.93 (1H, d, J 
= 4.5 Hz, H-1), 5.43 (1H, d, J = 4.5 Hz, H-2), 2.52, 2.322 1.90, 1.75 (each 2H, m, 
camphanoyl-CH2), 1.57, 1.50 (each 3H, s, CH3-3,3), 1.14, 1.12, 1.03, 1.00, 0.93, 
0.89 (each 3H, s, camphanoyl-CH3); [α]D -22.7 o (c  = 0.0015, CH3Cl). 
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    1R,2R-(-)-dicamphanoyl-3,3-dimethyl-6-methoxy-1,2-dihydropyrano[2,3-
c]xanthen-7(1H)-one  (131). 88% yield (starting from 52 mg of 183b); white solid; 
mp = 134-135 oC; ESI+ (m/z, %), 703 (M++1, 100); 1NMR δ 8.40 (1H, d, J = 7.8 Hz, 
H-8), 7.72 (1H, t, J = 7.5, 8.1 Hz, H-10), 7.46 (1H, t, J = 7.8, 7.5 Hz, H-9), 7.39 (1H, 
d, J = 8.1 Hz, H-11), 6.98 (1H, d, J = 4.5 Hz, H-1), 6.46 (1H, s, H-5), 5.53 (1H, d, J = 
4.5 Hz, H-2), 4.12 (3H, s, OCH3-6), 2.60, 2.33, 2.10, 1.80 (each 2H, m, camphanoyl-
CH2), 1.69, 1.61 (each 3H, s, CH3-3,3), 1.25, 1.25, 1.15, 1.12, 1.02, 1.01 (each 3H, s, 
camphanoyl-CH3); [α]D -40.9 o (c  = 0.0069, CH3Cl). 
    1R,2R-(-)-dicamphanoyl-3,3,11-trimethyl-6-methoxy-1,2-dihydropyrano 
[2,3-c]xanthen-7(1H)-one  (133). 85% yield (starting from 41 mg of 183c); white 
solid; mp = 174-175 oC; ESI+ (m/z, %), 717 (M++1, 100); 1NMR δ 8.12 (1H, d, J = 
7.6 Hz, H-8), 7.36 (1H, d, J = 7.2 Hz, H-10), 7.24 (1H, t, J = 7.6, 7.2 Hz, H-9), 6.87 
(1H, d, J = 4.4 Hz, H-1), 6.34 (1H, s, H-5), 5.44 (1H, d, J = 4.4 Hz, H-2), 4.01 (3H, s, 
OCH3-6), 2.45, 2.25, 1.90, 1.67 (each 2H, m, camphanoyl-CH2), 2.39 (3H, s, CH3-
11), 1.60, 1.49 (each 3H, s, CH3-3,3), 1.14, 1.14, 1.03, 1.00, 0.93, 0.89 (each 3H, s, 
camphanoyl-CH3); [α]D -40.9 o (c  = 0.0069, CH3Cl); [α]D -42.5 o (c  = 0.0051, CH3Cl). 
    1R,2R-(-)-dicamphanoyl-3,3,10-trimethyl-6-methoxy-1,2-dihydropyrano 
[2,3-c]xanthen-7(1H)-one  (134). 80% yield (starting from 50 mg of 183d); white 
solid; mp = 174-175 oC; ESI+ (m/z, %), 739 (M++Na, 100); 1NMR δ 8.15 (1H, d, J = 
8.1 Hz, H-8), 7.13 (1H, d, J = 8.1 Hz, H-9), 7.07 (1H, s, H-11), 6.87 (1H, d, J = 4.8 
Hz, H-1), 6.32 (1H, s, H-5), 5.39 (1H, d, J = 4.8 Hz, H-2), 3.99 (3H, s, OCH3-6), 2.41 
(3H, s, CH3-10), 2.45, 2.20, 1.95, 1.80 (each 2H, m, camphanoyl-CH2), 1.56, 1.49 
130 
 
(each 3H, s, CH3-3,3), 1.14, 1.13, 1.04, 1.00, 0.90, 0.87 (each 3H, s, camphanoyl-
CH3); [α]D -37.2 o (c  = 0.0018, CH3Cl). 
    1R,2R-(-)-dicamphanoyl-3,3,9-trimethyl-6-methoxy-1,2-dihydropyrano[2,3-
c]xanthen-7(1H)-one  (135). 77% yield (starting from 100 mg of 183e); Light yellow 
solid; mp = 179-180 oC; 1NMR δ 8.05 (1H, s, H-8), 7.41 (1H, d, J = 8.7 Hz, H-11), 
7.18 (1H, d, J = 8.7 Hz, H-10), 6.86 (1H, d, J = 4.5 Hz, H-1), 6.32 (1H, s, H-5), 5.40 
(1H, d, J = 4.5 Hz, H-2), 4.00 (3H, s, OCH3-6), 2.44 (3H, s, CH3-9), 2.45, 2.20, 1.90, 
1.70 (each 2H, m, camphanoyl-CH2), 1.57, 1.49 (each 3H, s, CH3-3,3), 1.14, 1.13, 
1.03, 1.00, 0.90, 0.88 (each 3H, s, camphanoyl-CH3); [α]D -34.6 o (c  = 0.0028, 
CH3Cl).  
    1R,2R-(-)-dicamphanoyl-3,3,8-trimethyl-6-methoxy-1,2-dihydropyrano[2,3-
c]xanthen-7(1H)-one  (136). 75% yield (starting from 70 mg of 183f); white solid; mp 
= 240-242 oC; ESI+ (m/z, %), 717 (M++1, 100); 1NMR δ 7.39 (1H, t, J = 8.4, 7.6 Hz, 
H-10), 7.09 (1H, d, J = 8.4 Hz, H-9), 7.06 (1H, d, J = 7.6 Hz, H-11), 6.82 (1H, d, J = 
4.8 Hz, H-1), 6.29 (1H, s, H-5), 5.37 (1H, d, J = 4.8 Hz, H-2), 3.98 (3H, s, OCH3-6), 
2,86 (3H, s, CH3-8), 2.46, 2.18, 1.90, 1.65 (each 2H, m, camphanoyl CH2), 1.56, 
1.55 (each 3H, s, CH3-3,3), 1.11, 1.10, 1.01, 1.00, 0.88, 0.86 (each 3H, s, 
camphanoyl CH3); [α]D -29.3 o (c  = 0.003, CH3Cl). 
    1R,2R-(-)-dicamphanoyl-3,3-dimethyl-6,11-dimethoxy-1,2-dihydropyrano 
[2,3-c]xanthen-7(1H)-one  (137). 53% yield (starting from 25 mg of 183g); white 
solid; mp = 179-180 oC; ESI+ (m/z, %), 733 (M++1, 100); 1NMR δ 7.82 (1H, d, J = 
8.0 Hz, H-8), 7.25 (1H, t, J = 8.0, 8.0 Hz, H-9), 7.09 (1H, d, J = 8.0 Hz, H-10), 6.82 
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(1H, d, J = 4.4 Hz, H-1), 6.33 (1H, s, H-5), 5.44 (1H, d, J = 4.4 Hz, H-2), 4.00, 3.91 
(each 3H, s, OCH3-6,11), 2.44, 2.27, 1.95, 1,70 (each 2H, m, camphanoyl-CH2), 
1.57, 1.47 (each 3H, s, CH3-3,3), 1.13, 1.13, 1.03, 1.01, 0.91, 0.87 (each 3H, s, 
camphanoyl-CH3); [α]D -40.8 o (c  = 0.0013, CH3Cl). 
    1R,2R-(-)-dicamphanoyl-3,3-dimethyl-6,10-dimethoxy-1,2-dihydropyrano 
[2,3-c]xanthen-7(1H)-one  (138). 43% yield (starting from 10 mg of 183h); white 
solid; mp = 177-178 oC; ESI+ (m/z, %), 733 (M++1, 100); 1NMR δ 8.12 (1H, d, J = 
8.7 Hz, H-8), 6.84 (1H, dd, J = 8.7, 2.4 Hz, H-9), 6.79 (1H, d, J = 4.5 Hz, H-1), 6.59 
(1H, d, J = 2.4 Hz, H-11), 6.26 (1H, s, H-5), 5.33 (1H, d, J = 4.5 Hz, H-2), 3.92 (3H, s, 
OCH3-6), 3.77 (3H, s, OCH3-10), 2.40, 2.15, 1.95, 1.65 (each 2H, m, camphanoyl-
CH2), 1.50, 1.42 (each 3H, s, CH3-3,3), 1.07, 1.06, 0.97, 0.93, 0.85, 0.81 (each 3H, s, 
camphanoyl-CH3); [α]D -16.2 o (c  = 0.0052, CH3Cl). 
    1R,2R-(-)-dicamphanoyl-3,3-dimethyl-6,9-dimethoxy-1,2-dihydropyrano 
[2,3-c]xanthen-7(1H)-one  (139). 60% yield (starting from 20 mg of 183i); white solid; 
mp = 168-170 oC; ESI+ (m/z, %), 732 (M+, 100); 1NMR δ 7.66 (1H, s, H-8), 7.21, 
7.21 (each 1H, d, H = 9.2 Hz, H-10,11), 6.85 (1H, d, J = 4.8 Hz, H-1), 6.32 (1H, s, H-
5), 5.40 (1H, d, J = 4.8 Hz, H-2), 4.00 (3H, s, OCH3-6), 3.88 (3H, s, OCH3-9), 2.5, 
2.20, 1.90, 1.70 (each 2H, m, camphanoyl-CH2), 1.57, 1.49 (each 3H, s, CH3-3,3), 
1.14, 1.13, 1.03, 1.00, 0.90, 0.88 (each 3H, s, camphanoyl-CH3); [α]D -35.3o (c = 
0.0024, CHCl3). 
    1R,2R-(-)-dicamphanoyl-3,3-dimethyl-6,8-dimethoxy-1,2-dihydropyrano 
[2,3-c]xanthen-7(1H)-one  (140). 52% yield (starting from 10 mg of 183j); white solid; 
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mp = 155-156 oC; ESI+ (m/z, %), 733 (M++1, 100); 1NMR δ 7.44 (1H, t, J = 8.4, 8.4 
Hz, H-10), 6.82 (1H, d, J = 8.4 Hz, H-11), 6.80 (1H, d, J = 4.4 Hz, H-1), 6.75 (1H, d, 
J = 8.4 Hz, H-9), 6.27 (1H, s, H-5), 5.36 (1H, d, J = 4.4 Hz, H-2), 3.94, 3.93 (each 3H, 
s, OCH3-6.8), 2.50, 2.20, 1.90, 1.70 (each 2H, camphanoyl-CH2), 1.54, 1.46 (each 
3H, s, CH3-3,3), 1.13, 1.11, 1.03, 1.00, 0.88, 0.85 (each 3H, s, camphanoyl-CH3); 
[α]D -131.7 o (c = 0.003, CHCl3). 
    1R,2R-(-)-dicamphanoyl-3,3-dimethyl-6-methoxy-8-hydroxy-1,2-dihydro 
pyrano[2,3-c]xanthen-7(1H)-one  (141). 30% yield (starting from 10 mg of 183k); 
white solid; mp = 155-157 oC; ESI+ (m/z, %), 719 (M++1, 100); 1NMR δ 12.94 (1H, s, 
OH-8), 7.43 (1H, t, J = 8.0, 8.4 Hz, H-10), 6.78 (1H, d, J = 4.8 Hz, H-1), 6.74 (1H, d, 
J = 8.0 Hz, H-9), 6.67 (1H, d, J = 8.4 Hz, H-11), 6.31 (1H, s, H-5), 5.36 (1H, d, J= 4.8 
Hz, H-2), 3.99 (3H, s, OCH3-6), 2,45, 2.18, 1.90, 1.65 (each 2H, m, camphanoyl-
CH2), 1.52, 1.45 (each 3H, s, CH3-3,3), 1.10, 1.09, 1.00, 0.96, 0.91, 0.88 (each 2H, s, 
camphanoyl-CH3); [α]D -62.5 o (c = 0.0018, CHCl3). 
    1R,2R-(-)-dicamphanoyl-3,3-trimethyl-6-methoxy-11-fluoro-1,2-dihydro 
pyrano[2,3-c]xanthen-7(1H)-one  (142). 80% yield (starting from 45 mg of 183l); 
white solid; mp = 183-184 oC; ESI+ (m/z, %), 721 (M++1, 100); 1NMR δ 8.05 (1H, d, 
J = 8.0 Hz, H-8), 7.39 (1H, t, J = 8.0, 8.4 Hz, H-9), 7.28 (1H, d, J = 8.4 Hz, H-10), 
6.76 (1H, d, J = 4.4 Hz, H-1), 6.36 (1H, s, H-5), 5.43 (1H, d, J = 4.4 Hz, H-2), 4.01 
(3H, s, OCH3-6), 2.51, 2.20, 1.92, 1.75 (each 2H, m, camphanoyl-CH2), 1.58, 1.48 
(each 3H, s, CH3-3,3), 1.13, 1.13, 1.06, 1.04, 1.00, 0.99 (each 3H, s, camphanoyl-
CH3);  [α]D -41.2 o (c = 0.0052, CHCl3). 
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    1R,2R-(-)-dicamphanoyl-3,3-trimethyl-6-methoxy-9-fluoro-1,2-dihydro 
pyrano[2,3-c]xanthen-7(1H)-one  (143). 48% yield (starting from 45 mg of 183m); 
white solid; mp = 204-205 oC; ESI+ (m/z, %), 721 (M++1, 100); 1NMR δ 7.92 (1H, d, 
J = 8.0 Hz, H-10), 7.28-7.36 (2H, m, H-9,11), 6.85 (1H, d, J = 4.4 Hz, H-1), 6.35 (1H, 
s, H-5), 5.40 (1H, d, J = 4.4 Hz, H-2), 4.00 (3H, s, OCH3-6), 2.49, 2.19, 1.90, 1.68 
(each 2H, m, camphanoyl-CH2), 1.56, 1.49 (each 3H, s, CH3-3,3), 1.14, 1.13, 1.04, 
1.00, 0.90, 0.90 (each 3H, s, camphanoyl-CH3); [α]D -23.6 o (c = 0.0025, CHCl3).  
    1R,2R-(-)-dicamphanoyl-3,3-trimethyl-6-methoxy-8-fluoro-1,2-dihydro 
pyrano[2,3-c]xanthen-7(1H)-one  (144). 80% yield (starting from 5 mg of 183n); 
white solid; mp = 148-150 oC; ESI+ (m/z, %), 743 (M++Na, 100); 1NMR δ 7.44 (1H, t, 
J = 8.7, 8.4 Hz, H-10), 7.01 (1H, d, J = 8.4 Hz, H-11), 6.92 (1H, d, J = 8.7 Hz, H-9), 
6.76 (1H, d, J = 4.5 Hz, H-1), 6.26 (1H, s, H-5), 5.32 (1H, d, J = 4.5 Hz, H-2), 3.91 
(3H, s, OCH3-6), 2.40, 2.12, 1.91, 1.67 (each 2H, m, camphanoyl-CH2), 1.51, 1.42 
(each 3H, s, CH3-3,3), 1.07, 1.05, 0.97, 0.93, 0.83, 0.83 (each 3H, s, camphanoyl-
CH3);  [α]D -17.1o (c = 0.0035, CHCl3). 
    1R,2R-(-)-dicamphanoyl-3,3-dimethyl-6-methoxy-10-bromo-1,2-dihydro 
pyrano[2,3-c]xanthen-7(1H)-one  (145). 52% yield (starting from 35 mg of 183o); 
white solid; mp = 159-160 oC; ESI+ (m/z, %), 781 (M+, 100); 1NMR δ 8.11 (1H, d, J = 
8.4 Hz, H-8), 7.48 (1H, d, J = 1.6 Hz, H-11), 7.44 (1H, dd, J = 8.4 Hz, H-9), 6.80 (1H, 
d, J = 4.8 Hz, H-1), 6.32 (1H, s, H-5), 5.46 (1H, d, J = 4.8 Hz, H-2), 3.97 (3H, s, 
OCH3-6), 2.45, 2.08, 1.90, 1.70 (each 2H, m, camphanoyl CH2), 1.61, 1.61 (each 3H, 
s, CH3-3,3), 1.46, 1.14, 1.12, 1.05, 1.04, 1.02 (each 3H, s, camphanoyl CH3); [α]D -
25.3 o (c = 0.0035, CHCl3). 
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    1R,2R-(-)-dicamphanoyl-3,3-dimethyl-9-bromo-6-methoxy-1,2-dihydro 
pyrano[2,3-c]xanthen-7(1H)-one  (146). 50% yield (starting from 10 mg of 183p); 
white solid; mp = 159-160 oC; ESI+ (m/z, %), 781(M+, 100); 1NMR δ 8.35 (1H, d, J = 
2.8 Hz, H-8), 7.67 (1H, dd, J = 8.8, 2.8 Hz, H-10), 7.20 (1H, d, J = 8.8 Hz, H-11), 
6.81 (1H, d, J = 4.4 Hz, H-1), 6.32 (1H, s, H-5), 5.47 (1H, d, J = 4.4 Hz, H-2), 3.98 
(3H, s, OCH3-6), 2.40, 2,10, 1.90, 1.60 (each 2H, m, camphanoyl-CH2), 1.56, 1.46 
(each 3H, s, CH3-3,3), 1.14, 1.12, 1.03, 1.02, 1.01, 0.77 (each 3H, s, camphanoyl-
CH3); [α]D -13.0 o (c = 0.004, CHCl3). 
    1R,2R-(-)-dicamphanoyl-3,3,8-trimethyl-6, 10-dimethoxy-1,2-dihydropyrano 
[2,3-c]xanthen-7(1H)-one  (148). 52% yield (starting from 10 mg of 183q); white 
solid; mp = 183-184 oC; ESI+ (m/z, %), 781(M+, 100); 1NMR δ 6.85 (1H, d, J = 4.8 
Hz, H-1), 6.64 (1H, d, J = 2.4 Hz, H-9), 6.53 (1H, d, J = 2.4 Hz, H-11), 6.30 (1H, s, 
H-5), 5.39 (1H, d, J = 4.8 Hz, H-2), 3.99 (3H, s, OCH3-6), 3.81 (3H, s, OCH3-10), 
2.84 (3H, s, CH3-8), 2.45, 2.20, 1.90, 1.70 (each 2H, m, camphanoyl CH2), 1.56, 
1.48 (each 3H, s, CH3-3,3), 1.13, 1.13, 1.04, 1.00, 0.91, 0.88 (each 2H, s, 
camphanoyl CH3); [α]D -23.6 o (c = 0.0012, CHCl3). 
    1R,2R-(-)-dicamphanoyl-3,3-dimethyl-6-methoxy-10-cyano-1,2-dihydro 
pyrano[2,3-c]xanthen-7(1H)-one  (152). 80% yield (starting from 36 mg of 183r); 
white solid; mp = 164-165 oC; ESI+ (m/z, %), 728(M++1, 100); 1NMR δ 8.36 (1H, d, J 
= 8.0 Hz, H-8), 7.60 (1H, d, J = 8.0 Hz, H-9), 7.55 (1H, s, H-11), 6.78 (1H, d, J = 4.4 
Hz, H-1), 6.35 (1H, s, H-5), 5.39 (1H, d, J = 4.4 Hz, H-2), 3.99 (3H, s, OCH3-6), 2.50, 
2.20, 1.90, 1.70 (each 2H, m, camphanoyl-CH2), 1.56, 1.47 (each 3H, s, CH3-3,3), 
135 
 
1.12, 1.11, 1.05, 1.02, 0.98, 0.95 (each 3H, s, camphanoyl-CH3); [α]D -30.0 o (c = 
0.0012, CHCl3). 
    1R,2R-(-)-dicamphanoyl-3,3-dimethyl-6-hydroxy-1,2-dihydropyrano[2,3-
c]xanthen-7(1H)-one  (132). Compound 131 (20mg, 0.028 mmoL)  was heated with 
48% HBr (2.0 mL) at reflux temperature for 12 h. The reaction mixture was allowed 
to cool, diluted with water, filtered and the residue was thoroughly washed with water. 
The crude product was purified by prepare TLC with hexanes:EtOAc = 1:1 to yield 
132 as a white solid. 63% yield; MS (ESI+) m/z (%) 689 (M+ + 1, 100); 1NMR δ 13.67 
(1H, s, OH-6), 8.25 (1H, d, J = 7.2 Hz, H-8),  7.74 (1H, d, J = 8.8, 8.4 Hz, H-10), 7.46 
(1H, d, J = 8.4 Hz, H-11), 7.41 (1H, d, J = 8.8, 7.2 Hz, H-10), 6.63 (1H, d, J = 4.8 Hz, 
H-1), 6.44 (1H, s, H-5), 5.36 (1H, d, J = 4.8 Hz, H-2), 2.50, 2.20, 1.90, 1.70 (each 2H, 
m, camphanoyl CH2), 1.50, 1.47 (each 3H, s, CH3-3,3), 1.17, 1.11, 1.08, 1.07, 0.98, 
0.97 (each 3H, s, camphanoyl CH3). 
    1R,2R-(-)-dicamphanoyl-3,3-dimethyl-5-bromo-6-methoxy-1,2-dihydro 
pyrano[2,3-c]xanthen-7(1H)-one  (147). A mixture of 131 (50 mg, 0.071 mmoL), 
NBS (17.0 mg, 0.10 mmol) and CH2Cl2 (2 mL) was heated to 100 oC for 2 h under 
high-absorption microwave conditions. At completion, the mixture was concentrated 
and purified by PTLC with an eluent of hexane:EtOAc = 3:2 to afford pure 147 as 
white solid (43.7 mg). 78.9% yield; mp = 139-140 oC; MS (ESI+) m/z (%) 803, 805 
(M++Na-1, 50; M+ + Na+1, 50); 1NMR δ 8.29 (1H, d, J = 8.0 Hz. H-8), 7.65 (1H, t, J = 
7.6, 7.6 Hz, H-10), 7.39 (1H, t, J = 8.0, 7.6 Hz, H-9), 7.29 (1H, d, J = 7.6 Hz, H-11), 
6.90 (1H, d, J = 4.8 Hz, H-1), 5.44 (1H, d, J = 4.8 Hz, H-2), 4.05 (3H, s, OCH3-6), 
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2.53, 2.21, 1.95, 1.75 (each 2H, m, camphanoyl CH2), 1.14, 1.13, 1.05, 1.01, 0.94, 
0.93 (each 3H, s, camphanoyl CH3); [α]D -51.3 o (c = 0.0023, CHCl3). 
    1R,2R-(-)-dicamphanoyl-3,3,9-trimethyl-5-Bromo-6-methoxy-1,2-dihydro 
pyrano[2,3-c]xanthen-7(1H)-one  (149). The procedure was identical to that used 
for the preparation of 147. 56% yield (starting from 50 mg of 135); white solid; mp = 
170-171 oC; MS (ESI+) m/z (%) 795, 797 (M+-1, 50; M+ +1, 50); 1NMR δ 8.06 (1H, s, 
H-8), 7.45 (1H, d, J = 8.4 Hz, H-10), 7.19 (1H, d, J = 8.4 Hz, H-11), 6.88 (1H, d, J = 
4.4 Hz, H-1), 5.43 (1H, d, J = 4.4 Hz, H-2), 4.04 (3H, s, OCH3-6), 2.44 (3H, s, CH3-9), 
2.50, 2.20, 1.90, 1.70 (each 2H, m, camphanoyl CH2), 1.58, 1.58 (each 3H, s, CH3-
3,3), 1.41, 1.13, 1.04, 1.01, 0.93, 0.91 (each 3H, s, camphanoyl CH3); [α]D -10.8 o (c 
= 0.0078, CHCl3). 
    1R,2R-(-)-dicamphanoyl-3,3-dimethyl-6-hydroxy-9-bromomethyl-1,2-
dihydropyrano[2,3-c]xanthen-7(1H)-one  (150). A mixture of 135 (50 mg, 0.07 
mmoL), NBS (18.6 mg, 0.105 mmoL), and 3-chloroperbenzoic acid (2 mg, 0.01 
mmoL), dissolved in 1 mL of anhydrous CCl4 was heated to 100 oC for 5 h under 
high-absorption microwave conditions. At completion, the mixture was concentrated 
and the residue was purified by PTLC with hexane:EtOAc = 1:1 to afford pure 150 
(31.3 mg, white solid).  56.1% yield; MS (ESI+) m/z (%) 795, 797 (M+-1, 50; M+ +1, 
50); 1NMR δ 13.62 (1H, s, OH-6), 8.20 (1H, d, J = 2.0 Hz, H-8), 7.74 (1H, dd, J = 8.8, 
2.0 Hz, H-10), 7.48 (1H, d, J = 8.8 Hz, H-11), 6.89 (1H, s, H-5), 5.30, 5.30 (each 1H, 
s, H-1,2), 2.44 (2H, s, CH2Br-9), 2.40, 2.15, 1.90, 1.70 (each 2H, m, camphanoyl 
CH2), 1.56, 1.55 (each 3H, s, CH3-3,3), 1.11, 1.10, 1.04, 1.03, 0.98, 0.85 (each 3H, s, 
camphanoyl CH3). 
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    1R,2R-(-)-dicamphanoyl-3,3-dimethyl-6-methoxy-10-amine-1,2-dihydro 
pyrano[2,3-c]xanthen-7(1H)-one  (151). A THF solution of 144 (10 mg, 0.013 
mmoL), 25% ammonium hydroxide solution  (0.004 mL, 0.03 mmoL) was stirred at rt 
for 3.5 h. The mixture was poured into water (excess) and extracted with EtOAc. The 
crude product was purified by PTLC with hexane:EtOAc = 7:1 to afford pure 151 as 
white solid. 15% yield; MS (ESI+) m/z (%) 741 (M+ +Na, 100); 1NMR δ 8.12 (1H, d, J 
= 8.4 Hz, H-8), 7.50 (1H, s, H-11), 7.45 (1H, d, J = 8.4 Hz, H-9), 6.64 (1H, d, J = 5.2 
Hz, H-1), 6.31 (1H, s, H-5), 5.46 (1H, d, H-2), 3.96 (3H, s, OCH3-6), 2.60 (2H, s, 
NH2-10), 2.40, 2.10, 1.90, 1.65 (each 2H, m, camphanoyl-CH2), 1.54, 1.46 (each 3H, 
s, CH3-3,3), 1.14, 1.12, 1.06, 1.05, 1.02, 0.89 (each 3H, s, camphanoyl-CH3). 
5.6.2 HIV-1 Infectivity Assay 
         Anti-HIV-1 activity was measured as reductions in Luc reporter gene 
expression after a single round of virus infection of TZM-bl cells. HIV-1 at 200 
TCID50 and various dilutions of test samples (eight dilutions, 4-fold stepwise) were 
mixed in a total volume of 100 μL growth medium in 96-well black solid plates 
(Corning-Costar). After 48-h incubation, culture medium was removed from each 
well and 100 μL of Bright Glo luciferase reagent was added to each culture well. The 
luciferase activity in the assay wells was measured using a Victor 2 luminometer. 
The 50% inhibitory dose (IC50) was defined as the sample concentration that caused 
a 50% reduction in Relative Luminescence Units (RLU) compared to virus control 
wells after subtraction of background RLU.  
5.6.3 Cytotoxicity Assay 
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        The general procedure was performed according to CytoTox-GloTM cytotoxicity 
assay instructions for using product G9290, G9291 and G9292. (Promega) 
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CHAPTER 6 
DESIGN, SYNTHESIS AND SAR STUDY OF 3’,4’-DI-SUBSTITUTED-2’,2’-
DIMETHYLDIHYDROPYRANO[2,3-f]CHROMONE (DSP) ANALOGS AS POTENT 
CHEMOSENSITIZERS TO OVERCOME MULTIDRUG RESISTANCE IN CANCER 
TREATMENT 
Copyright © 2010 American Chemical Society, J. Med. Chem. In press 
6.1 Introduction 
        Resistance of cancer cells to anticancer drugs remains one of the major 
obstacles in achieving an effective treatment for cancer. Three primary mechanisms 
of anti-cancer drug resistance have been identified by applying cellular and 
molecular biology methods, including decreased uptake of water-soluble drugs, such 
as nucleoside analogues and cisplatin, which require transporters to enter cells; 
various changes in cells that affect the capacity of cytotoxic drugs to kill cells; and 
the most commonly encountered, increased energy-dependent efflux of hydrophobic 
cytotoxic drugs by one of a family of energy-dependent transporters, such as P-
glycoprotein (P-gp, also known as MDR1).1 One approach used in clinical research 
to reverse multi-drug resistance (MDR) is focused on the development of 
chemosensitiziers especially those drugs that target to P-gp and inhibit its activity. 
Verapamil and cyclosporine A (Figure 6-1) are examples of first generation 
chemosensitizers that inhibit the activity of P-gp and were evaluated in the  clinic as 
adjuvants for chemotherapy.  Both compounds are able to increase the intracellular 
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concentration of cytotoxic agents, such as vincristine (VCR), cyclophosphamide, 
dexamethasone, doxorubicin in MDR cells. 2, 3 Moreover, both verapamil and 
cyclosporine A are wildly used medications as either a calcium channel blocker 
(verapamil) to treat hypertension or an immunosuppressant (cyclosporine) to reduce 
the activity of the patient’s immune system in post-allogeneic organ transplant.   
However, clinical studies showed both were generally toxic at the doses required to 
attenuate P-gp function. Since then, several potent and selective next generation 
inhibitors have been developed and investigated yet significant clinical benefit of any 
of them have yet to emerge. The approach to inhibit P-gp may be problematic since 
drug distribution and elimination can be affected by these agents however it is also 
possible that the ideal chemotype for a chemosensitizer has yet to be identified and 
developed .4 
         It has been reported that naturally existing pyranocumarin (±)-praeruptorin A 
(PA) and its khellactone analogs, with 3’,4’-modifications can reverse P-gp-mediated 
MDR.5, 6 (Figure 6-2) (±)-3’-O-4’-O-bis(3,4-Dimethoxycinnamoyl)-cis-khellactone 
(DMDCK, 187)  showed the highest potency among its analogs . 187 is able to 
increase the activity of the chemotherapy drug vinblastine over 110-fold at the 
concentration of 4 µM.6 However, even at such high concentration, compound 187 is 
unable to completely reverse vinblastine resistance in the liver cancer cell system 
used. 6 In addition, it was also reported that the side chains at 3’ and 4’ positions of 
khellactone system play an important role in maintaining high activity. Unfortunately, 
there are only few khellactone analogs with 3’,4’ modifications reported to show 
potent chemosensitizing activity so detailed SAR information is unavailable. 
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Therefore, continuing research to develop novel active analogs  is worthwhile and is 
the basis for the work on the 3’R,4’R-di-substituted-pyranochomons (DSP) series 
reported herein. 
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Figure 6-1  
6.2 Design 
        Even before the structure of P-gp protein was resolved, a general 
pharmacophore model of verapamil essential for P-gp binding and inhibition was 
proposed.7 The pharmacophore consists of a butterfly-shaped molecule with two 
hydrophobic motifs (aromatic ring system) connected with a linker that contains 
some HB acceptors and/or donors. DMDCK (187) was subsequently shown to fit the  
pharmacophore and could be well-docked into the verapamil hypothetical binding 
site on the protein subunit of P-gp.6, 7 
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        DSPs (Figure 6-2) share certain structural similarity to DMDCK (187). This 
prompted us to design and synthesize a series of DSP derivatives as new 
chemosensitizing agents. It is likely that the pyranochromone moiety has similar HB 
properties to those of khellactone in DMDCK. Incorporation of two side chains at 3’ 
and 4’ positions with substitutions containing aromatic moieties could well-mimic the 
hydrophobic moieties in verapamil and DMDCK (187). Based on this rationale, a 
series of DSP derivatives with varied 3’ and 4’ side chains were designed, 
synthesized, and screened against the MDR human esophageal cancer cell line 
(KB-Vin) with or without combination of the chemotherapy drug VCR. This approach 
allowed us to evaluate the intrinsic cytotoxicity of DSP analogs as well as their ability 
to reverse MDR.  
6.3 Chemistry 
        Compound 126c, 3’R,4’R-2’,2’-dimethyl-pyranodihydrochromone, is a core 
structure of all the target compounds and a key intermediate of all the synthetic 
pathways. The synthesis of 126c has been illustrated in Scheme 4-2 (Chapter 4).  A 
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series of side chains with varied chain length and aromatic or non-aromatic 
functional groups at the chain end were introduced to the 3’and 4’ positions of the 
core scaffold (Schemes 6-1, 6-2).  
    The synthesis of 3’,4’-dibenzoyl-pyranodihydrochromone derivateves (188 – 
204 and 206) is showed in Scheme 6-1. 3’,4’-dihydroxy-pyranochrmone (126c) 
stirred with substituted benzoyl chloride or cyclohexal carbonyl chloride afforded 
compound 188 - 199 and 206, in the presence of DMAP at room temperature. 
Reacting phenylacetyl chlorides or 3- phenylpropanoyl chloride with compound 126c 
obtained compounds 200 – 202. Reaction of 126c with trans-cinnomoyl chlorides 
afforded compounds 203- 204.  
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        3’,4’- Di-benzyloxy substituted DSP (205) was also generated by reacting 
compound 126c with benzyl bromide in the presence of NaH in DMF under N2 
atmosphere. (Scheme 6-2) 8 
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        The synthesis of carbamates 207 - 211 was accomplished upon treatment of 
126c with N,N-dialkylcarbamylchloride, or pyrrolidine and piperidine carbonyl 
chlorides respectively, in anhydrous tetrahydrofuran, in the presence of NaH 
(Scheme 6-2). 9  
6.4 Results and Discussion 
6.4.1 Chemosensitization Activity In Vitro 
        VCR is a potent mitotic inhibitor, and is widely used in the combination 
chemotherapy  of acute leukemias and some solid tumors. The GI50 of VCR against 
KB cell line (drug-sensitive) is 0.009 µg/mL (Table 6-1). In KB-Vin cell line, a multi-
 
 
147 
 
drug resistant cancer cell line, the cytotoxic effect of VCR dramatically decreased 
over 270-fold, with GI50 at 2.44 µg/mL (Table 6-1). In order to detect the potential of 
DSPs to reverse MDR in KB-Vin cells, the cytotoxic effect of VCR was evaluated 
with or without the combination of each newly synthesized DSP analog. 
    In order to exclude the possibility that cytotoxicity of the combination treatment 
with VCR and DSP might result from the cytotoxic effect of DSPs, all newly 
synthesized DSPs were screened individually against KB-Vin cells and the results 
are shown in Table 6-1.  In general, all DSP analogs displayed low intrinsic cytotoxic 
activity and similar to the prototype first generation P-gp inhibitor verapamil. 
    The chemosensitizing activity of DSPs was then evaluated by measuring 
reversal of the  cytotoxic effect of VCR in the presence of DSP analogs at 1 µg/mL 
and using  verapamil as the positive control. The results shown in the table 6-2 
reveal that most DSP analogs could reverse VCR resistance by lowing GI50 values 
of VCR in combination treatment in the range of 12-349 folds, compared to 
verapamil which increased VCR sensitivity 141- fold. 
        Compounds 188 – 199 are pyranochromones with benzoyloxy groups 
substituted at 3’ and 4’ positions. Different functional groups were selectively 
introduced on the o, m or p position of benzoyl rings. As shown in Table 6-2, non-
subsituted or o, m-substiuted benzoyloxy-DSPs (188 and 189-192) displayed only 
weak chemosensitizing activity. Compounds 188, 189, and 191 failed to decrease 
the GI50 of VCR below 0.2 µg/ml. o and m-Methoxy-substituted benzoyloxy-DSPs 
(190 and 192) displayed only moderate chemosensitizing activity and increased the 
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potency of VCR around 28 times. 193 with a m-CN substituent, exhibit a better 
chemosensitizing activity (160- fold).    
        DSP analogs with p-substituted benzoyloxy rings (194-199) showed 
substitution-dependent activity. GI50 values of the combination of 194 and 197 with 
VCR were 0.007 and 0.0095 µg/mL, respectively, corresponding to 349- and 257-
fold increased potency relative to VCR alone. The improved potency was greater 
than that with verapamil. Interestingly compound 195, with an ethyl group had a 
substantially lower effect (20.3-fold VCR increase), and   196, substituted with a 
trifluoromethyl group, improved VCR activity by only 16.3-fold. Compounds 198-199, 
with electron-withdrawing groups at p-position, also showed enhancements of 
approximately 200-fold, which was better than that of verapamil. These results 
suggested that, p-substitutions are generally preferred over o- or m-substituents for 
chemosensitizing activity. Substitutions with extended conjugation, e.g., CN or NO2 
groups, and smaller less sterically hindered groups may benefit the aefficacy of 
DSPs as new potent chemosensitizers. 
    Compounds 200-204 were designed, synthesized, and evaluated in order to 
understand the effects of adding a linker between the ester carbonyl group and the 
aromatic substituents in the side chains. Introducing a saturated linker slightly 
increased the chemosensitizing ability, with improved GI50 values of VCR-DSP 
combination from over 0.2 µg/mL for 188 (-O2CC6H5), 0.03 µg/mL for 200 (-
O2CCH2C6H5), and 0.023 µg/mL for 202 (-O2CCH2CH2C6H5). Unexpectedly, 
replacing the phenyl group of 200 with a p-methoxyphenyl in 201 resulted in an 2.4-
fold reduction in chemosensitizing efficacy, and 7.5 times reduction compared with 
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197, which also contains a  p-methoxyphenyl group, but linked directly to the ester 
carbonyl moiety. Compounds 203 and 204 have a conjugated double bond between 
the ester carbonyl group and the phenyl ring. Interestingly, combination of either 
compound with VCR led to significantly enhanced activity.  Compound 203, with an 
unsaturated vinyl group, showed a twofold increased efficacy compared with 202, 
with a saturated ethylene group. 204, with a p-methoxycinnamoyloxy 3’,4’ side 
chains, was able to fully restore the cytotoxicity of VCR. The GI50 value of the VCR-
204 combination was 0.0085 µg/mL, which was comparab to the values with 194 
and 197. Thus, cinnamic and p-methoxycinnamic esters linked to the core 
dihydropyranochromone structure favored MDR reversal activity.  
        In order to investigate the impact of the carbonyl group in the active analogs, 
205 was synthesized. In this compound, the carbonyl moieties at 3’ and 4’ side 
chains have been replaced with methylene groups.  With an ether rather than ester 
side chain, 205 will likely be chemically and metabolically more stable than its 
analog 188. Interestingly, 205 showed better capability to reverse MDR than 188.  
This finding shows that the carbonyl group may not be essential for activity. Further 
SAR studies are needed to confirm this hypothesis.   
    To further investigate the importance of the aromatic substitution at the end of 
3’,4’-side chains, compounds 206-211 were designed and synthesized.  Most  
compounds without an aromatic substitutions at the side chains showed either none  
or marginal chemosensitizing activity, except 208, which showed ten times better 
activity than its counterparts, 207and 209. 208 also presented 5-fold more potency 
than its cyclic analogs 210 and 211, suggesting that the orientation of the N-alkyl 
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substitutions at 3’ and 4’ positions affect the interactions of the drug molecules and 
the binding pocket on the target protein, for example, the different orientation 
between chain alkyl goups (208) and cyclo-alkyl groups (210, 211), which, in turn 
affects the activity. 
    In summary, three compounds, 194, 197 and 204 were found to be the most 
potent chemosensitizers of VCR among 24 newly synthesized compounds. At non-
toxic concentration, they are able to fully restore the activity of VCR against KB-Vin 
so that the MDR cell line was as sensitive as the parent KB cell line. They are also 
over two times better than positive control, verapamil (Table 6-2). While most of the 
active compounds with 3’,4’-ester side chains ending in an aromatic ring, 208, which 
contains two carbamate side chains and no  aromatic system, also exhibited 
considerable potency. The dicarbamate 208 should also exhibit increased polarity 
and different physicochemical properties, which may benefit to further develop new 
analogs with interesting biological activity.   
    The SAR study on 3’,4’ side chains suggested the following conclusions. 1. A 
terminal aromatic ring is important but not necessary to maintain the high 
chemosensitizing capability; 2. Substitutions on the aromatic rings can significant 
impact on the activity.  Moieties that have increased electron density, extended 
conjugation system, or HB effects could benefit the activity; 3. The characteristic of 
the linker between the core structure and the aromatic ring system also affect the 
chemosensitizing potential. Extending the conjugation system by adding double 
bond(s) benefits the activity.  
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    Previous modification of PA and khellactone analogs revealed that the aromatic 
rings at 3’ and 4’ side chains of khellactone benefit the chemosensitizing activity6 
and in addition, methoxy group substituted on cinnamoyl side chains could impact 
the activity. Those results are mostly, but not fully, consistent with those reported 
here for pyranochromone-based DSP active analogs. For example, we found that 
208, without an aromatic ring in the 3’,4’-side chains displayed good 
chemosensitizing ability, and thus, an aromatic ring is not essential for activity.  In 
addition, our studies showed both positive (197 vs 188, 204 vs 203) and negative 
(201 vs 200) effects for the addition of p-methyl group on a phenyl ring. Fong et al. 
also reported that 186 exhibited a decreased potency compared to185. 6 
    Due to the different cell lines and MDR substrates, it is difficult to directly 
compare the activities between prior khellacton analogs and  DSP analogs  reported 
here. However, in both HepG2/Dox and KB-V1 cell lines, the best reported DMDCK 
(187) at 4 µM, could not completely restore the cytotoxicity of vinblastine, an alkaloid 
analog of VCR. In contrast, DSP analogs 194, 197 and 204 completely restored the 
activity of VCR suggesting they are more efficacious and more potent than 187. 
Table 6-1 Cytotoxicity of DSP derivatives, verapamil and VCR 
Compound GI 50  (µg/mL) a Compound GI 50  (µg/mL) 
188 8.79 201 13.3 
189 > 31.5 202 10.1 
190 >31.5 203 9.44 
191 > 31.5 204 >36.4 
192 > 35.8 205 >15.7 
193 > 2.5 206 >20 
194 20.6 207 >20 
195 > 13.6 208 >20 
196 >31.5 209 >20 
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197 9.0 210 >20 
198 >5.5 211 >20 
199 >34.0 verapamil >31.5 
200 8.33 VCR 2.44 
  VCRb (in KB cell) 0.009 
a Cytotoxicity as GI50 values for KB-Vin cell line or as indicated, the concentration of 
compound that caused 50% reduction in absorbance at 562 nm relative to untreated 
cells using the sulforhodamine B assay.  
b cytotoxicity for KB cell line 
Table 6-2 Cytotoxicity of VCR + DSP formula 
 
Compound 
used in 
combination 
R GI50 of VCR 
against KB-
Vin 
(µg/mL) a 
Cytotoxicity 
fold 
increase of 
VCR 
188 >0.2 <12.2 
189 >0.2 < 12.2 
190 0.087 28.1 
191 >0.2 < 12.2 
192 0.09 27.1 
193 O
CN
0.0152 160.5 
194 0.007 348.6 
 
 
153 
 
195 0.12 20.3 
196 0.15 16.3 
197 0.0095 256.8 
198 0.013 187.7 
199 0.012 203.3 
200 0.03 81.3 
201 0.071 34.4 
202 0.023 106.1 
203 0.011 221.8 
204 0.0085 287.1 
205 0.060 40.7 
206 >0.2 < 12.2 
 
207 >0.2 < 12.2 
208 0.021 116.2 
209 >0.2 < 12.2 
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210 0.098 24.9 
211 0.11 22.2 
verapamil  0.017 141.2 
a Cytotoxicity as GI50 values for KB-Vin cell line, the concentration of VCR + DSP 
(1µg/mL) that caused 50% reduction in absorbance at 562 nm relative to untreated 
cells using the sulforhodamine B assay.  
 
6.4.2 Effect on Cellular P-gp Activity 
        The acquired VCR-resistance in KB-Vin cell line  is due to enhanced drug efflux 
via  P-gp over-expression.10 Our research results demonstrate that addition of DSPs 
could restore VCR’s cytotoxicity against KB-Vin, suggesting that DSP analogs might 
function like verapamil as P-gp inhibitors. To test this hypothesis, the effect of DSP 
analogs on efflux of the P-gp substrate Calcein-AM was investigated using the 
established and widely used assay for cellular P-gp function 11. Inhibition of P-gp 
leads to the accumulation of Calcein-AM in the cytoplasm and concomitant 
degredation by esterase action to give a fluorescent derivative that can be 
conveniently monitored as a quatitative measurement of P-gp inhibition. Four DSP 
analogs (191, 196-198) were selected and their ability to facilitate Calcein-AM influx 
was examined and compared to verapamil as the positive inhibitor control. The 
results are shown in Figure 6-3. Compounds 198 and 197 which showed improved 
activity versus verapamil in the chemosensitization assay (Table 6-2) also exerted 
more potent inhibition of cellular P-gp based on the functional assay results. 
Compound 196 which showed weaker chemosensitizing activity versus verapamil 
(16- and 142- fold respectively, Table 6-2) was correspondingly less active as a P-gp 
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inhibitor. Compound 191 exerted no effect on Calcein-AM efflux, which is consistent 
with its lack of chemosensitization activity. These results demonstrate that the rank-
order of chemosensitizing efficacy of DSP analogs is consistent with their relative 
inhibitory activity toward cellular P-gp. Thus, DSP analogs most likely act as pump 
inhibitors in the KB-MDR cell system.  
 
6.5 Conclusion 
        Novel DSP analogs with significant chemosensitizing activity in a MDR human 
cancer cell line were discovered. A SAR study on the 3’ and 4’ side chains of the 
pyranochormone ring was conducted with the following conclusions. p-Substitution 
on the aromatic ring in the side chain is better than o- and m-substitution. Small 
substitutions that can increase electron density or provide HB capacity at the 
putative interaction domain on P-gp benefit the activity. The length and identity of the 
linker is also important and a conjugated double-bond is favorable. Compared with 
verapamil, a prototype first generation chemosensitizer, nine DSPs exhibited 
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improved or comparable chemosensitizing potential. Compounds 194, 197, and 204 
fully overcame VCR resistance in KB-Vin cancer cells at a concentration of 1µg/mL 
(1.63-1.89 µM range). Compared to recent work on khellactone-based 
chemosensitizers our study provides a more comprehensive SAR and the 
discovered DSP analogs with more promising potency at lower concentration. 
Preliminary work indicates that the chemosensitizing activity of DSP analogs results 
from P-gp inhibition. Detailed mechanistic studies are currently under ongoing.  
6.6 Experimental Section 
6.6.1 Chemistry 
       Melting points were measured with a Fisher Johns melting apparatus without 
correction. 1H NMR spectra were measured on a 300MHz varian Gemini 2000 
spectrometer and varian Inova 400 spectrometer using TMS as internal standard. 
The solvent used was CDCl3 unless indicated. Microwave reactions were performed 
with a Biotage initator EXP US. Mass spectra were measured on Shimazu LCMS-
2010 (ESI-MS). Optical rotation was measured with a Jasco Dip-2000 digital 
polarimeter at 20oC at the sodium D line. Thin-layer chromatography (TLC) was 
performed on PLC silica Gel 60 F254 plate (20 x 20, Merck). Biotage Flash and Isco 
companion systems were used as medium-pressure column chromatography. Silica 
40 µM columns from Grace Inc. were used for column chromatography. All final 
compounds are > 95% pure on the basis of the two HPLC conditions. 
        Synthesis of compounds 188-204 and 206. A mixture of compound 126c (1 
equiv), substituted benzoyl cholorde, cyclohenxal chloride,  phenylcaetyl chlorides,  
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3-phenylpropanoyl chloride, or trans-cinnamoyl chlorides (3 equiv), and DMAP (4 
equiv) were stirred in CH2Cl2 for 1-2 H at rt, monitored by TLC. At completion, the 
mixture was diluted with CH2Cl2 and washed by water and brine. The solvent was 
then removed under reduced pressure and the residue was purified by PTLC with 
hexane:EtOAc = 3:2 to afford the appropriatel compounds (188-204 and 206). 
        3’R,4’R-Di-benzoyloxy-2’,2’-dimethyl-2-ethyldihydropyrano[2,3-f] 
chromone (188). 85% yield (starting from 30 mg of 126c); MS-ESI + (m/z, %) 521 
(M+ + Na, 100); 1NMR δ 8.15 (1H, d, J = 8.8 Hz, H-5), 8.10-8.13 (1H, m, benzoyl-
3’,4’), 7.87-7.90, 7.46-7.61, 7.32-7.46 (each 3H, m, bezoyl-3’,4’), 7.01 (1H, d, J = 4.8 
Hz, H-4’), 6.99 (1H, d, J = 8.8 Hz, H-6), 6.08 (1H, s, H-3), 5.66 (1H, d, J = 4.8 Hz, H-
3’), 2.34 (2H, q, J = 8.0 Hz, CH2CH3-2), 1.69, 1.54 (each 3H, s, CH3-2’), 1.02 (3H, t, 
J = 8.0 Hz, CH2CH3-2); [α]D -82.9 o (c = 0.0035, CHCl3); HRMS for  (M+ + H): calcd 
m/z 499.1757, found: 499.1735. 
        3’R,4’R-Di-(2-trifluoromethylbenzoyloxy)-2’,2’-dimethyl-2-ethyldihydro 
pyrano[2,3-f]chromone (189). 88% yield (starting from 30 mg of 126c); MS-ESI + 
(m/z, %) 634 (M+, 100); 1NMR δ 7.95 (1H, d, J = 8.8 Hz, H-5), 7.50-7.80 (8H, m, 
benzoyl-3’,4’), 6.65 (1H, d, J = 8.8 Hz, H-6), 6.30 (1H, s, H-3), 5.85 (1H, d, J = 4.8 
Hz, H-4’), 5.50 (1H, d, J = 4.8 Hz, H-3’), 2.34 (2H, q, J = 8.0 Hz, CH2CH3-2), 1.69, 
1.54 (each 3H, s, CH3-2’), 1.02 (3H, t, J = 8.0 Hz, CH2CH3-2); [α]D -34.7 º (c = 
0.0019, CHCl3); HRMS for  (M+ + H): calcd m/z 635.1504, found: 635.1493. 
        3’R,4’R-Di-(2-methoxybenzoyloxy)-2’,2’-dimethyl-2-ethyldihydropyrano 
[2,3-f]chromone (190). 80% yield (starting from 30 mg of 126c); MS-ESI + (m/z, %) 
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559 (M+ + 1, 100); 1NMR δ 8.18, 7.81, 7.63, 7.07 (each 1H, d, J = 7.6 Hz, 
methoxybenzoyl-3’,4’), 8.11 (1H, d, J = 8.8 Hz, H-5), 7.44, 7,42, 6.93, 6.90 (each 1H, 
t, J = 7.6 Hz, methoxybenzoyl-3’,4’), 7.00 (1H, d, J = 4.8 Hz, H-4’), 6.94 (1H, d, J = 
9.0, H-5), 6.09 (1H, s, H-3), 5.62 (1H, d, J = 4.8 Hz, H-3’), 3.77, 3.70 (each 3H, s, 
methoxybenzoyl-OCH3-3’,4’), 2.48 (2H, q, J = 7.5 Hz, CH2CH3-2), 1.63, 1.56 (each 
3H, s, CH3-2’), 1.14 (3H, t, J = 7.5 Hz, CH2CH3-2); [α]D -40.0 º (c = 0.0007, CHCl3); 
HRMS for  (M+ + H): calcd m/z 559.1963, found: 559.1937. 
        3’R,4’R-Di-(3-trifluoromethylbenzoyloxy)-2’,2’-dimethyl-2-ethyldihydro 
pyrano[2,3-f]chromone (191). 80% yield (starting from 100 mg of 126c); MS-ESI + 
(m/z, %) 635 (M+ + 1, 100); 1NMR δ 8.15 (1H, d, J = 8.8 Hz, H-5), 8.02-8.07 (4H, m, 
benzoyl-3’,4’), 7.77-7.82 (2H, m, benzoyl-3’,4’), 7.49-7.55 (2H, m, benzoyl-3’,4’), 
6.99 (1H, d, J = 4.2 Hz, H-4’), 6.98 (1H, d, J = 8.8 Hz, H-6), 6.06 (1H, s, H-3), 5.67 
(1H, d, J = 4.2 Hz, H-3’), 2.33 (2H, q, J = 7.6 Hz, CH2CH3-2), 1.68, 1.54 (each 3H, s, 
CH3-2’), 1.02 (3H, t, J = 7.6 Hz, CH2CH3-2); [α]D -74.6 º (c = 0.0013, CHCl3); HRMS 
for  (M+ + H): calcd m/z 635.1504, found: 635.1514. 
        3’R,4’R-Di-(3-methoxybenzoyloxy)-2’,2’-dimethyl-2-ethyldihydropyrano 
[2,3-f]chromone (192). 80% yield (starting from 30 mg of 126c); MS-ESI + (m/z, %) 
559 (M+ + 1, 100); 1NMR δ 8.09 (1H, d, J = 8.4 Hz, H-5), 7.71, 7.68 (each 1H, d, J = 
7.6 Hz, benzoyl-3’,4’), 7.61 (2H, s, benzoyl-3’,4’), 7.38 (2H, t, J = 8.4, 7.6 Hz, 
benzoyl-3’,4’), 7.15 (2H, J = 8.4 Hz, benzoyl-3’,4’), 6.93 (1H, d, J = 8.4 Hz, H-6), 
6.17 (1H, s, H-3), 5.53 (1H, d, J = 4.8 Hz, H-4’), 5.41 (1H, d, J = 4.8 Hz, H-3’), 3.87, 
3.85 (each 3H, s, 3-methoxybenzoyl-OCH3-3’,4’), 2.65 (2H,  q, J = 7.6 Hz, CH2CH3-
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2), 1.61, 1.49 (each 3H, s, CH3-2’), 1.30 (3H, t, J = 7.6 Hz, CH2CH3-2); [α]D -116.3 º 
(c = 0.0008, CHCl3); HRMS for  (M+ + H): calcd m/z 559.1968, found: 559.1986.  
        3’R,4’R-Di-(3-cyanobenzoyloxy)-2’,2’-dimethyl-2-ethyl-dihydropyrano[2,3-
f]chromone (193). 65% yield (starting from 100 mg of 126c); MS-ESI + (m/z, %) 
549 (M+ + 1, 100); 1NMR δ 8.19 (1H, d, J = 9.0 Hz, H-5), 8.11 (4H, m, benzoyl-3’,4’), 
7.86, 7.58 (each 2H, m, benzoyl-3’,4’), 7.02 (1H, d, J = 9.0 Hz, H-6), 7.00 (1H, d, J = 
5.4 Hz, H-4’), 6.16 (1H, s, H-3), 5.66 (1H, d, J = 5.4 Hz, H-3’), 2.36 (2H, q, J = 7.8 
Hz, CH2CH3-2), 1.69, 1.57 (each 3H, s, CH3-2’), 1.03 (3H, t, J = 7.8 Hz, CH2CH3-2); 
[α]D -125.0 º (c = 0.0004, CHCl3); HRMS for  (M+ + H): calcd m/z 549.1662, found: 
549.1666.  
        3’R,4’R-Di-(4-methylbenzoyloxy)-2’,2’-dimethyl-2-ethyldihydropyrano[2,3-
f]chromone (194). 80% yield (starting from 25 mg of 126c); MS-ESI + (m/z, %) 527 
(M+ + 1, 100); 1NMR δ 8.13 (1H, d, J = 9.0 Hz, H-5), 7.78, 7.78 (each 2H, d, J = 8.1 
Hz, COOC(CHCH)2CCH3-3’,4’), 7.17, 7.17 (each 2H, d, J = 8.1 Hz, 
COOC(CHCH)2CCH3-3’,4’), 6.97 (1H, d, J = 9.0 Hz, H-6), 6.96 (1H, d, J = 4.8 Hz, H-
4’), 6.07 (1H, s, H-3), 5.62 (1H, d, J = 4.8 Hz, H-3’), 2.39, 2.38 (each 3H, s, 
methylbenzoyl-CH3-3’,4’), 2.34 (2H, q, J = 7.5 Hz, CH2CH3-2), 1.67, 1.53 (each 3H, 
s, CH3-2’), 1.02 (3H, t, J = 7.5 Hz, CH2CH3-2); [α]D -81.3 º (c = 0.0015, CHCl3); 
HRMS for  (M+ + H): calcd m/z 527.2070, found: 527.2063. 
        3’R,4’R-Di-(4-ethylbenzoyloxy)-2’,2’-dimethyl-2-ethyldihydropyrano[2,3-
f]chromone (195). 70% yield (starting from 65 mg of 126c); MS-ESI + (m/z, %) 555 
(M+ + 1, 100); 1NMR δ 8.13 (1H, d, J = 9.0 Hz, H-5), 7.80, 7.80 (each 2H, d, J = 7.2 
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Hz, COOC(CHCH)2CCH2CH3-3’,4’), 7.20, 7.17 (2H, d, J = 7.2 Hz, 
COOC(CHCH)2CCH2CH3-3’,4’), 6.98 (1H, d, J = 9.0 Hz, H-6), 6.97 (1H, d, J = 4.8 
Hz, H-4’), 6.07 (1H, s, H-3), 5.63 (1H, d, J = 4.8 Hz, H-3’), 2.69, 2.68 (each 2H, q, J 
= 7.5 Hz, ethylbenzoyl-CH2CH3-3’,4’), 2.32 (2H, q, J = 7.5 Hz, CH2CH3-2), 1.68, 1.53 
(each 3H, s, H-2’), 1.24(3H, t, J = 7.5 Hz, CH2CH3-2), 1.23, 1.03 (each 3H, t, J = 7.2 
Hz ethylbenzoyl-CH2CH3-3’,4’); [α]D -93.6 º (c = 0.01, CHCl3); HRMS for  (M+ + H): 
calcd m/z 555.2383, found: 555.2366.  
        3’R,4’R-Di-(4-trifluoromethylbenzoyloxy)-2’,2’-dimethyl-2-ethyl-dihydro 
pyrano[2,3-f]chromone (196). 60% yield (starting from 25 mg of 126c); MS-ESI + 
(m/z, %) 635 (M+ + 1, 100); 1NMR δ 8.22 (2H, d, J = 8.1 Hz, trifluoromethylbenzoyl-
H), 8.16 (1H, d, J = 8.7 Hz, H-5), 8.99 (2H, d, J = 8.4 Hz, trifluoromethylbenzoyl-H), 
7.74, (2H, d, J = 8.1 Hz, trifluoromethylbenzoyl-C(CHCH)2CCF3-3’,4’), 7.65 (2H, d, J 
= 8.4 Hz, trifuoromethylbenzoyl- C(CHCH)2CCF3-3’,4’), 7.00 (1H, d, J = 8.7 Hz, H-6), 
7.00 (1H, d, J = 4.8 Hz, H-4’), 6.12 (1H, s, H-3), 5.67 (1H, d, J = 4.8 Hz, H-3’), 2.33 
(2H, q, J = 7.8 Hz, CH2CH3-2), 1.68, 1.56 (each 3H, s, CH3-2’), 1.02 (3H, t, J = 7.8 
Hz, CH2CH3-2); [α]D -74.0 º (c = 0.0025, CHCl3); HRMS for  (M+ + H): calcd m/z 
635.1504, found: 635.1488.  
        3’R,4’R-Di-(4-methoxybenzoyloxy)-2’,2’-dimethyl-2-ethyl-dihydropyrano 
[2,3-f]chromone (197). 80% yield (starting from 100 mg of 126c); MS-ESI + (m/z, 
%) 559 (M+ + 1, 100); 1NMR δ 8.13 (1H, d, J = 8.7 Hz, H-5), 7.85, 7.85 (each 2H, d, 
J = 8.7 Hz, COOC(CHCH)2COCH3-3’,4’), 6.97 (1H, d, J = 8.7 Hz, H-6), 6.95 (1H, d, J 
= 4.8 Hz, H-4’), 6.85, 6.82 (each 2H, d, J = 8.7 Hz, COOC(CHCH)2COCH3-3’,4’), 
6.06 (1H, s, H-3), 5.61 (1H, d, J = 4.8 Hz, H-3’), 3.85, 3.84 (each 3H, s, 
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methoxybenzoyl-OCH3-3’,4’), 2.33 (2H, q, J = 7.2 Hz, CH2CH3-2), 1.66, 1.53 (each 
3H, s, CH3-2’), 1.03 (3H, t, J = 7.2 Hz, CH2CH3-2); [α]D -105.0 º (c = 0.0012, CHCl3); 
HRMS for  (M+ + H): calcd m/z 559.1968, found: 559.1954. 
         3’R,4’R-Di-(4-cyanobenzoyloxy)-2’,2’-dimethyl-2-ethyl-dihydropyrano[2,3-
f]chromone (198). 80% yield (starting from 100 mg of 126c); MS-ESI + (m/z, %) 
549 (M+ + 1, 100); 1NMR δ 8.17 (1H, d, J = 8.7 Hz, H-5), 7.98, 7.97 (each 2H, d, J = 
8.7 Hz, benzoyl-COC(CHCH)2CCN-3’,4’), 7.71, 7.68 (each 2H, d, J = 8.7 Hz, 
benzoyl-COC(CHCH)2CCN-3’,4’), 6.99 (1H, d, J = 8.7 Hz, H-6), 6.98 (1H, d, J = 5.1 
Hz, H-4’), 6.08 (1H, s, H-3), 5.66 (1H, d, J = 5.1 Hz, H-3’), 2.34 (2H, t, J = 7.8 Hz, 
CH2CH3-2), 1.67, 1.56 (each 3H, s, CH3-2’), 1.01 (3H, t, J = 7.8 Hz, CH2CH3-2); [α]D 
-104.8 º (c = 0.0014, CHCl3); HRMS for  (M+ + H): calcd m/z 549.1662, found: 
549.1648. 
        3’R,4’R-Di-(4-nitrobenzoyloxy)-2’,2’-dimethyl-2-ethyl-dihydropyrano[2,3-
f]chromone (199). 50% yield (starting from 50 mg of 126c); MS-ESI + (m/z, %) 589 
(M+ + 1, 100); 1NMR δ 8.23, 8.22 (each 2H, d, J = 9.0 Hz, COOC(CHCH)2CNO2-
3’,4’), 8.14 (1H, d, J = 8.4 Hz, H-5), 8.06, 8.04 (each 2H, d, J = 9.0 Hz, 
COOC(CHCH)2CNO2-3’,4’), 6.99 (1H, d, J = 8.4 Hz, H-6), 6.98 (1H, d, J = 4.8 Hz, H-
4’), , 6.06 (1H, s, H-3), 5.67 (1H, d, J = 4.8 Hz, H-3’), 2.33 (2H, q, J = 7.2 Hz, 
CH2CH3-2), 1.68, 1.57 (each 3H, s, CH3-2’), 1.00 (3H, t, J = 7.2 Hz, CH2CH3-2); [α]D 
-74.7 º (c = 0.0015, CHCl3); HRMS for  (M+ + H): calcd m/z 589.1458, found: 
589.1437. 
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        3’R,4’R-Di-(2-phenylacetoxy)-2’,2’-dimethyl-2-ethyl-dihydropyrano[2,3-f] 
chromone (200). 53% yield (starting from 30 mg of 126c); MS-ESI + (m/z, %) 549, 
527 (M+ + Na, 60; M+ + 1, 40); 1NMR δ 8.07 (1H, d, J = 8.8 Hz, H-5), 7.30 (10H, m, 
phenyl-3’,4’), 6.85 (1H, d, J = 8.8 Hz, H-6), 6.58 (1H, d, J = 4.8 Hz, H-4’), 6.05 (1H, 
s, H-3), 5.20 (1H, d, J = 4.8Hz, H-3’), 3.53, 3.46 (each 2H, d, J = 15.9 Hz, acetoxy-
COOCH2-3’,4’), 2.25 (2H, q, J = 7.6 Hz, CH2CH3-2), 1.32, 1.25 (each 3H, s, CH3-2’), 
1.12 (3H, t, J = 7.6 Hz, CH2CH3-2); [α]D -60.0 º (c = 0.0015, CHCl3); HRMS for  (M+ + 
H): calcd m/z 527.2070, found: 527.2060. 
        3’R,4’R-Di-[2-(4-methoxyphenylacetoxy)]-2’,2’-dimethyl-2-ethyl-dihydro 
pyrano[2,3-f]chromone (201). 50% yield (starting from 25 mg of 126c); MS-ESI - 
(m/z, %) 585 (M- - 1, 100); 1NMR δ 8.07 (1H, d, J = 9.0 Hz, H-5), 7.20, 7.17 (each 
2H, d, J = 8.7 Hz, phenyl-C(CHCH)2COCH3-3’,4’), 6.87, 6.85 (each, 2H, d, J = 8.7 
Hz, phenyl-C(CHCH)2COCH3-3’,4’), 6.78 (1H, d J = 9.0 Hz, H-6), 6.44 (1H, d, J = 4.8 
Hz, H-4’), 6.10 (1H, s, H-3), 4.03 (1H, d, J = 4.8 Hz, H-3’), 2.25 (2H, q, J = 7.5 Hz, 
CH2CH3-2), 1.49, 1.34 (each 3H, s, CH3-2’), 1.13 (3H, t, J = 7.5 Hz, CH2CH3-2); [α]D 
-47.7 º (c = 0.0013, CHCl3); HRMS for  (M+ + H): calcd m/z 587.2281, found: 
587.2266. 
        3’R,4’R-Di-(3-phenylpropanoyloxy)-2’,2’-dimethyl-2-ethyl–dihydropyrano 
[2,3-f]chromone (202). 70% yield (starting from 25 mg of 126c); MS-ESI + (m/z, %) 
555 (M+ + 1, 100); 1NMR δ 8.09 (1H, d, J = 9.0 Hz, H-5), 7.22 (10H, m, phenyl-
C(CHCH)2CH-3’,4’), 6.88 (1H, d, J = 9.0 Hz, H-6), 6.59 (1H, d, J = 4.8 Hz, H-4’), 6.09 
(1H, s, H-3), 5.26 (1H, d, J = 4.8 Hz, H-3’), 2.95, 2.95 (4H, t, J = 7.6 Hz, propanoyl-
CH2CH2-3’.4’), 2.67, 2.58(each 2H, t, J = 7.6 Hz, propanoyl-CH2CH2-3’,4’), 2.46 (2H, 
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q, J = 7.5 Hz, CH2CH3-2), 1.43, 1.33 (each 3H, s, CH3-2’), 1.67 (3H, t, J = 7.5 Hz, 
CH2CH3-2); [α]D -74.8 º (c = 0.0023, CHCl3); HRMS for  (M+ + H): calcd m/z 
555.2393, found: 555.2378.  
        3’R,4’R-Di-(E)-phenylacryloyloxy-2’,2’-dimethyl-2-ethyl-dihydropyrano 
[2,3-f]chromone (203). 65% yield (starting from 50 mg of 126c); MS-ESI + (m/z, %) 
551 (M+ + 1, 100); 1NMR δ 8.05 (1H, d, J = 9.0 Hz, H-5), 7.63, 7.63 (each 1H, d, J = 
15.9 Hz COOCHCH-3’,4’), 7.36-1.40 (5H, m, phenyl-3’,4’), 1.23-1.29 (5H, m, phenyl-
3’,4’), 6.88 (1H, d, J = 9.0 Hz, H-6), 6.75 (1H, d, J = 4.8 Hz, H-4’), 6.38 (2H, d, J = 
15.9 Hz, COOCHCH-3’.4’), 6.02 (1H, s, H-3), 5.42 (1H, d, J = 4.8 Hz, H-3’), 2.42 
(2H, q, J = 6.9 Hz, CH2CH3-2), 1.52, 1.43 (each 3H, s, CH3-2’), 1.17 (3H, t, J = 6.9 
Hz, CH2CH3-2); [α]D -75.3 º (c = 0.0017, CHCl3); HRMS for  (M+ + H): calcd m/z 
551.2070, found: 551.2074. 
        3’R,4’R-Di-(E)-4-methoxyphenylacryloyloxy-2’,2’-dimethyl-2-ethyl-dihydro 
pyrano[2,3f]chromone (204). 50% yield (starting from 25 mg of 126c); MS-ESI + 
(m/z, %) 611 (M+ + 1, 100); 1NMR δ 8.10 (1H, d, J = 9.0 Hz, H-5), 7.66, 7.65 (each 
1H, d, J = 15.3 Hz, (E)-acryloxy-OCOCHCH-3’,4’), 7.40 (4H, dd, J = 8.7, 3.0 Hz, 4-
methoxyphenyl-C(CHCH)2COCH3-3’,4’), 6.93 (1H, d, J = 9.0 Hz, H-6), 6.85 (4H, dd, 
J = 8.7, 3.0 Hz, 4-methoxyphenyl-C(CHCH)2COCH3-3’,4’), 6.80 (1H, d, J = 4.8 Hz, 
H-4’), 6.33, 6.32 (each 1H, d, J = 15.3 Hz, (E)-acryloxy-OCOCHCH-3’,4’), 6.10 (1H, 
s, H-3), 5.47 (1H, d, J = 4.8 Hz, H-3’), 6.65 (6H, s, OCH3-3’,4’), 2.47 (2H, q, J = 7.5 
Hz, CH2CH3-2), 1.58, 1.49 (each 3H, s, CH3-2’), 1.59 (3H, t, J = 7.5 Hz, CH2CH3-2); 
[α]D -70.0 º (c = 0.0043, CHCl3); HRMS for  (M+ + H): calcd m/z 611.2281, found: 
611.2260.  
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        3’R,4’R-Di-(cyclohexanecarbonyloxy)-2’,2’-dimethyl-2-ethyl –
dihydropyrano [2,3-f]chromone (206). 20 % yield (starting from 25 mg of 126c); 
MS-ESI + (m/z, %) 511 (M+ + 1, 100); 1NMR δ 8.08 (1H, d, J = 9.0 Hz, H-5), 6.88 
(1H, d, J = 9.0 Hz, H-6), 6.61 (1H, d, J = 4.5 Hz, H-4’), 6.12 (1H, s, H-3), 5.27 (1H, d, 
J = 4.5 Hz, H-3’), 2.56 (2H, q, J = 7.5 Hz, CH2CH3-2), 2.35 (2H, m, 
cyclohexanecarbonyl-3’,4’), 2.80 (12H, m, cyclohexanecarbonyl-3’,4’), 1.49, 1.42 
(each 3H, s, CH3-2’), 1.35 (8H, m, cyclohexanecarbonyl-3’,4’), 1.23 (3H, t, J = 7.5 
Hz, CH2CH3-2); [α]D -15.4 º (c = 0.005, CHCl3); HRMS for  (M+ + H): calcd m/z 
511.2696, found: 511.2713. 
        Synthesis of 3’R,4’R-Dibenzyloxy-2’,2’-dimethyl-2-ethyl-dihydropyrano 
[2,3-f]chromone (205). NaH (20.4 mg, 0.51 mmoL) was suspended in dry DMF. To 
this suspension were added at 0 oC a solution of compound 126c (50 mg, 0.17 
mmoL) in dry DMF (0.5 mL), and benzyl bromide (0.05 mL, 0.43 mmoL), under the 
protection of N2. After 1h, the mixture was poured  into 5% aqueous NaHCO3 
solution and extracted with Et2O for 3 times. The organic layers were combined and 
dried over Na2SO4.  The crude product was purified utilizing preparing TLC with 
hexane : EtOAc = 1 : 1 to afford 205 (16.2 mg). 57.3 % yield; MS-ESI + (m/z, %) 493 
(M+ + Na, 100); 1NMR δ 8.00 (1H, d, J = 8.7 Hz, H-5), 7.41, 7.28 (each 5H, m, 
benzyl-3’,4’), 6.81(1H, d, J = 8.7 Hz, H-6), 6.13 (1H, s, H-3), 5.10, 4.95, 4.85, 4.75 
(each 1H, d, J = 11.4 Hz, benzyl-CH2-3’,4’)5.09 (1H, d, J = 4.2 Hz, H-4’), 3.75 (1H, d, 
J = 4.2 Hz, H-3’), 2.60 (2H, q, J = 7.5 Hz, CH2CH3-2), 1.57, 1.50 (each 3H, s, CH3-
2’), 1.28 (3H, t, J = 7.5 Hz, CH2CH3-2); [α]D -40.9 º (c = 0.01, CHCl3); HRMS for  (M+ 
+ H): calcd m/z 471.2171, found: 471.2155. 
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        Synthesis of compounds 207-211. NaH (5 equiv) was added to a solution of 
compound 126c in dry THF at ice-bath condition and diverse carbamyl chlorides (3 
equiv) were added. Stir at room temperature and monitored by TLC. At completion, 
the reaction mixture was poured carefully onto ethyl acetate and saturated aqueous 
NaHCO3. The organic layer was washed with water for 3 times, dried over 
anhydrous MgSO4, and evaporated under reduced pressure. The crude product was 
purifed utilizing prepare TLC.  
        3’R,4’R-Di(dimethylcarbamoyloxy)-2’,2’-dimethyl-2-ethyl–dihydropyrano 
[2,3-f]chromone (207). 30% yield (starting from 100 mg of 126c); MS-ESI + (m/z, 
%) 433 (M+ + 1, 100); 1NMR δ 8.07 (1H, d, J = 8.8 Hz, H-5), 6.88 (1H, d, J = 8.8 Hz, 
H-6), 6.52 (1H, d, J = 4.8 Hz, H-4’), 6.11 (1H, s, H-3), 5.22 (1H, d, J = 4.8 Hz, H-3’), 
2.97, 2.85 (each 6H, m, dimethylcarbamoyl-CH2-3’,4’), 2.55 (2H, q, J = 7.2 Hz, 
CH2CH3-2), 1.49, 1.46 (each 3H, s, CH3-2’), 1.24 (3H, t, J = 7.2 Hz, CH2CH3-2); [α]D 
-28.6 º (c = 0.01, CHCl3); HRMS for  (M+ + H): calcd m/z 433.1957, found: 433.195. 
        3’R,4’R-Di(diethylcarbamoyloxy)-2’,2’-dimethyl-2-ethyl–dihydropyrano 
[2,3-f]chromone (208). 25% yield (starting from 25 mg of 126c); MS-ESI + (m/z, %) 
489 (M+ + 1, 100); 1NMR δ 8.07 (1H, d, J = 8.8 Hz, H-5), 6.88 (1H, d, J = 8.8 Hz, H-
6), 6.59 (1H, d, J = 4.8 Hz, H-4’), 6.11 (1H, s, H-3), 5.25 (1H, d, J = 4.8 Hz, H-3’), 
3.35, 3.35, 3.18, 3.18 (each 2H, q, J = 6.8 Hz, diethylcarbamoyl-CH2-3’,4’), 2.55 (2H, 
q, J = 7.6 Hz, CH2CH3-2), 1.49, 1.47 (each 3H, s, CH3-2’), 1.23 (3H, t, J = 7.6 Hz, 
CH2CH3-2), 1.16 (6H, t, J = 6.8 Hz, diethylcarbamoyl-CH3-4’), 1.09, 0.98 (each 3H, t, 
J = 6.8 Hz, diethylcarbamoyl-CH3-3’); [α]D -30.0 º (c = 0.001, CHCl3); HRMS for  (M+ 
+ H): calcd m/z 489.2601, found: 489.2594. 
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        3’R,4’R-Di(dibutylcarbamoyloxy)-2’,2’-dimethyl-2-ethyl–dihydropyrano 
[2,3-f]chromone (209). 30% yield (starting from 50 mg of 126c); MS-ESI + (m/z, %) 
601 (M+ + 1, 100); 1NMR δ 8.06 (1H, d, J = 8.8 Hz, H-5), 6.86 (1H, d, J = 8.8 Hz, H-
6), 6.58 (1H, d, J = 4.8 Hz, H-4’), 6.11 (1H, s, H-3), 5.23 (1H, d, J = 4.8 Hz, H-3’), 
3.25 (8H, m, dibutylcarbamoyl-3’,4’), 2.56 (2H, q, J = 7.6 Hz, CH2CH3-2), 1.57 (6H, 
m, dibutylcarbamoyl-CH2), 1.47, 1.46 (each 3H, s, CH3-2’), 1.33 (8H, m, 
dibutylcarbamoyl-CH2), 1.25 (3H, t, J = 7.6 Hz, CH2CH3-2), 1.08 (2H, q, J = 7.2 Hz, 
dibutylcarbamoyl-CH2-3’), 0.95, 0.94 (each 3H, t, J = 7.6 Hz, dibutylcarbamoyl-CH3-
4’), 0.86, 0.72 (each 3H, t, J = 7.2 Hz, dibutylcarbamoyl-CH3-3’); [α]D -13.5 º (c = 
0.012, CHCl3); HRMS for  (M+ + H): calcd m/z 601.3853, found: 601.3833. 
        3’R,4’R-Di(pyrrolidine-1-carbonyloxy)-2’,2’-dimethyl-2-ethyl–dihydro 
pyrano[2,3-f]chromone (210). 35% yield (starting from 25 mg of 126c); MS-ESI + 
(m/z, %) 485 (M+ + 1, 100); 1NMR δ 8.05 (1H, d, J = 8.8 Hz, H-5), 6.87 (1H, d, J = 
8.8 Hz, H-6), 6.54 (1H, d, J = 4.8 Hz, H-4’), 6.11 (1H, s, H-3), 5.23 (1H, d, J = 4.8 
Hz, H-3’), 3.48, 3.26 (each 4H, m, pyrrolidine-N(CH2)2(CH2)2-3’,4’), 2.55 (2H, q, J = 
7.6 Hz, CH2CH3-2), 1.86 (8H, m, pyrrolidine-N(CH2)2(CH2)2-3’,4’), 1.50, 1.47 (each 
3H, s, CH3-2’), 1.21 (3H, t, J = 7.6 Hz, CH2CH3-2); [α]D -23.8 º (c = 0.011, CHCl3); 
HRMS for  (M+ + H): calcd m/z 485.2288, found: 485.2277. 
        3’R,4’R-Di-(piperidine-1-carbonyloxy)-2’,2’-dimethyl-2-ethyl–dihydro 
pyrano[2,3-f]chromone (211). 32% yield (starting from 25 mg of 126c); MS-ESI + 
(m/z, %) 513 (M+ + 1, 100); 1NMR δ 8.06 (1H, d, J = 8.8 Hz, H-5), 6.87 (1H, d, J = 
8.8 Hz, H-6), 6.56 (1H, d, J = 4.8 Hz, H-4’), 6.11 (1H, s, H-3), 5.24 (1H, d, J = 4.8 
Hz, H-3’), 3.77 (8H, m, piperidine-N(CH2)2(CH2)2CH2-3’,4’), 2.57 (2H, q, J = 7.6 Hz, 
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CH2CH3-2), 1.58 (12H, m, piperidine-N(CH2)2(CH2)2CH2-3’,4’), 1.47, 1.46 (each 3H, 
s, CH3-2’), 1.26 (3H, t, J = 7.6 Hz, CH2CH3-2); [α]D -28.2 º (c = 0.0017, CHCl3); 
HRMS for  (M+ + H): calcd m/z 513.2601, found: 513.2620. 
6.6.2 Chemosensitization (MDR Modulation) Assay:   
    Three thousand drug-resistant cells, KB-vin cells (MDR-1) selected using VCR12 
were treated for 2 or 3 days with test agent in the presence or absence of VCR . The 
end-point is cellular protein measured using the Sulforhodamine B (SRB) method 
developed at NIH-NCI for in vitro anticancer drug screening 13.  The degree of 
chemoreversal was determined by fixing the concentration of test agent and 
measuring the alteration in dose-response of cells to VCR toxicity. Verapamil was 
used as chemosensitizer control and data  from replicate experiments was plotted 
and the apparent GI50 value were determined  using statistical software (GraphPad 
Prizm, CA).  
6.6.3 Calcein-AM Loading Assay: 
        10,000 KB-Vin (MDR) cells per well were seeded into 96-well plates with 
medium containing 5% FBS and incubated   for 1 day for adhesion and equilibration. 
Treatment involved supplementing cultures with distinct concentrations of test 
compounds for 30 minutes at 37oC. After removing medium, fresh medium with both 
1 µM Calcein-AM (Alexis Biochemicals) and test compounds as needed. Following  
incubation for 30 minutes at 37 medium was removed  and wells washed  gently and 
quickly with cold PBS buffer in low ambient light condition.. Cell were lysed using 20 
mM Tris buffer and fluorescence measured using  a BioTek TLx800 ELISA reader 
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set to Ex. 494 nm and  Em. 517 nm. Composite data obtained from two or more 
independent experiments were analyzed using PrizmTM (Graphpad Software, San 
Diego, CA)11 
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CHAPTER 7 
SUMMARY, CONCLUSIONS, AND FUTURE DIRECTIONS 
7.1 General Conclusions 
       In this research work, we first optimized the synthetic methodology for the 2,2-
dimethyl-2H-chromone motif that provides key intermediates to synthesize DCK and 
DCP analogs. The resulting microwave-assisted method dramatically shortened the 
reaction time and also increased the yields of the desired angular 2.2-dimethyl-2H-
chromone products compared with linear side products.  
    Using the optimized synthetic method, we next designed and synthesized 23 
novel DCP analogs to further improve anti-HIV activity against both wild-type and 
drug-resistant HIV strains and to improve water-solubility.  A more comprehensive 
SAR was generated for DCP analogs, and two compounds with increased activity 
against both virus strains were identified with improved water-solubility.  A reliable 
QSAR model was established based on novel DCP analogs, and pharmacophore 
analysis identified potential pharmacophores in DCP that opened a new avenue to 
design new analogs.  
    Next, a new anti-HIV entity, 1,2-dicamphanoyl-pyranoxanthone (DCX), was 
developed, synthesized, and evaluated. Skeleton-modified DCX analogs maintained 
anti-HIV activity against both wild-type and drug-resistant HIV strains. A SAR study 
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of the substitutions on the planar xanthone ring system was conducted, and Three 
DCX analogs exhibited better anti-HIV activity against both virus strains than the 
control, 2-EDCP. Six DCXs presented enhanced TI than 2-EDCP. 
        Finally, 3’,4’-di-substituted-2’,2’-dimethyldihydropyranochromone (DSP) 
analogs were designed and synthesized as potent chemosensitizers against multi-
drug resistant cancer cells. A comprehensive SAR study concerning the 3’ and 4’ 
side chains was conducted, and three DSP analogs were identified with improved 
chemosensitizing potential to reverse MDR in the KB-Vin human esophageal cancer 
cell line compared with verapamil, the first identified chemosensitizer. A preliminary 
mechanism of action study revealed that DSP analogs might function as P-gp 
inhibitors to reverse MDR. 
7.1.1 Development of Efficient Microwave-assisted One-pot Reaction to Form 
Angular 2,2-Dimethyl-2H-chromone Containing Compounds 
 
    Conventional synthesis of angular 2,2-dimethyl-2H-chromones, which are key 
intermediates in the preparation of DCK and DCP analogs, was not efficient in 
reaction time or yield, partially due to the low selectivity of the desired angular a-
product. (Figure 7-1) In this research work, we were able to develop the first 
microwave initiation method to synthesize these key intermediates. We also tested 
this method on a broad range of starting materials with diverse ring systems. 
Through alkylation and cyclization of an appropriate starting material with 4,4-
dimethoxy-2-methyl-2-butanol as the alkylating reagent, the desired 2,2-dimethyl-
2H-chromone-related products, 8,8-dimethyl-8H-pyrano[2,3-f]chromenes, 3,3-
dimethyl-pyrano[2,3-c]xanthen-7(3H)-ones, or 3,3,12-trimethyl-3H-pyrano[2,3-
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c]acidin-7(12H)-ones were obtained in a one-pot reaction. Compared with reported 
literature methods, the newly developed microwave synthesis conditions shortened 
the reaction time dramatically from 2 days to 4 hours with much higher to 
comparable yields. Increasing the reaction temperature from 140 to 220 °C and 
extending the reaction time favored the formation of both a- and b-products with 
relatively better selectivity of the desirable a-product. (Figure 7-1)  
HO X
OR1
O X
OR1
R2 R2
Figure 7-1. Synthesis of 2,2-dimethyl-2H-chromone containing compounds. Conditions and
reagents: (i) 4,4-dimethoxy-2-methyl-2-butanol, pyridine, microwave 220oC/4h.
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The factors that might affect the yield and regioselectivity in this reaction were 
also analyzed:  
1. Electronic effects on the A-ring significantly influenced the reaction yield as 
well as regioselectivity. Electron-donating groups on the A-ring could increase 
the electron density at the 3-position, which consequently enhanced alkylation 
reactivity. (Figure 7-1) 
2. The lone-electron pair on the hydroxy group introduced at the R1-position of 
xanthone resulted in higher electron density at the next open position and, 
therefore, reduced the regioselectivity between a- and b-products.  
3. Steric effects of the substituents may also play a role in the alkylation and 
cyclization. Large groups on the 6-position blocked alkylation from occurring at 
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the 5-position, which led predominately to the desired angular product.  
        The significant advancement of this study is that the microwave method, with 
appropriately optimized conditions, can be widely applied to diverse ring systems, 
including phenoyl, chromone, and xanthone, as well as acridinone, which 
dramatically broadens the possibility of efficiently exploring DCK and DCP analogs 
as novel anti-HIV agents.  
7.1.2 Design, Synthesis, Molecular Modeling, and SAR of Novel Dicamphanoyl-
2’,2’-dimethyldihydropyranochromone (DCP) Analogs as Potent Anti-HIV 
Agents 
 
    Our study designed, synthesized, and evaluated a series of new DCP analogs 
to explore the structural requirements of dihydropyranochromones for anti-HIV 
activity, especially against HIV/RTMDR1 drug-resistant virus, and to improve water 
solubility. Twenty-three novel DCPs were obtained, and compounds 98, 102, 107 
and 115 exhibited comparable or even better anti-HIV activity than the reported best 
the lead, 2-EDCP (69), against HIVNL4-3 virus with EC50 values ranging from 0.036 – 
0.14 µM. (EC50 of 69 is 0.07 µM). (Figure 7-2) Compounds 98 and 102 also 
presented two-fold higher potency than 2-EDCP against the drug-resistant 
HIVRTMDR1 strain with EC50 values of 0.049 and 0.054 µM, respectively. In addition, 
the water-solubility assay indicated that compounds 98 and 115 are 5-fold and 10-
fold more water-soluble than 2-EDCP (69). The following SAR conclusions were 
drawn from this study:  
 (1)
(2)
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        SAR studies of DCK and DCP analogs suggested that the planar ring system in 
DCK and DCP analogs might interact with the binding pocket through π-π 
interaction or DNA chelation. To investigate such interactions, a new chemical entity, 
1,2-dicamphanoyl-pyranoxanthone (DCX), was designed, synthesized, and 
evaluated. Most of the synthesized DCX analogs were active against both wild-type 
and drug-resistant HIV strains. Compared to the control 2-EDCP (69), three 
compounds (131, 135, and144) showed better activity against both HIV strains, and 
four additional compounds (134, 139, 143, and 148) exhibited comparable anti-HIV 
potency to 2-EDCP. Six analogs showed enhanced TI values in comparison to the 
control.  
 
        The following SAR conclusions were drawn: (Figure 7-4) 
1. The planar ring extension from pyranochromone (DCP) to pyrano-xanthone 
(DCX) resulted in maintained anti-HIV activity against both wild-type and 
drug-resistant strains, which confirmed our hypothesis that the conjugated 
planar ring is significant when interacting with the binding pocket. 
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2. Substitution at R5 of the DCX xanthone ring is critical for anti-HIV activity 
against both viral strains. A methoxy group influenced the anti-HIV activity in 
a positive way, while a hydroxy group dramatically decreased the efficacy and 
selectivity. 
3. The R1-position could not tolerate large functional groups. Compounds with 
R2 and R3 substituents, especially R3 with small alkyl or O-alkyl substitution, 
retained a high level of anti-HIV activity against both wild-type and drug-
resistant strains. (compounds 134-136, 138-140, and 148) 
4. A bromine group on the xanthone ring was generally not favorable to anti-HIV 
activity and TI value; while a fluorine group was acceptable for sustained 
activity. 
5. Polar substitutions on different positions resulted in different anti-HIV profiles. 
A hydroxy group at R4 resulted in much better anti-HIV activity than the same 
group at R5. A cyano group at R2 led to maintained activity; however, an 
amino group at the same position abolished anti-HIV efficacy completely.  
 7.1.4
dime
Over
 
    
chem
comp
proto
resol
and 
comp
posit
vincr
 Design,
thyldihyd
come MD
We design
osensitize
arable or 
type first 
ved the vin
recovered 
ound 208 
ions also e
istine to 0.0
 Synthes
ropyranoc
R in Cance
ed and sy
rs in the tre
better che
generation
cristine re
the cytotox
with carbam
xhibited co
21 µg/mL.
is, and 
hromone 
r Treatme
nthesized a
atment of 
mosensitiz
 chemose
sistance in 
icity of vin
ate moiet
nsiderable
 (Figure 7-
178 
SAR St
(DSP) a
nt 
 series of 
MDR canc
ing activity
nsitizer. Co
the KB-Vin
cristine to a
ies rather t
 activity an
5) 
udy of 
s Potent
DSP  deri
er cells. N
 in compa
mpounds 
 human es
s low as 0
han aroma
d could reg
3’,4’-Disu
 Chemos
vatives as 
ine compou
rison with 
194, 197,
ophageal 
.008 µg/m
tic side cha
enerate th
bstituted-2
ensitizers
a new clas
nds prese
verapamil
 and 204
cancer cel
L. Surprisi
ins at 3’ a
e cytotoxic
’,2’-
 to 
s of 
nted 
, the 
fully 
l line 
ngly, 
nd 4’ 
ity of 
179 
 
 
        The SAR study of 3’ and 4’ side chains suggested the following conclusions: 
1. Aromatic rings at the 3’ and 4’ positions are important but not necessary to 
maintain high chemosensitizing activity. 
2. Substitutions on the aromatic rings have significant impacts on the activity. 
The moieties that can increase electron density, such as in compounds 194 
and 197, extend the conjugation system, or provide HB acceptors could 
benefit the activity. 
3. The characteristics of the linker between the pyranochromone and the 
aromatic side chains influenced the chemosensitizing potential. Adding 
double bond(s), such as in compound 204, benefited the activity. 
    Finally, we conducted a mechanism of action study related to DSP analogs, 
and the results indicated that the chemosensitizing efficacy of DSP analogs was 
180 
 
consistent with their relative inhibitory capability toward cellular P-gp. The result 
demonstrated that DSPs act as pump inhibitors in the KB-Vin cell system.  
7.2 Future Directions 
7.2.1 Further Design and Synthesis of Water-soluble DCP and DCX Analogs. 
        Previous studies to improve the anti-HIV activity and water-solubility of DCPs 
coupled with SAR study of DCXs suggested that introducing small polar groups on 
the pyranochromone ring in DCP or pyranoxanthone ring in DCX could result in 
preserved high anti-HIV activity, while also benefiting the pharmacological profile 
and consequently improving the water solubility. Therefore, in our future study 
directions, we have designed new series of novel DCP and DCX analogs to follow 
up on these results. Various small polar groups are substituted on the 2, 3, 5, or 6-
position of newly designed DCPs (Figure 7-6), while the polar groups are 
incorporated at R1 to R3 in DCX analogs (Figure 7-7). We hope to identify new anti-
HIV agents as clinical drug candidates in this future study.     
        The proposed synthetic pathways for the newly designed DCP analogs are 
shown in Schemes 7-1 to 7-3. 
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Figure 7-6. Newly designed DCP analogs
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Figure 7-7. Newly designed DCX analogs  
182 
 
OO
O
OR
OR
OO
O
OR
OR
OO
O
OR
OR
OO
O
OR
OR
Br
OO
O
OR
OR
HO
OO
O
OR
OR
H3CO
Scheme 7-1. Synthetic pathway for newly designed DCP--- part A: Reagent and Conditions: (i)
acetic anhydride, NaOAc, reflux; (ii) HCl (2N) in EtOH, reflux; (iii) NaCN, DMF, 0oC; (iv) H3PO4,
155oC, 4h; (v) NH4OH, THF, rt; (vi) MeI, K2CO3, acetone.
CH2Br CH2OAc CH2OHi ii
OO
O
OR
OR
Br iii
OO
O
OR
OR
CN
OO
O
OR
OR
COOH
iv
i, ii
OO
O
OR
OR
H2N
v
vi
R1, R2, R3 = CH3, H, CH2CH3
R = (S)-camphanoyl
212, 213 214, 215
216, 217
218 219
220
OO
O
OR
OR
R1
R2
R3 R1
R2
R3
R1
R2
R3
R1
R2
R3
Br
R1
R2
OO
O
OR
OR
H2N
R1
R2v
221
 
183 
 
 
184 
 
 
        All newly synthesized DCP and DCX analogs will be screened for anti-HIV-1 
activity against both HIV-1/NL4-3 and HIV/RTMDR1 strains. The method has been 
described in detail in Chapter 4.4.2.  
        To test whether the newly designed compounds show improved water-solubility, 
those with high anti-HIV potential will be tested for their water-solubility following the 
method mentioned in Chapter 4.4.3. 
7.2.2 Design and Synthesis of Dihydropyrano[2,3-c]acridinone Derivatives as 
Anti-HIV Agents 
 
    Bioisosteric modification may profoundly affect pharmacological action, 
metabolism, activity, and toxicity. As we described in Chapter 2.3.3, this basic 
principle of analog design was successfully applied in DCK modifications. DCK 
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lactam analogs, e.g., compound 57, showed better anti-HIV activity than 4-MDCK 
(26).1  We have designed a series of DCX lactam analogs,  (1R,2R)-dicamphanoyl-
1,2-dihydroxy-3,3,12-trimethyl-2,3-dihydro-1H-pyrano[2,3-c]acridin-7(12H)-ones 
(Figure 7-8), modeled after this successful DCK modification, The novel DCX lactam 
analogs with new core structures should provide more insight into the SAR of this 
molecular scaffold. 
 
The synthetic route to DCX lactam derivatives is shown in Scheme 7-4. A mixture 
of methyl anthranilate, phloroglucinol, and p-toluenesulfonic acid in hexanol heated 
at reflux gives ring closure acridin-9(10H)-one products (240). Pyrano ring closure 
product 241 is prepared using an optimized microwave-assisted one-pot reaction, as 
described in Chapter 3. Methylation using (CH3)2SO4 adds methyl groups on both 
10-NH and 6-OH groups to give 242. The subsequent reaction steps are similar to 
those used to synthesize DCXs.  Demethylation of the 6-methoxy group in 243 
should give the 6-hydroxy compound (244). 
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  In our most recent study, compound 243 (R1 = R2 = R3 = H, Scheme7-4) was 
successfully synthesized utilizing this method, which confirmed that the synthetic 
pathway shown in Scheme 7-4 is workable. More analogs will be synthesized as 
shown in Scheme 7-4 to discover new leads, establish the SAR and explore the 
mechanism of action.   
        6-Hydroxy-3,3,12-trimethyl-3H-pyrano[2,3-c]acridin-7(12H)-one (241, R1 = 
R2 = R3 = H). 50% yield. 1H NMR (300 MHz, CDCl3, ppm): δ 7.77 (1H, d, J = 7.2 Hz, 
H-8), 7.61 (1H, t, J = 7.2, 7.2 Hz, H-10), 7.52 (1H, t, J = 7.2, 7.2 Hz, H-9), 7.43 (1H, 
d, J = 7.2 Hz, H-11),  
        6-Methoxy-3,3,12-trimethyl-3H-pyrano[2,3-c]acridin-7(12H)-one (242, R1 = 
R2 = R3 = H, R4 = OCH3). 10% yield. 1H NMR (300 MHz, CDCl3, ppm): δ 8.40 (1H, d, 
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J = 8.1 Hz, H-8), 7.62 (1H, t, J = 8.1, 7.2 Hz, H-10), 7.35 (1H, d, J = 8.1 Hz, H-11), 
7.24 (1H, t, J = 7.2, 8.1 Hz, H-9), 6.55 (1H, d, J = 9.3 Hz, H-1), 6.31 (1H, s, H-5), 
5.52 (1H, d, J = 9.3 Hz, H-2), 3.97 (3H, s, OCH3-6), 3.83 (3H, s, NCH3-12), 1.54, 
1.54 (each 3H, s, CH3-2,2). 
        1R,2R-Dicamphanoyl-6-methoxy-3,3-dimethyl-2,3-dihydro-1H-pyrano[2,3-
c]acridin-7(12H)-one (243, R1 = R2 = R3 = H). 1H NMR (300 MHz, CDCl3, ppm): δ 
8.34 (1H, d, J = 8.7 Hz, H-8), 7.63 (1H, t, J = 6.6, 8.7 Hz, H-10), 7.41 (1H, d, J = 8.7 
Hz, H-9), 7.24 (1H, t, J = 8.7, 6.6 Hz, H-9), 6.26 (1H, s, H-5), 5.46 (1H, d, J = 3.0 Hz, 
H-1), 5.28 (1H, d, J = 3.0 Hz, H-2), 4.07 (3H, s, NCH3-12), 3.96 (3H, s, OCH3-6), 
2.50, 2.20, 2.06, 1.90 (each 2H, m, camphanoyl-CH2), 1.58, 1.49 (each 3H, s, CH3-
2,2), 1.13, 1.12, 1.06, 1.03, 0.94, 0.92 (each 3H, s, camphanoyl-CH3). 
        All newly synthesized DCX lactam analogs will be screened for anti-HIV-1 
activity against both HIV-1/NL4-3 and HIV/RTMDR1 strains. The method has been 
described in detail in Chapter 4.4.2.  
7.2.3 Development of Pyranochromone Analogs with Dual-functions to 
Improve Outcome of HAART 
 
        HAART regiments have some limitations, the major one being the failure to 
eradicate HIV even after several years of therapy. One reason for this failure is that, 
despite potent antiretroviral treatment, compartments of replication-competent virus 
persist, suggesting that antiretroviral agents do not reach all of the infected cells. In 
addition, all PIs suffer from poor pharmacokinetic properties. 
 7.2.3.1 Expression of P-gp and Outcome of HAART  
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    Membrane transporters (efflux and influx) are now recognized as playing an 
important role in anti-HIV drug absorption and disposition, and they explain, at least 
in part, the broad diversity in intracellular concentrations of drugs.  As mentioned in 
Chapter 6, P-gp is the most well characterized ATP-binding cassette (ABC) 
transporter by far, and has the ability to reduce intracellular concentrations of many 
anticancer agents, such as vincristine, doxorubicine, etc. This protein is widely 
expressed in the many barrier tissues, such as intestine, liver, kidney , blood-brain 
barrier (BBB), 2-4 and lymphocytes.5, 6 Recent studies revealed that expression and 
function of P-gp also impact the intracellular concentrations of many anti-HIV agents. 
        It is now well established that most PIs are substrates of P-gp, which is 
expressed in the GI tract and the liver, and acts with CYP3A to reduce the 
bioavailability of PIs.7 In combination treatment, the PI booster ritonavir inhibits both 
CYP3A and P-gp and markedly increased the bioavailability of PIs.  
        P-gp is also expressed on lymphocytes, including CD4+ lymphocytes and may 
reduce cellular accumulation of anti-HIV agents in HIV-infected lymphocytes. An 
earlier study showed that HIV-infected T cell and monocytic cell lines have increased 
P-gp expression, and accumulate significantly less AZT in comparison to uninfected 
cells.8 
    The central nervous system (CNS) has been cited as a reservoir for the HIV-1 
virus due to incomplete suppression of the viral replication.9 Suboptimal 
concentrations of anti-HIV-1 drugs in the CNS can provide ideal conditions for the 
selection of more virulent mutants.10  P-gp is highly expressed on the (BBB.2 As 
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substrates of P-gp, the limited ability of PIs to transverse the BBB is attributed to the 
activity of this efflux transporter. Another in vivo brain distribution study showed that 
P-gp may play a significant role in restricting the distribution of abacavir, which is a 
NRTI and also a P-gp substrate, to the CNS. 11   
        Although the NNRTIs nevirapine, efavirenz and delavirdine are not substrates 
of P-gp, all of these drugs acted as P-gp modulators to induce the expression and 
function of P-gp in the LS180 human colon adenocarcinoma cell line. The observed 
induction could be reversed by the potent P-gp inhibitor verapamil.  12  
       Collectively, these studies suggested that the selective inhibition of P-gp may 
facilitate the entry of PIs and certain NRTIs across the BBB and into HIV infected 
lymphocytes and, therefore, enhance the concentration of anti-HIV drugs in these 
sites to therapeutic levels. Inhibition of P-gp may also help increase the 
bioavailability of PIs.  
7.2.3.2 Preliminary Studies of DCP and DCX analogs to Overcome P-gp 
Mediated MDR in Cancer Cells 
 
    The pyranochromone in DCP is a critical pharmacophore for the 
chemosensitizing activity of novel DSP analogs (Chapter 6) against multidrug 
resistant cancer cells. The structural similarity between DCPs and DSPs suggests 
that DCP analogs and their DCX derivatives might also reverse MDR in cancer cells, 
by functioning as P-gp inhibitors. Therefore, these analogs might act as dual-
inhibitors in the treatment of AIDS. In addition to inhibiting the proliferation of HIV-1, 
they could also block the P-gp efflux potential and, as a result, increase the cellular 
concentration of other anti-HIV agents, such as PIs, in HAART. 
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    In order to test our hypothesis, selected DCP and DCX analogs that exhibited 
high anti-HIV activity against both wild-type and drug resistant HIV strains were 
screened in combination with VCR against KB-Vin cells. The cytotoxicity data for the 
combinations, (VCR+DCP) or (VCR+DCX), are listed in Tables 7-1 and 7-2. Many 
compounds, such as 98, 131, 134, and 135, which showed considerable anti-HIV 
activity against both wild-type and drug-resistant HIV strains, also exhibited 
extremely high potency in the combination formula against the KB-Vin cell line.  
Table 7-1. Anti-HIV and chemosensitizing data of selected DCP analogs.  
. 
Compd. Structure EC50 against 
HIVNL4-3 (µM) 
GI50 of (VCR +  4 
µM DCPs) 
69 R1 = CH2CH3 0.089 0.022 
98 R1 = R3 = CH3 0.036 0.0068 
102 R1 = CH2CH3, R3 = CH3 0.10 >0.23 
verapamil   0.044 
VCR   2.64 
VCR in 
KBc 
  0.0020 
a This assay was performed in TZM-bl cell infected with HIV/NL4-3 strain. 
b Cytotoxicity as GI50 values for KB-Vin cell line, the concentration of VCR + 4µM DCP that 
caused 50% reduction in absorbance at 562 nm relative to untreated cells using the 
sulforhodamine B assay.  
c Cytotoxicity of VCR against KB parent cell line detected using sulforhodamine B assay. 
 
Table 7-2. Anti-HIV and chemosensitizing data of selected DCX analogs.  
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Compd. Structure EC50 against 
HIVNL4-3 (µM)a 
GC50 of (VCR + 4 
µM DCX) (µM) b 
130 R1 –R5 = H 0.308 0.0023 
131 R5 = OCH3 0.063 0.0096 
134 R2 = CH3, R5 = OCH3 0.095 0.0081 
135 R3 = CH3, R5 = OCH3 0.065 0.0074 
138 R2 = R5 = OCH3 0.362 0.0020 
139 R3 = R5 = OCH3 0.121 0.0083 
142 R1 = F, R5 = OCH3 0.23 0.0033 
verapamil  --- 0.044 
VCR   2.64 
VCR in KBc   0.0022 
a This assay was performed in TZM-bl cell infected with NL4-3 HIV strain. 
b Cytotoxicity as GI50 values for KB-Vin cell line, the concentration of VCR + DSP (1µg/mL) 
that caused 50% reduction in absorbance at 562 nm relative to untreated cells using the 
sulforhodamine B assay. 
 c Cytotoxicity of VCR against KB parent cell line detected using sulforhodamine B assay. 
 
7.2.3.3 SAR Study of DCP and DCX Analogs as Dual-functional Molecules 
        The preliminary results shown above provide a promising start for further 
investigation. To further improve the potential of DCP and DCX analogs as dual-
functional molecules, a detailed SAR study is needed. All DCP and DCX analogs 
(synthesized and to be synthesized) will been screened for their chemosensitizing 
activity applying the method described in Chapter 6.6.2. We will next combine the 
SAR information from both anti-HIV activity and chemosensitizing activity and locate 
our best lead that exhibits strong efficacy in both functions. The exploration and 
synthesis of new DCP and DCX analogs were described in Section 7.2.1.   
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7.2.3.4. Effect of DCP and DCX Analogs on Cellular P-gp Activity 
        In order to test that the ability of identified DCPs and DCXs to regenerate the 
cytotoxicity of VCR is due to the inhibition of P-gp, four dual-functional DCP and 
DCX analogs (98, 131, 134 and 135) will be tested in the calcein-AM loading assay 
to detect their potential against cellular P-gp function. Ten thousand KB-Vin (MDR) 
cells per well are seeded into 96-well plates with medium containing 5% RBS and 
incubated for 1 day for adhesion and equilibration. Treatment involves 
supplementing cultures with distinct concentrations of test DCP or DCX compounds 
(initial concentration of 20 µM with two-fold dilutions for eight concentrations of each 
compound) for 30 min at 37 oC. After removing medium, fresh medium with both 
1µM calcein-AM and test compounds as needed is added for 100 µL. Following 
incubation for 30 min, medium is again removed, and wells washed gently and 
quickly with cold PBS buffer in low ambient light condition (200 µL). Cell are lysed 
using 20 mM Tris buffer and fluorescent measured using a BioTek TLx800 ELISA 
reader set to Ex.494 nm and Em.517 nm. Composite data from two or more 
independent experiments are analyzed using PrizmTM. 
7.2.3.5 Effect of Combined Usage of Dual-functional Agent and PIs on HIV-1 
Replication 
        We will further explore whether identified dual-functional agents can in fact 
promote the efficacy of PIs, which are P-gp substrates. We will treat the HIV-1/NL4-3 
infected PBMC cell line with a combined formula of dual functional agent + 
saquinavir (PI, also a P-gp substrate13). Anti-HIV-1 activity is measured by p24 
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antigen capture. If test compound successfully inhibits the function of P-gp and 
increases the cellular concentration of saquinavir, the effect of the combined drug 
formula would be characterized as a synergistic effect; otherwise, an additive effect 
would be detected. 
        First of all, we need to detecte the MDR-reversal potency of DCP/DCX n order 
to locate the best concentraion of DCP/DCX which could be used in both 
chemosensiting and anti-HIV assay system. To do so, we will fixed the concentration 
of VCR at 0.1 μg/ml in the combination usage of DCP (DCX) with VCR and detected 
the EC50 value of DCP(DCX). 
       The selected concentration of DCP (DCX) in chemosensitizing assay will be 
used in the synergistic anti-HIV assay combined with protease inhibitor saquinavir. 
In each independent assay, HIV-1 at 200 TCID50 and various dilutions of test 
samples (eight dilutions, fourfold stepwise) are mixed in a total volume of 100 μL 
growth medium in 96-well black solid plates (Corning-Costar). In each independent 
assay, the samples include saquinavir alone, test compound alone, saquinavir + xx 
µM (to be determined from chemosensitizing assay mentioned above) test 
compound combination. A second set of samples was prepared identical to the first 
and were added to cells under identical conditions without virus (mock infection) for 
toxicity determination. In addition, verapamil and ritonavir (clinically used PI booster) 
were also assayed during each experiment as a positive drug control. On days 1 and 
4 postinfection, spent media was removed from each well and replaced with fresh 
media. On day 6 postinfection, the assay was terminated and cultured supernatants 
were harvested for analysis of virus replication by p25 antigen capture. The 
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compound toxicity was performed according to CytoTox-GloTM cytotoxicity assay 
instructions for using product G9290, G9291, and G9292. (Promega) 
        Composite data from two or more independent experiments are analyzed using 
CalcuSyn (Biosoft, Cambridge, United Kingdom) to identify the characteristics of the 
combination effect.  
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